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Abstract 
Malignant peripheral nerve sheath tumours (MPNSTs) are rare soft tissue 
sarcomas, which can arise de novo in a peripheral nerve or from a 
neurofibroma. The molecular mechanisms leading to progression of 
neurofibroma to MPNST remain largely unknown.  
In this thesis, I examined the role played by microRNAs (miRNAs) in the 
pathogenesis of MPNSTs from neurofibromas. I analysed miRNA microarray 
expression profiles from 10 MPNSTs and 10 neurofibromas and identified 
sixteen differentially expressed miRNAs; fourteen were downregulated and 
two upregulated in MPNSTs. One of these, miR-29c, was confirmed as 
downregulated in MPNSTs by qRT-PCR. Its expression was also shown to 
be relatively low in other sarcomas and low-grade tumours. In vitro functional 
studies revealed miR-29c inhibits cell migration following its ectopic 
expression in MPSNT-derived sNF96.2 cells. 
Using in silico prediction analyses, I identified extracellular matrix (ECM) 
genes COL1A1, COL1A2, COL4A1, COL4A2, COL5A2, COL21A1 and 
MMP2 as well as TGFB3 and DNA methyltransferases DNMT3A and 
DNMT3B as potential targets of miR-29c. I demonstrated direct inhibition of 
these genes and partial inhibition of MMP9 via an indirect mechanism in 
miR-29c-transfected sNF96.2 cells. DNMT3B mRNA expression was higher 
in MPNSTs vs neurofibromas and inversely correlated with miR-29c 
expression.  
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Using previous methylome and microarray data, I identified CDKN2A, WT1, 
and S100B as possible targets for epigenetic regulation in MPNSTs. I 
demonstrated hypermethylation of these genes’ regulatory regions in 
MPNSTs by pyrosequencing and, in a larger cohort of 80 MPNSTs and 80 
neurofibromas archival samples, I revealed increased levels of WT1 and 
S100B gene methylation in high-grade MPNSTs compared to low-grade 
MPNSTs and neurofibromas. S100B protein expression by 
immunohistochemistry was also shown to be downregulated in MPNSTs 
compared to neurofibromas and its expression inversely correlated with 
S100B gene methylation. Furthermore, introduction of S100B cDNA using an 
adenoviral expression vector resulted in reduced proliferation of sNF96.2 
cells. 
My results suggest miR-29c may function as a tumour suppressor in 
MPNSTs by targeting ECM genes as well as DNA methyltransferases and 
TGFB3. S100B was also identified as a potential tumour suppressor whose 
expression is epigenetically regulated in MPNSTs. These findings lead to a 
better understanding of MPNST pathogenesis and identify S100B and miR-
29c as potential targets for future intervention in MPNST patients. 
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1. Introduction 
1.1. Neurofibromatosis Type 1 
Neurofibromatosis type 1 (von Recklinghausen neurofibromatosis) is a 
common, familial autosomally dominant neurocutaneous disorder, affecting 
approximately one in 3000 individuals (Friedman 1999). Neurofibromatosis 
type 1 is caused by monoallelic inactivation of the tumour suppressor gene 
neurofibromin 1 located on chromosome 17q11.2 (Wallace et al. 1990; 
Cawthon et al. 1990). A “second hit” of the NF1 gene leads to biallelic 
inactivation is crucial to the development of certain manifestations, such as 
neurofibromas and café au lait macules (Jouhilahti et al., 2011). Adult 
heterozygotes always show some signs of the disease, therefore penetrance 
is said to be 100% in adults. Some patients may have café au lait spots, 
axillary skin freckles, and iris Lisch nodules, whereas others may have life-
threatening benign tumours involving the spinal cord or malignant sarcomas 
of an extremity reflecting the variable expressivity of the disease (Nussbaum 
et al. 2007). Examples are depicted and described further in section 1.1.2.  
Individuals with neurofibromatosis type 1 have a further risk of developing 
malignant peripheral nerve sheath tumours (MPNSTs). There are two types 
of MPNST, sporadic MPNST and neurofibromatosis type 1-associated 
MPNST. Neurofibromatosis type 1-associated MPNST is a malignant tumour 
arising from a pre-existing benign neurofibroma in neurofibromatosis type 1 
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patients, however sporadic MPNST occurs sporadically in patients with no 
known risk factors. MPNSTs are very difficult to detect, metastasise widely 
and usually have poor prognosis (Ferner & Gutmann, 2002).  
Approximately one-fourth to one-half of MPNSTs develop in patients with 
neurofibromatosis type 1 (Weiss & Goldblum 2007), and individuals with 
neurofibromatosis type 1 have an 8%–13% lifetime risk of developing 
neurofibromatosis type 1-associated MPNST (most commonly in individuals 
aged 20–35 years) (Evans et al. 2002). The five year survival from diagnosis 
of MPNST is 21% for patients with neurofibromatosis type 1 compared to 
42% for patients developing sporadic MPNST (Evans et al. 2002). 
1.1.1. History of Neurofibromatosis Type 1 
In 1882, Friedrich Daniel von Recklinghausen described the disorder that we 
nowadays call neurofibromatosis type 1; hence also named von 
Recklinghausen disease. However, more accurately the disorder’s first 
characterisation was earlier in 1849 by Robert William Smith, although Smith 
described the disorder originated from connective tissue not the nerves 
(Smith 1989; Reynolds et al. 2003; Brosius 2010). In 1956, a study by 
Crowe, Schull, & Neel described in detail various manifestations of 
neurofibromatosis type 1 (Crowe FW & Schull WJ 1956). In 1982, Riccardi 
classified the different neurofibromatosis disorders where 
Neurofibromatosis type 1 and 2 were described in details (Riccardi 1982). 
In 1987, the National Institutes of Health (NIH) consensus development 
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conference suggested the diagnostic criteria for neurofibromatosis type 1 
(Stumpf et al. 1988) These criteria are listed in (Table ‎1-1) and will be 
discussed in detail in the next section.  
1.1.2. Clinical diagnosis of Neurofibromatosis type 1 
Neurofibromatosis type 1 is diagnosed clinically using a set of criteria 
formulated by the National Institutes of Health consensus development 
conference (Stumpf et al. 1988); (Table ‎1-1). These criteria can diagnose 
about 50% of patients by the first year of life, 97% of patients by the age of 8 
years old, and 100% of patients by the age of 20 years (Abramowicz & Gos 
2014; DeBella et al. 2000). 
 
Table ‎1-1: National Institutes of Health diagnostic criteria of 
neurofibromatosis type 1 
 
Two or more of the following are required for the diagnosis 
 
 
Six or more café au lait macules over 5 mm in greatest diameter in prepubertal 
individuals and over 15 mm in greatest diameter in postpubertal individuals 
Two or more neurofibromas of any type or one plexiform neurofibroma 
Freckling in the axillary or inguinal regions (Crowe´s sign) 
Optic glioma 
Two or more Lisch nodules 
A distinctive osseous lesion such as sphenoid dysplasia or thinning of long bone 
cortex with or without pseudoarthrosis 
A first-degree relative (parent, sibling, or offspring) with neurofibromatosis type 1 by 
the above criteria 
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The most frequent clinical features are neurofibromas (Figure ‎1-1), café au 
lait macules (Figure ‎1-2), intertriginous freckling, iris Lisch nodules 
(Figure ‎1-3), and learning disabilities; however optic glioma, malignant 
peripheral nerve sheath tumours, and characteristic bone lesions can also be 
present.  
 
 
 
Figure ‎1-1: Multiple benign neurofibromas 
Numerous subcutaneous neurofibromas, some are marked with arrows, in a patient 
with neurofibromatosis type 1. Retrieved from Jett & Friedman (2010). 
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Figure ‎1-2: Café au lait macules 
Café au lait macules (CALMs) in the trunk of an 11-year-old child with 
neurofibromatosis type 1. Retrieved from Purkait et al. (2011). 
 
 
 
 
 
Figure ‎1-3: Iris Lisch nodules 
Multiple small, oval, yellow-brown papules (Lisch nodules) in the iris. Retrieved from 
Adams et al. (2011). 
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1.1.3. Genetics of Neurofibromatosis type 1 
1.1.3.1. NF1 Gene 
Neurofibromatosis type 1 is caused by germline mutations of the tumour 
suppressor NF1. The NF1 gene is one of the largest human genes and 
spans ~350 kb of 17q11.2, contains 60 exons, of which 3 are alternatively 
spliced, and encodes a 12 kb mRNA transcript. (Cichowski & Jacks 2001; 
Upadhyaya 2008).  
The NF1 encoded protein, neurofibromin, is a large multi-domain protein 
(2,839 amino acids; 319 kDa) that activates RAS-GTPase; and functions as 
negative regulator of RAS proteins (Figure ‎1-4) (Leondaritis et al. 2009; 
Dasgupta 2003; DeClue et al. 1992). Loss of NF1 function causes 
constitutive activation of RAS and its associated cascade of signaling 
pathways, promoting cell growth and proliferation (RAS–mitogen-activated 
protein kinase–extracellular signal–regulated kinase (RAS-MAPK-ERK) and 
phosphatidyl inositol 3-kinase (PI3K-AKT-mTOR) in human neurofibromas 
and MPNST-derived cell lines (Sherman et al. 2000; Cichowski & Jacks 
2001; Leondaritis et al. 2009).  
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Figure ‎1-4: Loss of NF1 expression leads to activation of RAS, 
dysregulation of cell growth and tumourigenesis 
Retrieved from Le & Parada (2007). 
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1.1.3.2. Germline mutational spectrum of NF1 
About 1300 different inherited mutations of NF1 gene have been reported 
(http://www.hgmd.org). For unknown reasons, the germline mutation rate for 
the NF1 gene is some 10-fold higher than that observed in most other 
comparable inherited disease genes, and de novo mutations are present in 
almost half of neurofibromatosis type 1 cases (Huson et al. 1988; Evans et 
al. 2010). These mutations vary in size from deletions of more than a 
megabase to a single base pair substitution. Examination of these germline 
mutations demonstrated that 80% are predicted to be truncating mutations, 
with about 30% of these truncating mutation expected to result in RNA 
splicing abnormalities (Ars et al. 2000).  
Post-zygotic NF1 mutations causes mosaic neurofibromatosis type 1 and 
usually have a milder clinical picture depending on the proportion and type of 
affected tissues. Mosaic neurofibromatosis type 1 can be either localised or 
generalised with clinical features varying from a narrow strip to one quadrant 
and occasionally to one half of the body, therefore called segmental 
neurofibromatosis type 1 (Ruggieri & Huson 2001; Kehrer-Sawatzki & 
Cooper 2008).  
Germline mosaicism is very rare in patients with neurofibromatosis type 1 
due to the fact that very few families have been reported with two or more 
affected child born to unaffected parents (Lázaro et al. 1994; Bottillo et al. 
2010; Trevisson et al. 2013). Molecular analysis is essential to confirm the 
germline mosaicism diagnosis as cases of two or more siblings with non-
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identical (de novo) mutations have been reported (Upadhyaya et al. 2003). 
Molecular analysis of fathers of cases who originated from germline 
mosaicism detected an NF1 mutation in 10% to 17% of spermatozoa (Bottillo 
et al. 2010). Trevisson et al. (2013) have also reported NF1 germline 
mosaicism in the maternal germline (Trevisson et al. 2013). 
1.1.3.3. Molecular diagnosis of neurofibromatosis 
type 1 
A diagnosis of neurofibromatosis type 1 is mainly made on the clinical 
phenotype. However, the identification of an NF1 mutation and hence 
understanding the impact of the NF1 gene may direct the overall clinical 
assessment of patients (Griffiths et al. 2007). The available mutation 
detection protocols reliably diagnose 95% of neurofibromatosis type 1 
patients (Messiaen et al. 2000). Negative results for NF1 mutations largely 
exclude the diagnosis neurofibromatosis type 1, eliminate the need and 
expense of specialist follow up, and can reassure the patient. Mutational 
analysis is useful for diagnostic confirmation in individuals who do not fulfil 
diagnostic criteria or when prenatal diagnosis is desired (Hirbe & 
Gutmann 2014). The NF1 mutation analysis has been found to be cost 
effective when taking in consideration all the costs of health care (Tsang et 
al. 2012) 
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1.1.4. Other RAS/MAPK pathway dysregulation 
(RASopathies) 
Having described neurofibromatosis in some detail, it is important to 
recognise that this disease belongs to a group of RAS/MAPK pathway 
dysregulation syndromes (RASopathies) which share characteristic facial 
features, cardiac abnormalities, cutaneous abnormalities, growth deficit, 
neurocognitive disorders, and predisposition to malignancies (Zenker 2011). 
RASopathies comprise neurofibromatosis type 1, Noonan syndrome, 
Leopard syndrome, Legius syndrome and Costello syndrome (Zenker 2011). 
Although not the main focus of this thesis, each of the other RASopathies is 
described briefly below. 
1.1.4.1. Noonan syndrome  
Noonan syndrome (NS) is an autosomal dominant, multisystem disorder with 
1 in 1000–2500 prevalence (Mendez & Opitz 1985). It is typically 
characterised by broad forehead, ocular hypertelorism, ptosis (drooping of 
the upper eyelid), pulmonary valve stenosis, short stature, mild intellectual 
disability, undescended testes, and skeletal malformations (Romano et al. 
2010).  
Understanding of the molecular genetics underlying Noonan syndrome has 
increased in the past decade, enabling the study of the pathophysiological 
mechanisms causing the varied medical and developmental features of the 
disorder.  
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Seven genes have been shown to cause Noonan syndrome: PTPN11 
(Tartaglia et al. 2001), K-RAS (Schubbert et al. 2006), N-RAS (Cirstea et al. 
2010), SOS1 (Roberts et al. 2007; Tartaglia et al. 2007), SHOC2 (Mendez & 
Opitz 1985), CBL (Martinelli et al. 2010) and RAF1 (Pandit et al. 2007; 
Razzaque et al. 2007).  
1.1.4.2. Leopard syndrome 
Leopard syndrome (LS) is a rare autosomal dominant disorder with a similar 
phenotype to NS, including a “Noonan-like” appearance as well as multiple 
Lentigines, ECG abnormalities, Ocular hypertelorism, Pulmonary valve 
stenosis, Abnormal genitalia, Retardation of growth, and Deafness (acronym 
LEOPARD) (Tidyman & Rauen 2009). LS is a very rare disorder; by the year 
2008 only 200 patients have been recorded worldwide however the real 
incidence of LS has not been assessed (Sarkozy et al. 2008). LS and NS are 
allelic disorders, caused by different heterozygous missense mutations in the 
same genes, PTPN11 (Digilio et al. 2002; Legius et al. 2002) 
and RAF1 (Pandit et al. 2007). This common genetic defect between LS and 
NS probably explains the phenotypic similarities between the two diseases. 
1.1.4.3. Legius syndrome 
Unlike NS and LS, Legius syndrome is an autosomal dominant disorder that 
shares many phenotypic features with neurofibromatosis type 1. Individuals 
may have café au lait maculae, axillary freckling, mild neurocognitive 
impairment, and macrocephaly. However, the phenotypic features common 
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in neurofibromatosis type 1 such as neurofibromas, iris Lisch nodules and 
central nervous system tumours are lacking (Brems et al. 2007). Legius 
syndrome is caused by heterozygous mutations in SPRED1 (Brems et al. 
2007). SPRED1 gene, encodes SPRED1, which is a member of the 
SPROUTY/SPRED family of proteins. SPRED1 functions as negative 
regulator of RAS by inhibiting phosphorylation of Raf (Wakioka et al. 2001). 
Neurofibromatosis type 1-like features encountered in Legius syndrome can 
be explained that neurofibromin is a SPRED1 interacting protein and 
SPRED1 binding to neurofibromin stimulates localisation of neurofibromin in 
the plasma membrane which in turn down-regulates RAS-GTP levels (Stowe 
et al. 2012). 
1.1.4.4. Costello syndrome 
Costello syndrome is a very rare disorder characterised by dysmorphic 
craniofacial features, cardiac, musculoskeletal and ectodermal abnormalities, 
failure to thrive and neurocognitive delay (Rauen 2007). The real incidence 
of Costello has not been assessed. Individuals with Costello syndrome are at 
increased risk of developing neoplasms, both benign and malignant 
(Tidyman & Rauen 2009). Heterozygous germline mutations in H-RAS cause 
Costello syndrome (Aoki et al. 2005) and explain the overlap in clinical 
features with the above diseases. 
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1.2. Pathology of Neurofibroma 
Neurofibromas are benign peripheral nerve tumours that may occur either as 
solitary lesions unrelated to a genetic syndrome (i.e. sporadic) or as multiple 
lesions in association with neurofibromatosis type 1. The main neoplastic 
cellular components of neurofibroma are Schwann cells, which are 
characterised cytologically by wavy nuclear contours and S100 protein 
expression (Weiss et al. 1983; Chaubal et al. 1994; Perry et al. 2001). 
Neurofibromas’ cellular component also contain a mixture of non–neoplastic 
cells, including fibroblasts, perineural cells, endothelial cells, smooth muscle 
cells, pericytes, mast cells, lymphocytes and nerve axons (Gray et al. 1990; 
Hirose et al. 2003; Fine et al. 2004). In addition, a population of CD34 
positive cells of unclear histogenesis are present (Carroll 2012; Weiss & 
Nickoloff 1993). 
Neurofibromas have three different subtypes based on architectural growth 
patterns: localised (nodular, discrete), diffuse, and plexiform. However mainly 
plexiform and diffuse neurofibromas are significant precursors of MPNST. 
Despite the fact that all neurofibromas have a risk of transformation to 
MPNST, neurofibromas that transform are usually deeply located. Plexiform 
neurofibromas have much greater risk of developing MPNST (Weiss & 
Goldblum 2007).  
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1.2.1. Gross pathology of neurofibromas 
1.2.1.1. Localised neurofibroma 
The localised neurofibroma is the most common form of neurofibroma, and 
occurs sporadically in the majority of cases. The majority of neurofibromas 
(90%) occur sporadically, however only 10% were proven to be associated 
with neurofibromatosis type 1. Localised neurofibromas are well-
circumscribed nodules but without a capsule (Figure ‎1-5). Localised 
neurofibromas usually occur in the dermis or soft tissue, however it may also 
involve a major nerve (intraneural subtype), and result typically in fusiform 
expansion of the nerve trunk (Huson et al. 1988).  
  
 
 
Figure ‎1-5: Localised neurofibroma, macroscopic 
The tumour is well circumscribed and has a homogenous fleshy cut surface. 
Retrieved from:  
http://www.humpath.com/IMG/jpg_jpg_localized_neurofibroma_08_NF1_2.jpg.   
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1.2.1.2. Diffuse neurofibroma 
Diffuse neurofibroma is an uncommon form of neurofibroma that occurs 
primarily in children and young adults. Diffuse neurofibroma is an ill-defined 
infiltrative lesion (Figure ‎1-6) and tends to involve the skin and subcutaneous 
tissues. It produces localised thickening and induration of the skin. Diffuse 
neurofibroma may occur in the skin, in the soft tissue, or in the viscera. The 
most commonly involved visceral organ is the gastrointestinal tract 
(Hochberg et al. 1974). 
 
 
 
 
Figure ‎1-6: Diffuse neurofibroma, macroscopic 
Diffuse cutaneous neurofibroma infiltrating the dermis which is thickened and firm. 
Retrieved from: http://www.humpath.com/spip.php?article3900. 
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1.2.1.3. Plexiform neurofibroma 
Plexiform neurofibroma is the least common variant of neurofibromas and it 
occurs almost exclusively in neurofibromatosis type 1 patients. Plexiform 
neurofibromas occur in 30 - 40% of neurofibromatosis type 1 patients 
develop in early childhood, and they are often multiple large lesions that 
grow along major nerve trunk of large nerves, expanding and distorting the 
nerves, acquiring a plexiform architecture (Figure ‎1-7). It is usually 
characterised by the involvement of numerous adjacent nerve fascicles or 
multiple components of a nerve plexus (McCarron & Goldblum 1998; Weiss 
& Goldblum 2007; Huson et al. 1988). Plexiform neurofibroma has a potential 
for malignant transformation (details in section ‎1.6). 
 
Figure ‎1-7: Plexiform neurofibroma, macroscopic 
The tumour involves multiple nerves with multinodular appearance. Retrieved from: 
http://www.humpath.com/spip.php?article3900.  
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1.2.2. Microscopy of neurofibromas 
Microscopically, solitary and plexiform neurofibroma shares common 
histological features. They both have a variable hypocellular, myxomatous 
background (Figure  1-8). Fine collagen fibres are also present at a variable 
density. The cellular component is composed of a mixture of neoplastic 
Schwann cells and a variety of non–neoplastic cells (including fibroblasts, 
perineural cells, endothelial cells, smooth muscle cells, pericytes, mast cells, 
lymphocytes and nerve axons). Immunohistochemical staining is typically 
positive for S100, CD34, calretinin and Factor XIIIa (Gray et al. 1990; Hirose 
et al. 2003; Fine et al. 2004).  
When neurofibromas show a low level of cytological atypia and areas of 
increased cellularity fascicle formation and even occasional numbers of 
mitotic figures they are referred to as atypical neurofibroma (Figure ‎1-9) and 
this variant has to be distinguished from low-grade MPNST (Yamaguchi et al. 
2003). Atypical neurofibroma may be precursors of MPNST and are usually 
encountered in patients with neurofibromatosis type 1. Differentiating atypical 
neurofibroma from low-grade MPNST is difficult, however, low-grade MPNST 
microscopically shows more generalised nuclear atypia with increased 
cellularity and low levels of mitotic activity (Weiss & Goldblum 2007). 
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Figure ‎1-8: Classic neurofibroma histology 
Hypocellular tumour with myxoid stroma and collagen strands. Retrieved from: 
http://dermnetnz.org/pathology/neurofibroma-path.html. 
 
 
 
 
Figure ‎1-9: Atypical neurofibroma histology 
Hypocellular tumour with myxoid stroma and collagen strands with mild atypia 
consisting of mild hypercellularity and hyperchromasia. Retrieved from: Babovic-
Vuksanovic et al. (2012). 
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1.3. Malignant Peripheral Nerve Sheath 
Tumours 
Malignant Peripheral Nerve Sheath Tumour (MPNST) is a malignant tumour 
arising from a peripheral nerve or from a pre-existing benign neurofibroma. 
MPNST display Schwann cell differentiation by histologic or 
immunohistochemical features. MPNST arise from a pre-existing benign 
neurofibroma in neurofibromatosis type 1 patient is called neurofibromatosis 
type 1-associated MPNST. However, MPNST that occur in a patient with no 
known risk factors is called sporadic MPNST. Other historical synonymous 
terms used previously to describe MPNST include malignant schwannoma, 
neurogenic sarcoma and neurofibrosarcoma (Evans et al. 2002). 
Neurofibromatosis type 1 has a risk of developing MPNST; where about one-
fourth to one-half of MPNSTs develop in patients with neurofibromatosis type 
1 (Weiss & Goldblum 2007). The life time risk for neurofibromatosis type 1 
patient to develop MPNST is 8%–13% (Most commonly in individuals aged 
20–35 years) (Evans et al. 2002). MPNST patients with neurofibromatosis 
type 1 have bad prognosis compared to sporadic MPNST; where the five 
year survival from diagnosis of MPNST is 21% for patients with 
neurofibromatosis type 1 compared to 42% for patients developing sporadic 
MPNST (Evans et al. 2002). It is very difficult to detect MPNSTs early, and it 
is usually metastasise widely and have a poor prognosis (Ferner & Gutmann 
2002).  
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1.3.1. Grading of MPNST 
The grading system used for MPNST grading is the same grading system for 
other soft tissue sarcomas (STS). Grading is important because it guides 
patient management. The two most commonly used grading systems are the 
National Cancer Institute (NCI) system and the French Federation of Cancer 
Centres Sarcoma Group (FNCLCC) system. The NCI system applies a 
combination of histological type, pleomorphism, cellularity and mitotic rate for 
attributing grade 1 to 3. MPNSTs categorized as grade 1 tumours when they 
had the appearance of neurofibroma except mitoses were present (< six 
mitoses per 10 HPF) and the tumour was composed of areas of high 
cellularity. MPNSTs are categorised as either grade 2 or grade 3 according 
to the amount of tumour necrosis, where 15% necrosis is considered the 
threshold for differentiating grade 2 from grade 3 tumours. The FNCLCC is a 
score based system that obtained by evaluating three parameters: tumour 
differentiation, mitotic rate and the amount of tumour necrosis. A score is 
assigned separately to individual parameter and the grade is obtained by 
summing the three assigned scores. Differentiation is scored from 1 to 3 
where 1 is well differentiated; 2 is well defined histogenetic type; and 3 is 
poorly differentiated. Mitotic rate is scored from 1 to 3 where 1 for mitotic 
count of 0-9 / 10 high-power fields (HPF), 2 for mitotic count of 10-19 / 10 
HPF and 3 for mitotic count of 20 / 10 HPF or more. Necrosis is scored from 
0-2 where 0 means no necrosis, 1 means 50% necrosis or more and 2 
means more than 50% necrosis. Grading depends on the sum of all the 
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above score as grade 1 is given for total score of 2 or 3, grade 2 is given for 
total score 4 or 5 and grade 3 is given for total score 6, 7 or 8 (Guillou et al. 
1997; Trojani et al. 1984; Coindre 2006). It is usually difficult to distinguish 
low-grade MPNST from neurofibromas with varying degrees of atypia 
(Yamaguchi et al. 2003).  
1.3.2. Diagnosis and management of MPNST 
Careful clinical monitoring is required for individuals who have a personal or 
family history of cancer, after radiotherapy, optic pathway glioma, multiple 
subcutaneous neurofibromas, whole gene deletion, or neurofibromatosis 
neuropathy; These group might have an increased risk of developing 
MPNST (De Raedt et al. 2003; Khosrotehrani et al. 2005; Ferner & Gutmann 
2002). Urgent expert opinion (from specialist neurofibromatosis clinics or soft 
tissue tumour units) is needed if neurofibromatosis type 1 patients develop 
any of the following in association with a subcutaneous or plexiform 
neurofibroma: persistent pain lasting for longer than a month or pain that 
disturbs sleep; new or unexplained neurological deficit or sphincter 
disturbance; alteration in the texture of a neurofibroma from soft to hard; and 
rapid increase in the size of a neurofibroma (Ferner & Gutmann 2002). 
Fluorodeoxyglucose positron emission tomography allows the visualisation 
and quantification of glucose metabolism in cells and is a useful diagnostic 
tool in differentiating benign plexiform neurofibromas from MPNST (Ferner et 
al. 2000). 
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Any sarcoma involves a major nerve, without definite line of differentiation or 
arising from benign neurofibroma would have been accepted by most 
authors to be categorised as MPNST (Allison et al. 2005; Weiss & Goldblum 
2007). Additionally, any spindle cell tumour in neurofibromatosis type 1 
patient should be considered as MPNST until proved otherwise (Weiss & 
Goldblum 2007). 
Schwann cell differentiation and Immunohistochemical finding of partial S100 
expression must be present for the diagnosis of MPNST specially for those 
that more difficult to classify and unrelated to major nerves (Weiss & 
Goldblum 2007). Some MPNSTs (malignant triton tumour) may show 
heterologous differentiation e.g., bone, cartilage, skeletal muscles, smooth 
muscle, angiosarcoma and even well-formed glands (Brown et al. 1992; 
Ducatman & Scheithauer 1984; Rodriguez et al. 2007). A different, 
uncommon subtype of MPNST that raises a totally separate differential 
diagnosis is portrayed by a prevalence of extensive epithelioid cells, i.e. 
epithelioid MPNST (DiCarlo et al. 1986; Laskin et al. 1991; Lodding et al. 
1986). These tumours are more common in superficial sites and as opposed 
to ordinary MPNSTs, express S100 protein unequivocally and normally, 
diffusely (Laskin et al. 1991). For obscure reasons, the immense dominant 
part of MPNST emerging inside prior schwannoma (an exceptionally 
uncommon occasion) are of epithelioid sort (McMenamin & Fletcher 2001). 
The differential diagnosis of epithelioid MPNST includes melanoma, clear 
cell sarcoma, epithelioid sarcoma, and carcinoma. Absence of representation 
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of melanocytic markers (e.g., MelanA, HMB45, MITF) is exceptionally useful 
in the differentiation of epithelioid MPNST from melanoma and clear cell 
sarcoma, and loss of cytokeratin expression recognises them from 
carcinoma and epithelioid sarcoma (Carter et al. 2012; Hollmann & Hornick 
2011). 
The treatment for MPNST is primarily surgical, although radiotherapy can be 
employed in pre-operative, intraoperative, and post-operative settings (Yang 
et al. 1998). Surgical treatment aims for complete removal of the lesion with 
tumour free margins (Ferner & Gutmann 2002). Adjuvant radiotherapy has a 
role in treating high-grade lesions or post-operative for incompletely excised 
tumours. Chemotherapy offers little benefit to patients with MPNST (Angelov 
et al. 1998). With the recent advances in molecular genetics, there is a hope 
for targeted therapy to be discovered (Ferner & Gutmann 2002). New agents 
targeting RAS-RAF-MAPK/ERK kinase-extracellular signal-regulated kinase 
pathway, may prove effective against MPNST in neurofibromatosis type 1. 
One of those drugs is farnesyl transferase, which blocks the ability of RAS to 
reach membrane and hence its activation (Cox 2001). Inhibitors or RAS 
downstream targets are developed for clinical trials such as MAPK/ERK 
kinase (Ferner & Gutmann 2002). Ifosfamide and doxorubicin are 
administered as palliative therapy in patients with metastatic disease and to 
reduce the size of tumour with the aim of making it amenable to surgery 
(Ferner & Gutmann 2002). A study by Wojtkowiak et al. showed that 
combination of farnesyl transferase inhibitors and lovastatin induce apoptosis 
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in neurofibromatosis type 1 associated MPNST cell lines with low or no 
detectable toxicity (Wojtkowiak et al. 2008). 
1.3.3. Pathology of Malignant Peripheral 
Nerve Sheath Tumours 
1.3.3.1. Gross pathology of Malignant Peripheral 
Nerve Sheath Tumour 
Malignant Peripheral Nerve Sheath Tumour is usually a fusiform mass and 
their gross appearance is similar to other soft-tissue sarcomas. They are 
usually large (10-15 cm in greatest dimension and infrequently less than 5 
cm) with heterogeneous cut surface, tan white and foci of necrosis and 
haemorrhage (Figure ‎1-10). 
 
 
Figure ‎1-10: Malignant Peripheral Nerve Sheath Tumour, macroscopic 
Malignant Peripheral Nerve Sheath Tumour mass, homogeneous with areas of 
haemorrhage and necrosis. Retrieved from:  
http://www.humpath.com/spip.php?article15440. 
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1.3.3.2. Microscopic features of MPNST 
MPNSTs (Figure ‎1-11) are cellular tumours composed of spindled, 
pleomorphic cells with areas of haemorrhage and necrosis. In some cases, 
MPNST often displays extensive pleomorphism, simulating a high-grade 
undifferentiated pleomorphic sarcoma.  
 
 
 
Figure ‎1-11: Malignant Peripheral Nerve Sheath Tumour  
Cellular tumour composed of spindled, pleomorphic cells. Retrieved from:  
http://www.sarcomaimages.com/index.php?v=Malignant-Peripheral-Nerve-on 
Sheath-Tumour-(MPNST). 
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1.3.3.3. Malignant Triton tumour 
Malignant Triton tumour refers to the presence of skeletal muscle 
differentiation in an MPNST. These tumours are rare (accounts for about 5% 
of all MPNSTs) and often occur in the setting of neurofibromatosis type 1 
(Tripathy et al. 2010; Brooks 1999). Histologically, the defining feature is the 
presence of variable number of rhabdomyoblasts with abundant eosinophilic 
cytoplasm (Figure ‎1-12). Differentiation into cartilage or bone is also 
common, whereas liposarcomatous differentiation is very rare. Where the 
five year survival from diagnosis of MPNST is 21% for patients with 
neurofibromatosis type 1, 42% for patients developing sporadic MPNST 
(Evans et al. 2002), malignant triton tumour showed five-year survival rates 
of 26% (Tripathy et al. 2010; Yakulis et al. 1996). 
 
 
Figure ‎1-12: Triton tumour 
MPNST with rhabdomyoblasts with abundant eosinphilic cytoplasm  
Retrieved from: http://www.sarcomaimages.com/sub.php?v=malignant-peripheral-
nerve-sheath-tumor-with-rabdomyoblastic-differentiation-triton-tumor. 
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1.3.3.4. Glandular MPNST 
Glandular MPNST is a rare subtype of MPNST. Histologically, it shows 
scattered well-differentiated glands in a background of spindle cells. The 
glands are lined with cuboidal epithelium containing mucin (Figure ‎1-13). 
MPNST with epithelial glandular structures is very rare and usually occurs in 
neurofibromatosis type 1 (Woodruff & Christensen 1993). 
 
 
Figure ‎1-13: Glandular MPNST 
MPNST containing well differentiated glandular element. Retrieved from:  
http://www.sarcomaimages.com/sub.php?v=mpnst-with-glandular-elements& 
p=malignant-peripheral-nerve-sheath-tumor-mpnst. 
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1.3.3.5. Epithelioid MPNST 
Epithelioid MPNST is a rare variant of MPNST (less than 5% of all MPNSTs). 
It contains epithelioid cells with abundant eosinphilic cytoplasm 
(Figure ‎1-14). A greater percentage of epithelioid MPNSTs than conventional 
MPNST show S100 positivity (Perry et al. 2002). 
 
 
 
Figure ‎1-14: Epithelioid MPNST 
Contains epithelioid cells with abundant eosinphilic cytoplasm. Retrieved from: 
http://www.sarcomaimages.com/sub.php?v=epithelioid-mpnst&p=malignant-
peripheral-nerve-sheath-tumor-mpnst. 
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1.4. S100B as a marker of nerve sheath 
tumours 
S100 protein-immunoreactivity in formalin-fixed paraffin-embedded material 
was first suggested as a diagnostic tool for tumour diagnosis in 1982 by 
Nakajima et al. (Nakajima et al. 1982). They showed that S100 was 
expressed in the cells of eosinophilic granuloma, Langerhans cell 
histocytosis as well as in interdigitating reticulum cells sarcoma in the lymph 
node, spleen and thymus (Nakajima et al. 1982). Subsequently, further 
studies identified the expression of S100 in different types of sarcomas 
including rhabdomyosarcoma, Ewing sarcoma, and synovial sarcoma 
(Coindre et al. 1988; Shimada et al. 1988; Fisher & Schofield 1991).  
The S100 proteins family consist of twenty-one known human members 
(Zimmer et al. 2013). They are small proteins of molecular weight between 9 
kDa and 14 kDa  (Marenholz et al. 2004; Donato 2003). S100 proteins have 
been shown to regulate different cellular functions using a calcium-
dependent mechanism, they have also been shown to have a potential role 
in tumour formation and metastasis (Böni et al. 1997; Petersson et al. 2009; 
Keijser et al. 2006; Maelandsmo et al. 1997).  
One particular variant, S100B, is most abundant in neural tissue and it is 
commonly used by pathologists as a marker to indicate glia cell and 
Schwann cell differentiation (Hachem et al. 2005). S100B function is through 
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intracellular and extracellular mechanisms and depending on its 
concentration, secreted S100B exerts either cytotrophic or cytotoxic effects 
(Astrand et al. 2013). Some studies in the literature have discussed the 
expression of S100B protein in MPNST. For instance, Lévy et al. studied 
S100B mRNA expression in 14 neurofibromas and 9 MPNSTs using real-
time quantitative RT-PCR. Their results showed that S100B mRNA is 
significantly downregulated in MPNST as compared to neurofibromas (Lévy 
et al. 2004). Nonaka et al. studied S100B expression in 86 neurofibromas 
and 77 MPNSTs using immunohistochemistry. Their results showed that 
S100B was stained diffusely in all neurofibroma, but its reaction was 
observed only in 30% of MPNSTs in a focal fashion (Nonaka et al. 2008). 
Karamchandani et al. studied S100B expression in 55 neurofibromas and 78 
MPNSTs using immunohistochemistry. Their results showed that S100B was 
stained diffusely in 52 out of 55 neurofibroma, but its reaction was observed 
only in 15 out of 78 MPNSTs (Karamchandani et al. 2012). 
There appears to be some alteration in expression correlated with 
tumorigenic transformation, but strikingly I have not found any study 
investigating S100B regulation and function in MPNST.  
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1.5. Management of neurofibromatosis 
type 1 
When neurofibromatosis type 1 is diagnosed, it has been recommended that 
they are referred to a specialised clinic that includes geneticists, 
paediatricians, neurologists and/or dermatologists (Ferner 2007). The 
management is determined by the age of the patient: specific monitoring of 
disease manifestations aiming to detect severe disease complications such 
as malignant peripheral nerve sheath tumours (MPNST) is important.  
1.5.1. Neurofibroma variants and likelihood 
of malignant transformation 
As discussed, neurofibromas are generally benign peripheral nerve sheath 
tumours and can be dermal (cutaneous), subcutaneous or plexiform. Dermal 
neurofibromas develop from the terminal branches of peripheral nerves and 
can be classified as focal/discrete or diffuse (Riccardi 2007). There have 
been no reports of focal or diffuse lesions undergoing malignant change but 
they often catch on clothing and cause cosmetic problems, transient stinging, 
itching and when numerous can cause major disfigurement and 
psychological stress (Riccardi 1981).  
Subcutaneous neurofibromas, in contrast, develop within a peripheral nerve 
and are surrounded by the perineurium (Riccardi 2007). Maunter et al. 
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(2008) observed association of MPNSTs with subcutaneous, but not 
cutaneous, neurofibromas (Mautner et al. 2008). 
Plexiform neurofibromas cause significant morbidity because they can grow 
along a nerve and may involve multiple nerves and form a plexus (Korf 1999; 
Tucker et al. 2005). The lesions can be nodular, and multiple discrete 
tumours may develop on nerve trunks. Plexiform neurofibromas can infiltrate 
soft tissue causing hypertrophy, or infiltrate bone in some cases (Korf 1999). 
The growth rate is variable and may be rapid, especially in adolescence, 
followed by periods of inactivity. Surgical removal of benign plexiform 
neurofibromas is usually very difficult due to encroachment of the tumour on 
surrounding structures and nerves. In addition, due to its inherent vascular 
nature severe haemorrhage may occur, especially with facial plexiform 
neurofibromas. Expert advice from experienced soft tissue tumour or plastic 
surgeons is essential before removal of facial plexiform neurofibromas 
(Ferner 2007). 
1.5.2. Neurological problems 
One of the important medical complications of neurofibromatosis type 1 is 
neurological dysfunction, which can include acute or progressive sensory 
disturbance, lack of coordination or sphincter disturbance and motor deficit, 
which might be the result of an intracranial lesion or spinal cord compression. 
Headaches on waking, morning vomiting and altered consciousness are 
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suggestive of raised intracranial pressure and constitute a neurological 
emergency (Ferner 2007).  
Neurological complications develop from tumours and malformations, 
including aqueduct stenosis; a narrowing of the aqueduct of Sylvius which 
blocks the flow of cerebrospinal fluid (CSF) in the ventricular system leading 
to hydrocephalus (Créange et al. 1999), skull deformities due to sphenoid 
wing dysplasia leads to pulsating exophthalmos as the temporal lobe 
herniates into the orbit (Korf 1992), severe scoliosis deforms the spine and 
can result in spinal cord compression and respiratory compromise (Korf 
1992). Neurological manifestations are the consequence of pressure on 
peripheral, spinal nerves or the spinal cord. Epilepsy occurs in approximately 
6–7% of neurofibromatosis type 1 individuals and it is usually mild, and is 
likely to be related to an underlying cortical dysgenesis (Vivarelli et al. 
2003). Sudden neurological deficit should be evaluated promptly for 
cerebrovascular disease. Cerebrovascular diseases include carotid artery 
stenosis or occlusion, cerebral haemorrhage or aneurysms. Treatment of 
cerebrovascular abnormalities in individuals with neurofibromatosis type 1 is 
identical to that in other patients and may include both surgical and medical 
options (Friedman et al. 2002). 
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1.5.3. Cognitive problems and behavioural 
difficulties 
Cognitive impairment is amongst the most common neurological 
complications in neurofibromatosis type 1 individuals and usually presents 
with the patient having a low average IQ; however severe intellectual 
impairment (IQ < 70) is rare (Ferner et al. 1996; North et al. 1997; Ozonoff 
1999).  
Approximately 70% of neurofibromatosis type 1 patients have learning 
problems or neuropsychological problems. Behavioural problems, sleep 
disturbance and impaired socialisation may also be found in 
neurofibromatosis type 1 patients (H. Johnson et al. 2005) 
1.5.4. Optic pathway gliomas 
The most common astrocytic (glial) tumours affecting about 15% of children 
with neurofibromatosis type 1 are gliomas involving the optic pathway (Optic 
pathway gliomas, OPG) (Listernick et al. 1997).  
Children with neurofibromatosis type 1-associated OPG generally have 
impaired visual acuity, visual field loss, abnormal colour vision, pupillary 
abnormalities, squint, pale optic disc, proptosis, and hypothalamic 
dysfunction. The majority of symptomatic OPG are children under 7 years; 
however older individuals rarely require medical intervention (Listernick et al. 
2004; Listernick et al. 1997). 
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1.5.5. Orthopaedic problems 
Bone lesions in individuals with neurofibromatosis type 1 include short 
stature, bowing of the long bones particularly tibial pseudoarthrosis (a false 
joint), dystrophic scoliosis, and sphenoid wing dysplasia (Friedman 2002). 
Pathologic fractures often occur due to cortical bone thinning. Surgery is 
needed and sometimes amputation is required. Pseudoarthrosis results from 
repeated fractures and defective healing (Alwan et al. 2007).  
Neurofibromatosis type 1 children should undergo yearly assessment of the 
spine aiming for early detection of scoliosis which affects 10% to 26% of 
neurofibromatosis type 1 patients (Dulai et al. 2007). Scoliosis is either 
idiopathic or dystrophic, dystrophic scoliosis is more severe and is marked by 
rapid progression, distortion of the vertebral bodies and ribs and the need for 
early spinal fusion (Yilmaz et al. 2007; Akbarnia et al. 1992).  
1.5.6. Cardiovascular abnormalities in 
neurofibromatosis type 1 
Cardiovascular manifestations of neurofibromatosis type 1 include congenital 
heart disease, especially pulmonary stenosis, vasculopathy, and 
hypertension (Friedman et al. 2002). 
At diagnosis, a careful examination of the heart should be undertaken with 
auscultation and blood pressure measurement and if murmur is present, the 
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child should be evaluated by a cardiologist for a cardiology opinion and 
echocardiography (Friedman et al. 2002).  
1.5.7. Glomus tumours 
Glomus bodies are small, encapsulated arteriovenous anastomoses in the 
dermis, commonly occur in the fingertips. The glomus tumour is usually 
solitary but multiple lesions have been observed in neurofibromatosis type 1 
individuals. The lesion is located most frequently under the fingernail and 
presents with pain, cold sensitivity, and localised tenderness. Glomus tumour 
symptoms should be differentiated from those caused by subcutaneous 
neurofibromas and the treatment is local excision of the tumour. Despite it is 
a rare condition, it should be recognised as an integral component of the 
neurofibromatosis type 1 spectrum of disease (Brems et al. 2009). 
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1.6. Malignant transformation of 
neurofibroma to MPNST 
Individuals with neurofibromatosis type 1 have an 8%–13% lifetime risk of 
developing MPNST (Evans et al. 2002). Most MPNSTs arise in plexiform 
neurofibroma. Cutaneous and subcutaneous neurofibromas have lower risk 
of malignant transformation with subcutaneous neurofibromas carry a 
relatively high risk of malignant transformation than cutaneous neurofibroma 
(Riccardi 2007; Tucker et al. 2005). 
1.6.1. Genetic mechanisms 
The molecular mechanisms which lead to malignant progression of 
neurofibromas to MPNST are largely unknown (Dasgupta 2003), although 
some genetic events have been implicated in this process.  
TP53 mutations have been reported in some MPNSTs but not in 
neurofibromas (Upadhyaya et al. 2008; Birindelli et al. 2001; Verdijk et al. 
2010; Legius et al. 1994; Menon et al. 1990). Upadhyaya et al. used DNA 
from 20 tumours and found evidence for loss of heterozygosity (LOH) across 
the TP53 region in 11 samples, with novel TP53 point mutations were also 
identified in four tumours (Upadhyaya et al. 2008). Holtkamp et al. detected 
TP53 mutation in only 11% of MPNST and this was associated with high-
grade tumours. In addition metastasis was linked to TP53 Pro (72) 
polymorphism (Holtkamp et al. 2007). However, Lothe and colleagues have 
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analysed 16 MPNSTs (11 patients with neurofibromatosis type 1 and 5 
sporadic cases) for mutations in the coding sequence of the TP53 gene 
(exons 2–11) and found none of their MPNSTs harboured mutations (Lothe 
et al. 2001). Verdijk et al. tested TP53 mutations in 72 MPNST tumours and 
detected TP53 mutations in 24% of the tumours tested (Verdijk et al. 2010). 
From all the above, I can conclude that the extent of TP53 mutation in 
human MPNST samples is variable.  
In animal models, a mice with cis-linked Nf1 and Trp53 null mutations (cis-
Nf1+/−;Trp53+/− mice) develop de novo MPNSTs (not on top of 
neurofibroma) (Cichowski et al. 1999).  
Using MPNST-derived cell lines Fang et al. showed that not only the cycle 
regulators in Rb1-cyclin D1 and the p53 pathways but also the cyclin 
activators of CDKs and inhibitory proteins such as p16 are involved in their 
uncontrolled proliferation (Fang et al. 2009). P16INK4A (CDKN2A) inactivation 
is identified using immunohistochemistry in 50% of malignant peripheral 
nerve sheath tumours (Nielsen et al. 1999). Kourea et al. detected P16INK4A 
deletions in 4 out of 8 patients with MPNSTs studied but no deletion detected 
in neurofibromas (Kourea et al. 1999). Perry et al. studied the genetic 
changes in MPNST compared to benign nerve sheath tumours and detected 
p16 deletions in 75% of MPNSTs, but not in benign nerve sheath tumours 
(Perry et al. 2002).  
P a g e  | 66 
   
  
Gregorian et al. showed that K-RAS activation in combination with a single 
Pten allele deletion prompted 100% penetrable development of neurofibroma 
lesions and resulting progression to MPNST. Vitally, loss or decrease in 
PTEN expression was found in all murine MPNSTs and in most of human 
neurofibromatosis type 1-related MPNST lesions, recommending that PTEN 
dose and its controlled signaling pathways are critical for change of 
neurofibromas to MPNST (Gregorian et al. 2009). 
In another study, Keng et al. created transgenic mice that lack both Pten and 
Nf1 in Schwann cells and found that that complete loss 
of Pten accelerated neurofibroma development and led to the development 
of higher grade MPNSTs in the context of Nf1 loss compared to the control 
(WT) mice. They also showed that genetic analysis of human MPNSTs also 
showed downregulation of PTEN expression (Keng et al. 2012). 
Alterations of gene expression have been identified through a variety of 
different genome-wide analyses using different platform technologies 
including gene expression microarray (Henderson et al. 2005; Miller et al. 
2006; Subramanian et al. 2010), microRNA (miRNA) array (Subramanian et 
al. 2010; Itani et al. 2012; Masliah-Planchon et al. 2013) or methylome 
analysis (Feber et al. 2011). Mo et al. (2013) showed that the chemokine 
receptor CXCR4 and its ligand, CXCL12, promote MPNST growth by 
stimulating cyclin D1 expression and cell-cycle progression through PI3-
kinase (PI3K) and β-catenin signalling (Mo et al. 2013).  
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Rahrmann et al. compared human data sets and identified many cooperating 
mutations that are enriched in Wnt/β-catenin, PI3K-AKT-mTOR, and growth 
factor receptor signaling pathways. They also showed that Foxr2 (encoding 
fork head box R2) is involved in MPNST growth maintenance (Rahrmann et 
al. 2013).  
Recently, SUZ12 has been suggested to have a role in malignant 
progression of neurofibroma to MPNST where Zhang et al. performed 
targeted sequencing on 50 MPNST cases. They found that 16 MPNST cases 
have SUZ12 mutation however none of the neurofibroma cases was mutant 
for SUZ12 (M. Zhang et al. 2014). Lee et al. identified highly frequent loss of 
function somatic mutations in Polycomb repressive complex 2 (PRC2) 
components (SUZ12 and EED) in MPNSTs but not in neurofibromas (Lee et 
al. 2014). In another report De Raedet et al. described that SUZ12 function 
as tumour suppressor by cooperating with RAS activation pathway and has a 
role in MPNST progression (De Raedt et al. 2014). 
All the above observations suggest that progression of neurofibroma to 
MPNST may require many cooperating genomic alterations. In part due to 
this complexity, the process of MPNST pathogenesis is still poorly 
understood, this is exacerbated because of its complex histopathological 
characteristics (Upadhyaya 2011; Sedani et al. 2012).  
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1.6.2. Epigenetic mechanisms 
Epigenetics is defined as “the field of research study of heritable 
modifications which able to influence gene expression in a stable manner 
without altering the DNA sequence” (Russo et al. 1996; Bird 2007). These 
modifications include histone modifications, miRNA post-transcriptional 
regulation and DNA methylation (Russo et al. 1996; Bird 2007). Epigenetic 
modifications are as important in cancer development as genetic changes 
(Baylin & Ohm 2006; Issa 2004; Jones & Baylin 2007; Plass et al. 2013). 
As I discussed in the previous section (‎1.6.1) that progression of 
neurofibroma to MPNST may require many cooperating genomic alterations. 
In addition, the process of MPNST pathogenesis is still poorly understood, 
so I sought for epigenetic alterations that might have a role in the 
development and progression of nerve sheath tumours. 
1.6.2.1. MicroRNAs 
1.6.2.1.1. History and biogenesis of miRNAs 
MicroRNAs (miRNAs) are small (20 - 23 nucleotides) non-coding RNAs. 
MiRNAs are generally highly conserved among species (Lagos-Quintana et 
al. 2003). MicroRNAs are involved in fine-tuning gene expression networks 
controlling a wide range of biological and pathological processes. MicroRNAs 
can influence a wide variety of biological processes, including development, 
cell proliferation, differentiation and cell death (Schickel et al. 2008). 
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MicroRNAs regulate gene expression by hybridising to complementary target 
mRNAs, resulting in either translation inhibition or mRNA degradation 
(Ambros 2001; Bartel 2004). Guo et al. showed that the effect of miRNA is 
mostly on lowering mRNA level and lowered mRNA levels account for ≥ 84% 
of the decreased protein production in mammalian cells (Guo et al. 2010). 
The first miRNA discovered was lin-4 in 1993 by Victor Ambros and 
colleagues in a study on Caenorhabditis elegans (C. elegans). They 
discovered that lin-14 was able to be regulated by a short RNA product from 
lin-4, a gene that transcribed a 61 nucleotide precursor that matured to a 22 
nucleotide mature RNA which contained sequences partially complementary 
to multiple sequences in the 3′ UTR of the lin-14 mRNA. This 
complementarity was sufficient and necessary to inhibit the translation of lin-
14 mRNA (Lee et al. 1993). Seven years later the Ruvkin laboratory 
discovered another miRNA, let-7. They showed that let-7 directs the latter 
stages of C. elegans development in a similar manner to lin-4; let-7 
represses lin-41, lin-14, lin-42, lin-28 and daf-12 mRNA during transitions in 
developmental stages (Reinhart et al. 2000).   
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1.6.2.1.2. MicroRNAs and Cancer 
Like other developmental regulators, miRNAs have been shown to be 
involved in cancer. Early in miRNA research, Calin et al. (2002) detected a 
frequent deletion of miRNA genes miR-15 and miR-16 in 65% of B-cell 
chronic lymphocytic leukaemia patients (Calin et al. 2002). The link between 
miRNA dysregulated expression and cancer risk has since been 
demonstrated in different types of cancer. Breast cancer risk is found to be 
correlated the deregulation of miR-125b, miR-145, miR-21, and miR-155 
expression (Iorio et al. 2005). In addition, lung cancer patients poor survival 
is correlated with up-regulation of miR-155 and downregulation of let-7a 
(Yanaihara et al. 2006). Recently, Que et al. demonstrated a link between 
glioma poor prognosis and decreased expression of miR-637 and showed an 
increase in glioma cell growth and invasion with decreased expression of 
miR-637 (Que et al. 2015). In the diagnosis of the origin of metastatic 
tumour, miRNAs can be suggested to be accurately used for identification of 
tumour tissue origin and help in classification of the poorly differentiated 
cancers (Rosenfeld et al. 2008). 
A miRNA can act as a tumour suppressor when its functional loss can cause 
the malignant transformation of a normal cell. MicroRNAs with proven tumour 
suppressor functions are miR-15, miR-16, miR-29 family, and let-7 (Cimmino 
et al. 2005; S. M. Johnson et al. 2005; Mott et al. 2007). Cimmino et al. 
showed that miR-15 and miR-16 induce apoptosis by targeting BCL2 in 
BCL2-overexpressing chronic lymphocytic leukaemia (Cimmino et al. 2005). 
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Johnson et al. showed that let-7 regulate RAS genes in lung cancer by 
targeting let-60/RAS 3′ UTR, furthermore, let-7 expression is lower in lung 
tumours compared to normal lung tissue, while RAS protein is significantly 
higher in lung tumours (S. M. Johnson et al. 2005). Mott et al. identified that 
miR-29 family targets Mcl-1 mRNA and miR-29b was downregulated in 
malignant cells which is consistent with the upregulation of Mcl-1 protein 
(Mott et al. 2007). miR-29b was also found to be regulating angiogenesis, 
invasion, and metastasis of hepatocellular carcinoma partly through MMP2 
suppression (Fang et al. 2011). In addition, miR-155 has shown a tumour 
suppressor role in acute cell leukaemia through induction of apoptosis and 
suggested that miR-155 can be used as a target for therapy in future 
(Alizadeh et al. 2014). miR-145 was downregulated in a stepwise way in non-
tumourous gastric mucosa, primary gastric cancers, and theirs secondary 
metastases. In addition, ectopic expression of miR-145 suppresses gastric 
cancer cell migration and invasion (Gao et al. 2013). Decreased expression 
of miR-637 stimulated increase in glioma cell growth and invasion through 
targeting RAC-alpha serine/threonine-protein kinase (Akt1) protein (Que et 
al. 2015). In hepatocellular carcinoma, miR-7 inhibits tumourogenesis and 
metastasis through targeting PIK3CD, mTOR, and p70S6K (Fang et al. 
2012). Wang et al. showed that miR-194 acts as a tumour suppressor in 
colorectal cancer by regulating the MAP4K4/c-Jun/MDM2 signaling pathway 
and can serve as a target for colorectal cancer prevention and therapy 
(Wang et al. 2015). 
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Some other miRNAs, such as miR-21 and miR-155, act as oncogenes in 
different types of cancer (Kluiver et al. 2005; Chan et al. 2005; Medina et al. 
2010; Valeri et al. 2010). Chan et al. showed that miR-21 acts as an anti-
apoptotic factor in human glioblastoma (Chan et al. 2005). miR-21 
overexpression caused a pre-B malignant lymphoid like phenotype, while 
inactivation of miR-21 in the same model caused apoptosis and tumour 
suppression (Medina et al. 2010). miR-155 is highly expressed in Hodgkin’s, 
primary mediastinal and diffuse large B cell lymphomas (Kluiver et al. 2005). 
In colorectal cancer miR-155 repress the expression of the core MMR 
proteins, hMSH2, hMSH6, and hMLH1, inducing a mutator phenotype, and 
subsequently interferes with the process of mismatch repair (Valeri et al. 
2010). In colorectal Cancer miR-301a, which is upregulated, was found to 
function as an oncogene and promote cell growth and Invasion through 
targeting SOCS6 (Suppressor of cytokine signaling 6) protein (Fang et al. 
2015). 
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1.6.2.1.3. MicroRNA and nerve sheath tumours 
The role of miRNAs in the development of peripheral nerve sheath tumours 
in the context of neurofibromatosis type 1 has rarely been discussed. In 
2010, Subramanian et al. published a report on miRNA expression profiling 
for 482 known and predicted human miRNA on 23 peripheral nerve sheath 
tumours (6 MPNSTs, 11 neurofibromas, and 6 schwannomas). Not all of the 
tumours were obtained from patients with neurofibromatosis type 1. Five 
miRNAs (miR-214, miR-377, miR-409-3p, miR-487b, and miR-99b) were 
relatively up-regulated and five miRNAs (miR-517, miR-34a, miR-29a, miR-
30e-5p, and miR-27a) were downregulated in MPNST compared to 
neurofibromas (Subramanian et al. 2010). In addition, gene expression 
profiling performed on the same samples showed that the majority of 
MPNSTs selected for miRNA profiling in this study showed the gene 
signature for p53 inactivation. Because p53 is a transcription factor and miR-
34a is one of the known direct transcriptional targets of p53, they selected 
miR-34a for further functional characterisation. Forced expression of either 
p53 or its direct transcriptional target miR-34a in the MPNST-14 cell line 
induced apoptosis in these MPNST cells, thereby demonstrating that the 
expression of p53 mediates its effect through its target miR-34a. They also 
showed that the effect of miR-34a on apoptosis is mediated through targeting 
MYCN, E2F, and CDK4 whereas the expression of these genes in 
suppressed in miR-34a transfected MPNST cells. Subramanian et al. also 
showed that overexpressing wild-type p53 in the MPNST cell line caused a 
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significant increase in the levels of miR-34a, miR-34b, miR-34c, miR-638, 
miR-373∗, miR-492, miR-126, miR-140, miR-491, and miR-296; confirming 
that in MPNST, miR-34a expression is dependent on p53 activation status 
(Subramanian et al. 2010). 
Lee et al. exploited the findings from the functional studies of Subramanian 
et al., employing a computational systems biology approach, identified a 
regulatory network which involves E2F7/E2F8 transcription factors in several 
cell cycle related gene modules. They hypothesised that the interactions 
between E2F7/E2F8 and gene modules in the network are probably indirect 
since their expression levels are all increased after miR-34a overexpression. 
They concluded that the biological activities associated with p53/miR-34a 
that are commonly observed in cancers, including MPNST may also be 
mediated through the imbalance of the E2F transcription factor activities. 
This raises the possibility of modulating the interactions between miR-34a 
and E2F transcription factor family in cancer treatment (Lee et al. 2012). 
The loss of NF1 function is usually by bi-allelic inactivation that is classically 
brought about by a inactivation mutation of one allele followed by a second 
hit of inactivation mutation of the second wild-type allele in the tumour tissue 
(Berger et al. 2011). Chai et al. (2010) hypothesised that one of the two hits 
needed for the loss of function might result from silencing by a miRNA. There 
is good evidence that other tumour suppressor genes, including p53, can be 
silenced by a similar mechanism (Swarbrick et al. 2010). Chai et al 
performed a comparison between the neurofibromatosis type 1-associated 
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MPNST cell line (ST88-14) versus sporadic MPNST cell line (STS26T). 
Results showed that the oncogenic miRNAs, miR-10b, miR-155, and miR-
335, exhibited selective higher expression in ST88-14. However, expression 
of let-7 family members, let-7a-f, known to target RAS, was significantly 
lower in ST88-14 than in STS26T cells. They also tested the expression level 
of miR-10b in human samples and showed that the expression level of miR-
10b was significantly higher in comparison to benign neurofibromas in the 
setting of neurofibromatosis type 1 but not in sporadic MPNSTs, while let-7a 
and let-7b were significantly lower in both neurofibromatosis type 1 MPNSTs 
and sporadic MPNSTs. In addition, the expression level of miR-10b was 
significantly higher in neurofibromatosis type 1 MPNSTs than in sporadic 
MPNSTs although slightly elevated. However, insignificant expression levels 
of miR-335 and miR-155 were observed in neurofibromatosis type 1 
MPNSTs compared with in sporadic MPNSTs. To summarise, the expression 
of miR-10b is higher in neurofibromatosis type 1 MPNST samples and cell 
lines compared to sporadic MPNSTs. Next, Chai et al. (2010) investigated 
the functional significance of the deregulated miRNAs observed form the 
previous experiment by transfecting ST88-14 cells with antisense inhibitors 
(miR-10b, miR-155, and miR-335), mimic enhancers let-7a, or with negative 
controls. Results showed that inhibiting miR-10b expression in ST8814 cells 
significantly decreased cell proliferation, migration, and invasion (Chai et al. 
2010). 
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A tumour suppressor role is suggested for miR-204, which is downregulated 
in MPNST human samples and cell line. Restoration of miR-204 in MPNST 
cell lines In vitro, significantly suppressed cell proliferation migration and 
invasion. In addition, further in vivo study showed that Restoration of miR-
204 expression in STS26T suppressed tumour growth and malignant 
progression. They reported that these functions for miR-204 are through 
inhibition of RAS signalling by targeting HMGA2 (Gong et al. 2012).  
On that other hand, an oncogenic role is suggested for miR-210 through 
targeting ephrin-A3 (EFNA3) which has been proved to be a target of miR-
210. In vitro overexpression of miR-210 in MPNST cell line increased cellular 
viability, colony formation, S phase percentage, and invasiveness 
of MPNST cells. However, suppression of miR-210 expression decreased 
proliferation and invasion of MPNST cells (Z. Wang et al. 2013). 
Itani et al. (2012) examined the miRNA expression profile of six MPNSTs 
with those of six neurofibromas. Results showed that miR-21, miR-135b, 
miR-152, miR-130b, miR-92, and miR-15b were upregulated in MPNST 
compared to neurofibromas, whereas the expression levels of miR-125b, 
miR-127, and miR-302d were downregulated in MPNST compared to 
neurofibromas. They focused their research on miR-21 and found that 
transfection of miR-21 inhibitor significantly increased caspase activity, 
suppressed cell growth, and upregulated protein level of PDCD4, indicating 
that miR-21 inhibitor could induce cell apoptosis of MPNST cells (Itani et al. 
2012).  
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Another study analysed miRNAs expression in a large panel of dermal and 
plexiform neurofibromas and MPNSTs. Of those that the most significantly 
downregulated miRNAs in MPNST relative to neurofibroma were miR-139-
5p, miR-150, miR-338-3p, miR-195, miR-146a, miR-95, let7b, miR-186, 
miR885-5p and miR-200c. However, there were also a number of 
upregulated miRNAs in MPNST relative to neurofibroma including miR-301a, 
miR-301b, miR-9, miR-19a, miR-106b, miR-135a and miR-10b (Masliah-
Planchon et al. 2013). 
From the above in can be concluded that miRNA expression in nerve sheath 
tumour has been studied in few studies, which show different expression 
profiles. These discrepancy in results can be explained by differences in the 
methodologies used (different miRNA expression platform) or to the use of 
different groups of patients based on differences in NF1 diagnostic 
criteria. 
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1.6.2.2. DNA methylation 
1.6.2.2.1. Regulation of gene expression through 
DNA methylation 
DNA methylation is a covalent modification of the cytosine ring at the 5′ 
position of a CpG dinucleotide, where a methyl group is added on the carbon 
5 of that ring using S-adenosyl methionine as a methyl donor. In the DNA 
replication process, transfer of methyl group reaction is catalysed by DNA 
methyltransferases (DNMTs) present at the replication fork during the S-
phase (Klose & Bird 2006). 
The usual targets of DNA methylation in mammals, CpG dinucleotides, are 
scattered throughout the genome (Glass et al. 2007). Recently, abundant 
DNA methylation in non-CpG contexts has been described at a genome-wide 
level in stem cells and some other mammalian cells; however CpG 
dinucleotides remain the primary site for DNA methylation in mammals 
(Lister et al. 2009; Pinney 2014).  
CpG islands (CGIs) are areas of the genome where a high concentration of 
these CpG dinucleotides are found (Illingworth & Bird 2009). The average 
CGI is about 1000 base pairs and approximately 50% of genes have one or 
more CpG islands in the 5′ promoter region. In a non-neoplastic differentiated 
cell, CpG loci are highly methylated genome-wide; except for the promoter 
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CGIs, which are generally not methylated (Jones 2012; Illingworth & Bird 
2009).  
One of the mechanism of silencing by DNA methylation is through direct 
inhibition of transcription factors binding to their target sites using the methyl-
binding domain (MBDs) proteins (Klose & Bird 2006). The second possible 
mechanism is that methyl-CpG binding proteins (MBPs), that one family of 
proteins that recognise methyl-CpG and cause repressive effect on 
methylated DNA (Kass et al. 1997; Qu et al. 2013). 
Ball et al. observed a pattern of low promoter methylation coupled with 
high gene body methylation in highly expressed genes and confirmed 
that gene body methylation in highly expressed genes is a consistent 
phenomenon over the entire genome (Ball et al. 2009). One of the most 
commonly cited features of cancer DNA methylation concerns directional 
hypomethylation of DNA satellite repeats (Ehrlich 2002; Wilson et al. 2007). 
 
1.6.2.2.2. DNA methyltansferases (DNMTs) 
In mammals, DNA is methylated by a group of enzymes called DNMT1, 
DNMT3A, and DNMT3B. A further protein in this family lacks catalytic activity 
and is called DNMT3L (DNA methyltransferase 3-like). I will discuss each of 
these important methylation regulators here in the context of cancer and 
MPNST. 
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DNMT1 is responsible for maintenance of methylation and is therefore called 
the “maintenance methyltransferase.” DNMT1 prefers to target the 
hemimethylated DNA (with methylation of only one DNA strand) 10 fold more 
than the unmethylated strand. The function of DNMT1 in the cell is to keep 
the DNA methylation status stable throughout cell division (Jones & Liang 
2009), whereas DNMT3A and DNMT3B methylate previously unmethylated 
DNA in the mammalian cell, hence called de novo methyltransferases 
(Okano et al. 1999). 
1.6.2.2.3. DNA methylation and 
neurofibroma/MPNST 
Tumour development is a result of the activation of oncogenic and/or 
inactivation of tumour suppressor pathways. The hypermethylation of the 
promoters of tumour suppressor genes and the hypomethylation of the 
promoters of oncogenes have been shown to represent a distinct molecular 
pathway leading to cellular malignant transformation. DNA methylation 
silences a tumour suppressor gene in an equivalent manner to silencing the 
expression of genes through genetic changes (Baylin & Ohm 2006; Issa 
2004; Jones & Baylin 2007). The role of aberrant DNA methylation in the 
development and progression of human cancer has been studied in several 
tumours including breast, lung and colorectal cancers (Barault et al. 2008; 
Ordway et al. 2007; Vaissière et al. 2010) .  
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In the past 30 years, there was much Improvement in the technology to 
investigate DNA methylation. The first generation of methylation detection 
assays employed the digestion of genomic DNA with a methylation-sensitive 
restriction enzyme followed by either Southern blot analysis or PCR (Singer-
Sam et al. 1990) but these techniques have some limitations leading to the 
generation of false positive results due to incomplete digestion. 
A second generation of techniques uses bisulfite treatment of genomic DNA 
to convert unmethylated cytosines to uracils, while methylated cytosine 
residues will remain intact (Frommer et al. 1992). The bisulfite converted 
DNA can then be analysed either by methylation-specific PCR (MSP) or 
bisulfite sequencing. In MSP, PCR amplification was performed with primers 
that anneal specifically with either the converted methylated or converted 
unmethylated sequence (Herman et al. 1996). In contrast, in bisulfite 
sequencing the PCR reaction is undertaken by primers that do not 
themselves cover any CpG dinucleotides sites in the original genomic DNA 
(Frommer et al. 1992; Clark et al. 1994; Clark et al. 2006). A quantitative 
bisulfite sequencing method is called pyrosequencing, which produce 
quantifiable signals per each CpG being measured. Pyrosequencing has the 
disadvantage of allowing evaluation of only short regions (average 150 bp) 
per amplicon (Tost & Gut 2007; Shanmuganathan et al. 2013). One of the 
recent approaches to test regional DNA methylation changes at a genome-
wide scale is MeDIP sequencing which is based on the chromatin immune-
precipitation of methylated fragments (Weber et al. 2005). With this method, 
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methylated DNA is enriched from an initial DNA sample through 
immunoprecipitation with an anti-methylcytosine antibody (MeDIP). DNA 
samples enriched for methylated DNA are then hybridised to microarray 
chips (MeDIP-Chip) for identification of the locations with DNA methylation 
(Shanmuganathan et al. 2013; Weber et al. 2005).  
Feber et al. (2010) compared the methylome profile of neurofibromas and 
MPNSTs from patients with neurofibromatosis type 1 using a sequencing-
based comparative methylome analysis by MeDIP-seq. Results showed that 
there were no significant global hypomethylation in MPNST; this is different 
from what has been reported for other tumour types (Zhang et al. 2012; 
Baylin & Ohm 2006; Issa 2004). However, satellite repeats showed a highly 
significant (p < 0.001) directional difference DNA methylation, suggesting 
these repeats represent the main target for hypomethylation in MPNST 
(Feber et al. 2011).   
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1.7. Aims 
At present, there are no available markers either immunohistochemical, 
genetic or epigenetic to make this distinguish benign neurofibroma from 
MPNST. Therefore, from a clinical diagnostic and management perspective, 
one of the immediate needs is to identify molecular alterations that drive 
and/or are associated with this progression of this disease to use as 
candidate prognostic biomarkers for subsequent validation in clinical trials.  
In this thesis, the difference in miRNA expression between neurofibroma and 
MPNST will be tested with the aim of discovering if miRNAs have a role in 
transformation for neurofibroma to MPNST. In addition, the differences in 
DNA methylation between neurofibroma and MPNST based on the 
methylome analysis performed previously by my colleagues will be assessed 
(Feber et al. 2011). The relation between miRNA expression and DNA 
methylation in nerve sheath tumours will be assessed.  
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2. Materials and methods 
2.1. Clinical samples 
All research using human tissue samples complied with standards laid down 
by the Central Office for Research Ethics Committees (COREC) and was 
approved by the relevant ethics committees under the study number (REC 
07/Q0506/8). All human tissue was handled as recommended by the Human 
Tissue Act 2004. 
Fresh frozen tissue samples from 10 neurofibromas and 10 MPNSTs were 
obtained from the Royal National Orthopaedic Hospital Stanmore, UK and 3 
samples were kindly provided by Dr Fredrik Mertens from Lund University 
Hospital in Sweden. Details of the fresh frozen tissue samples used for this 
study are given in Table 2-1 and Table 2-2. The fresh frozen neurofibromas 
and MPNSTs were all from patients with neurofibromatosis 1. 
35 cases of soft tissue sarcomas were also obtained from the National 
Orthopaedic Hospital, Stanmore. These were comprised of 4 neurofibromas, 
3 MPNSTs, 4 liposarcomas, 4 osteosarcomas, 4 synovial sarcomas, 4 
rhabdomyosarcomas, 3 solitary fibrous tumours, 3 fibromatosis desmoid 
type, 2 chondromas and 2 chondroblastomas.  
Formalin fixed paraffin embedded (FFPE) tissue samples from 80 
neurofibromas and 80 MPNSTs were obtained from the histopathology 
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archives of the Royal National Orthopaedic Hospital, Stanmore, UK. Blocks 
with no evidence of tissue necrosis and minimal calcification were chosen 
dating from 2000 to 2010. Details of the FFPE neurofibromas and MPNSTs 
used are given in Table ‎2-3 and Table ‎2-4 respectively.  
All human tissue samples were sectioned and reviewed by a pathologist 
following H&E staining. Diagnosis and grading of samples was carried out in 
accordance with the World Health Organization (WHO) (Kleihues et al. 2002; 
Fletcher & Unni 2002).  All MPNSTs used in this study met with one of the 
following inclusion criteria: 
 The tumour arose from a peripheral nerve. 
 The tumour arose from a benign nerve sheath tumour (neurofibroma). 
 The tumour displayed histologic features of Schwann cell 
differentiation. 
 The tumour arose in a patient with neurofibromatosis type 1 and 
showed the same histological features of most MPNSTs. 
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Table ‎2-1: Neurofibroma (fresh frozen) 
 
Sample No. Atypia Classification  Aetiology 
1 No Plexiform NF1 
2 No Plexiform NF1 
3 No Plexiform NF1 
4 No Plexiform NF1 
5 No Plexiform NF1 
6 No Plexiform NF1 
7 No Plexiform NF1 
8 No Plexiform NF1 
9 No Plexiform NF1 
10 No Plexiform NF1 
 
Key: NF1= neurofibromatosis type 1. 
 
 
Table ‎2-2: MPNST (fresh frozen) 
 
Sample No. Grade Differentiation  Aetiology 
1 3 No NF1 
2 3 No NF1 
3 3 No NF1 
4 3 No NF1 
5 3 No NF1 
6 3 No NF1 
7 3 No NF1 
8 3 No NF1 
9 3 No NF1 
10 3 No NF1 
 
Key: NF1= neurofibromatosis type 1.  
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Table ‎2-3: Archival neurofibromas (continued on next page) 
 
No. Atypia Classification Aetiology Presentation Site Age Gender 
1 - N S P buttock 70 M 
2 - N S P forearm 22 F 
3 Yes Plexiform NF1 P finger 
  
4 - Plexiform NF1 R popliteal fossa 24 M 
5 - N S P cutaneous 37 F 
6 Yes N NF1 R multiple 47 F 
7 - N NF1 R arm 57 M 
8 - Plexiform NF1 P tibia 13 M 
9 - N S P cutaneous 40 F 
10 - N NF1 R arm-neck 22 M 
11 - N NF1 R abdominal wall 27 M 
12 - N S P arm 46 F 
13 - N S P leg 18 F 
14 - N S P buttock 29 M 
15 - N NF1 P cutaneous 89 F 
16 Yes N NF1 P leg 51 F 
17 - Plexiform NF1 P leg 15 
 
18 - N S P cutaneous  F 
19 - N S P abdominal wall  M 
20 - N S P arm  M 
21 - N S P buttock  F 
22 - N S P cutaneous  F 
23 - N S P cutaneous  F 
24 - N S P leg  F 
25 - N S P arm  F 
26 - N S P buttock  M 
27 - N S P cutaneous 46 F 
28 - N S P cutaneous  M 
29 - N S P buttock  F 
30 - N S P 
 
 M 
31 - N S P cutaneous  M 
32 - N S P forearm  F 
33 - N S P 
 
 F 
34 - N S P cutaneous  M 
35 - N S P buttock  F 
36 - N S P cutaneous  F 
37 - N S P arm  M 
38 - N S P arm  M 
39 - N S P 
 
38 M 
40 - N S P leg  M 
  
 Key: -= none; N= nodular; S= sporadic; NF1= constitutional NF1 gene mutation; 
 P= primary; R= recurrence; Blank box= unknown 
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Table 2-3:  Archival neurofibromas (continued)  
 
No. Atypia Classification Aetiology Presentation Site Age Gender 
41 Yes Plexiform NF1 P cutaneous  M 
42 - N NF1 P cutaneous  F 
43 - N NF1 P arm  F 
44 - Plexiform NF1 P arm  M 
45 - N S P buttock  F 
46 Yes Plexiform NF1 P arm  M 
47 - N S P cutaneous  F 
48 - Plexiform NF1 P leg  M 
49 - N S P cutaneous  F 
50 - N S P 
 
 F 
51 - N NF1 P buttock  F 
52 - Plexiform NF1 P arm  F 
53 - N S P leg  M 
54 - Plexiform NF1 P cutaneous  M 
55 Yes Plexiform NF1 P abdominal wall  M 
56 - N S P cutaneous  M 
57 - N S P 
 
 F 
58 - N S P arm  M 
59 - N S P cutaneous  M 
60 - N S P 
 
 M 
61 - N S P ulnar nerve  M 
62 - Plexiform NF1 P 
 
 M 
63 - No S P forearm  M 
64 - Plexiform NF1 P   M 
65 - N S P   M 
66 - Plexiform NF1 P   F 
67 - N S P cutaneous  F 
68 - Plexiform NF1 P cutaneous  M 
69 - N NF1 P cutaneous  
 
70 - Plexiform NF1 P   M 
71 - N S P   F 
72 - N S P arm  F 
73 - N S P 
 
 F 
74 - N S P leg  M 
75 - N S P cutaneous  M 
76 - N S P   M 
77 - N S P   F 
78 - Plexiform NF1 P cutaneous  F 
79 - N S P 
 
 F 
80 - N NF1 P Lumbar  29 M 
 
Key: -= none; N= nodular; S= sporadic; NF1= constitutional NF1 gene mutation;  
P= primary; R= recurrence; Blank box= unknown  
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Table ‎2-4: Archival MPNSTs (continued on next page) 
 
No. Grade Differentiation  
Aetiolo
gy 
Presentation Site Age 
 
Sex 
 
1 1 - S R leg 54 F 
2 1 - S P thigh 64 F 
3 1 - S P arm 15 F 
4 1 - S P paraspinal (lumbar) 23 F 
5 2 - S R brachial plexus 38 F 
6 2 Epithelioid S P elbow 69 M 
7 2 - S P thigh 24 F 
8 2 - S P shoulder 63 M 
9 2 - S P big toe 56 F 
10 2 - S P paraspinal (lumbar) 16 M 
11 2 - S P thigh 60 F 
12 2 - S P paraspinal (cervical) 34 M 
13 2 - S P forearm 12 M 
14 2 - S P leg 64 F 
15 2 - NF1 P leg 28 F 
16 2 - S R shoulder 31 F 
17 2 - NF1 R paraspinal (lumbar) 43 F 
18 2 - S P forearm 73 F 
19 2 - S P forearm 25 M 
20 2 - S P buttock 19 F 
21 2 Trition S P thigh 52 F 
22 2 Trition S R buttock 16 M 
23 2 - NF1 P thigh 43 F 
24 2 - NF1 P brachial plexus 12 M 
25 3 Trition S P thigh 35 M 
26 3 - S P thigh 62 M 
27 3 - S R arm 21 F 
28 3 - S P thigh 73 M 
29 3 - S P arm 5 F 
30 3 Trition S P pelvis 24 F 
31 3 Osteosarcomatous S P thigh 72 M 
32 3 - S R leg 44 F 
33 3 - S P brachial plexus 37 M 
34 3 - S R paraspinal (lumbar) 71 M 
35 3 - S P brachial plexus 50 M 
36 3 - NF1 P sacrum 19 F 
37 3 - S P 
iliac fossa 
/abdominal wall 
25 F 
38 3 - NF1 R buttock 32 M 
39 3 Trition S P thigh 78 M 
40 3 - S P thigh 52 M 
 
Key: -= none; S= sporadic; NF1= constitutional NF1 gene mutation; P= primary;           
R= recurrence; Blank box= unknown  
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Table 2-4: Archival MPNSTs (continued) 
 
No. Grade Differentiation Aetiology Presentation Site Age 
 
Sex 
 
41 3 No S P arm 64 M 
42 3 No S R paraspinal (lumbar) 18 M 
43 3 No S R paraspinal (thoracic) 27 M 
44 3 No S R arm 62 F 
45 3 No NF1 R leg 20 F 
46 3 No NF1 P arm 61 F 
47 3 Epithelioid NF1 R thigh 63 F 
48 3 No NF1 P brachial plexus 35 F 
49 3 No NF1 P pelvis 54 F 
50 3 No S  knee 23 M 
51 3 No S R knee NK M 
52 3 No S R pelvis 30 F 
53 3 No NF1 R back 58 M 
54 3 No S R chest wall 94 F 
55 3 No S R paraspinal (lumbar) 16 M 
56 3 No S R paraspinal lumbar 25 M 
57 3 No S R chest wall 61 F 
58 3 Trition S P chest wall 58 F 
59 3 No S P forearm 52 F 
60 3 No S P wrist 84 F 
61 3 Trition S R thigh 62 M 
62 3 No NF1 P buttock 49 M 
63 3 No S P arm 52 F 
64 3 No S R arm 78 F 
65 3 No NF1 P leg 49 F 
66 3 No S P chest wall 46 M 
67 3 No S P forearm 68 F 
68 3 Trition S R thigh 30 M 
69 3 No S P popliteal fossa 48 F 
70 3 No S P paraspinal  57 F 
71 3 No S P arm (brachial plexus) 60 F 
72 3 No S P thigh 36 M 
73 3 No S R leg 44 F 
74 3 No S P arm 27 F 
75 3 No S P buttock 36 F 
76 3 No NF1 P thigh 26 F 
77 3 Trition S P paraspinal 41 M 
78 3 No S P thigh 43 M 
79 3 No S P thigh 72 M 
80 3 Epithelioid S Re-existion brachial plexus 34 M 
 
Key: -= none; S= sporadic; NF1= constitutional NF1 gene mutation; P= primary;           
R= recurrence; Blank box= unknown   
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2.2. Cell Lines 
2.2.1. MPNST-derived cell line sNF96.2 
The human MPNST-derived cell line sNF96.2 was kindly provided by Dr 
Abhijit Guha from The Hospital for Sick Children, Toronto, Ontario, Canada. 
The cell line was originally derived from a nerve tissue-associated recurrent 
mass diagnosed as MPNST in a neurofibromatosis type 1 patient. The cell 
line is karyotypically abnormal with complete LOH (no detection of the 
remaining NF1 allele) and a mutation in exon 21 (3683delC) of the identified 
NF1 germline causing a frameshift which leads to a premature stop codon 
(Perrin et al. 2007). The reported germline mutation in exon 21 (3683delC) 
and loss of the remaining wild-type (WT) allele in the cell line were confirmed 
before use in my study. The presence/absence was compared to HT1080 
WT for NF1 (Table ‎2-5 for primers sequences).  
Table ‎2-5: List of primer sequences used for direct sequencing NF1 gene 
 
Primer Name Primer Sequence (5′ -> 3′) 
NF1-exon21-Forward TTGCATCTGTTTGTCCACATT 
NF1-exon21-Reverse CACTTTTCTTCCCCGCTTAC 
2.2.1. Other cell lines 
The HT1080 and HEK293T cell lines were originally purchased by our lab 
from the American Type Culture Collection (ATCC). These cell lines were 
used for various experiments detailed below. 
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2.3. RNA extraction from frozen cells 
sections and cell lines 
2.3.1. MiRNeasy Mini Kit (Qiagen) 
Total RNA was extracted from fresh frozen tissue and cell lines using the 
miRNeasy extraction kit (Qiagen Ltd, Crawley, West Sussex, UK), following 
the manufacturer’s instructions. This kit allows the extract of all RNA species 
including the small RNA fraction containing miRNAs amongst others.  
Before starting any RNA extraction, the bench surface and Pipettes were all 
cleaned with RNaseZAP (Ambion) and all precautions necessary were taken 
throughout RNA extraction procedure to avoid RNA degradation. RNA 
extractions were carried out on an RNA dedicated area. In addition, a 
separate set of pipettes was devoted for RNA extraction, and aerosol 
barrier pipette tips were used. 
For the fresh frozen tissue, between 20 to 30 tissue sections, 20 µm thick 
were used for RNA extraction. Every 10th section was stained with H&E and 
examined by a pathologist to ensure that all sections used for RNA extraction 
were comprised of at least 70% tumour cells. The fresh frozen sections were 
placed in Eppendorf tubes containing 700 µl of Qiazol lysis reagent and the 
tubes were then vortexed for 15 seconds to disrupt the cells before freezing 
at -80 ºC. 
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Subconfluent cell cultures were initially washed twice with phosphate 
buffered saline (PBS) and the PBS was then aspirated off using sterile 
Pasteur pipette. 700 μl of Qiazol reagent were added to the cells and swirled 
around the dish several times to lyse the cells. The lysate was then placed in 
a 1 ml Eppendorf tube and immediately frozen at – 80 ºC. 
The Qiazol treated tissues and cell cultures were stored at -80 ºC for up to a 
maximum of 2 weeks before continuing with the RNA extraction. The lysate 
was then thawed, vortexed and left at room temperature for 5 minutes to 
promote dissociation of nucleoprotein complexes. This was followed by the 
addition of 140 µl of chloroform to each sample. The tube was shaken 
vigorously for 15 s and then left to stand at room temperature for another 2-3 
minutes before spinning at 13,000 rpm, 15 minutes at 4 °C. Following the 
centrifugation step the sample becomes separated into three layers; an 
upper aqueous phase containing RNA, a white interface and a lower organic 
layer. The upper, aqueous layer was carefully removed and measured using 
a Gilson pipette before being placed in a 2 ml tube. 1.5 volumes of 100% 
ethanol were added to each sample and the tube was vortexed briefly to mix. 
700 µl of the mix was then transferred to a miRNeasy mini spin column 
placed inside a collecting tube and the column was centrifuged at 10,000 
rpm, 15 s at room temperature. The elute was discarded and the remainder 
of the sample was placed on the column which was spun again. The column 
was then washed by adding 350 μl of RWT buffer to the column and spinning 
at 10,000 rpm, for 15 s in room temperature. On column DNase digestion 
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was then performed by mixing 10 μl of DNase I with 70 μl of buffer RDD and 
pipetting the mixture directly onto the column membrane. The columns were 
then left at room temperature for 15 minutes. The 500 μl of RWT buffer was 
then pipetted into the column to wash the membrane and the column was 
then spun for 15 sec at 10,000 rpm, room temperature. The flow through was 
discarded and 500 μl of RPE buffer were added to the column which was 
spun again. The flow through was discarded and the column was washed by 
adding another 500 µl of RPE to the column and spinning for 2 minutes at 
10, 000 rpm to dry the column membrane. The column was then placed in a 
1.5 ml Eppendorf tube and 50 μl of RNase free water was added directly to 
the middle of the column membrane. The RNA was then eluted from the 
column by spinning at 10,000 rpm for 1 minute at room temperature. The 
concentration and purity of the RNA elute was examined using a NanoDrop 
Ultra-Violet/Visible micro-volume spectrophotometer (Thermoscientific). The 
A260/280 and 260/230 absorption ratios as well as RNA concentration were 
noted and the rest of the RNA sample was then aliquoted in several smaller 
tubes and stored at -80 ºC. 
2.4. cDNA synthesis 
Total RNA was reverse transcribed into cDNA using the Superscript III First-
Strand Synthesis kit (Invitrogen Ltd/Life Technologies Ltd, Paisley, Scotland, 
UK). Briefly, 200 ng of total RNA were mixed with 1 μl of 50 ng/μl random 
hexamers and 1 μl of 10 mM dNTP mix and the volume was made up to 10 
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μl with RNase free water. The mixture was incubated at 65 °C for 5 minutes 
then chilled on ice for 1 minute before adding the following: 2 μl of 10 x RT 
buffer, 4 μl of 25 mM MgCl2, 2 μl of 0.1M DTT, 1 μl of RNaseOUT (40U/μl) 
and 1 μl of SuperScript III RT (200 U/μl). The mixture was incubated for 10 
minutes at room temperature followed by a 50 minute incubation at 50 °C. 
The reaction was terminated by incubating the tube at 85 °C for 5 minutes 
and then chilling on ice. 1 μl (2U) of RNase H was added to the mix and 
incubated at 37 °C for 20 minutes before storing at – 20 °C.  
MicroRNA specific cDNA was prepared using the TaqMan® miRNA Reverse 
Transcription Kit (Applied Biosystems) following the manufacturers’ 
instructions. The following master mix was prepared in a polypropylene tube 
by scaling up the volumes to the desired number of RT reactions: 0.15 μl of 
100 mM dNTPs, 1 μl MultiScribe™ reverse transcriptase (50 units/μl), 1.5 μl 
10 x reverse transcription buffer, 0.19 μl of RNase Inhibitor (20 units/μl), 4.16 
μl nuclease-free water. For each RT reaction 7 μl of RT master mix was 
mixed with 5 μl RNA (1 ng/μl) and 3 μl of 5 x RT primer (custom made by 
Applied biosystems) in a separate tube on ice. The reaction components 
were mixed thoroughly by inverting then placed on a thermal cycler which 
was programmed to run for 30 minutes at 16 °C, 30 minutes at 42 °C and 5 
minutes at 85 °C followed by an infinite hold at 4 °C. All RT samples were 
stored at -20 ºC until ready for use. 
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2.5. Quantitative Reverse Transcription 
polymerase chain reaction (qRT-PCR) 
2.5.1. Quantitative PCR with double-stranded 
DNA-binding dyes as reporters (SYBR Green 
assay) to test gene expression 
qRT-PCRs were carried in Microamp optical 96-well plates (Applied 
Biosystems, Birchwood, Warrington, UK) using SYBR green PCR Master Mix 
(Applied Biosystems). The following qRT-PCR master mix was prepared in a 
polypropylene tube by scaling up the volumes to the desired number of PCR 
reactions: 12.5 μl of SYBR green PCR Master Mix, 0.75 μl of each forward 
and reverse oligonucleotide primer (10 μM), 10 μl nuclease-free H2O and 1 
μl of template cDNA (prepared using Superscript III First-Strand Synthesis 
kit). Thermal cycling was carried out on a Realplex4 Mastercycler 
(Eppendorf, Cambridge, UK) using a 520 nm filter and the following thermal 
cycling profile: 10 minutes at 95 °C followed by 40 cycles of 15 s at 95 °C 
and 1 minute at 60 °C followed by a final ramping step to generate a melt 
curve. All reactions were performed in duplicate.  
The different primers used for qRT-PCR are shown in Table 2-6. All Primers 
were designed using the online software Universal Probe Library Assay 
Design Centre (Roche, Burgess Hill, UK).  
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The mRNA expression of the gene of interest in human samples was 
quantified using 2^-dCt method (Livak & Schmittgen 2001; Schmittgen & 
Livak 2008). The relative gene expression level in cell lines was determined 
using the comparative Ct method (2^-ddCt) and normalised to GAPDH 
housekeeping gene.  
The forward and reverse primer concentration was optimised for 
amplification efficiency and primer-dimer formation monitored by a ramping 
step (melting curve).  
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Table ‎2-6: List of primer sequences used for qRT-PCR 
 
Primer name Primer Sequence (5′ -> 3′) 
NF1-Forward ATTACTTCAGCAAGGCCATGTTAG 
NF1-Reverse AAGGATTTGCTATGTGCCAGGGAC 
COL1A1-Forward GGGATTCCCTGGACCTAAAG 
COL1A1-Reverse GGAACACCTCGCTCTCCA 
COL5A2-Forward TGGAATCCCTGGACCCATTT 
COL5A2-Reverse CCTTCTTTACCTGAAGGACCAA 
COL21A1-Forward GCATGTGAGATTCCTGGATTTA 
COL21A1-Reverse GTTTTCCCGGAGGACAAATAC 
COL4A1-Forward GTATTTTCACACGTAAGCACATTCG 
COL4A1-Reverse CCCTGCTGAGGTCTGTGAACA 
COL4A2-Forward GTGGCCAATCACTGGTGTCA 
COL4A2-Reverse CCTCCATTGCATTCGATGAA 
ROBO1 Forward GCGTGCAGTACTAAGGGAACA 
ROBO1 Reverse GGCTTCTTACATGAACATAATGAA 
TGFB3-Forward TCAGCCTCTCTCTGTCCACTT 
TGFB3-Reverse CATCACCGTTGGCTCAGGG 
MMP2-Forward CCACTGCCTTCGATACAC 
MMP2-Reverse GAGCCACTCTCTGGAATCTTAAA 
MMP-9 Forward GGGACGCAGACATCGTCATC 
MMP-9 Reverse TCGTCATCGTCGAAATGGGC 
DNMT3A Forward AGTACGACGACGACGGCTA 
DNMT3A Reverse CACACTCCACGCAAAAGCAC 
DNMT3B Forward CCCATTTGACTTGGTGATTGGC 
DNMT3B Reverse CCGGCCTGTACCCTCATAC 
WT1 Forward CACAGCACAGGGTACGAGAG 
WT1 Reverse CAAGAGTCGGGGCTACTCCA 
S100B Forward TGGCCCTCATCGACGTTTTC 
S100B Reverse ATGTTCAAAGAACTCGTGGCA 
GAPDH Forward GGAGTCAACGGATTTGGTCGTA 
GAPDH Reverse GGCAACAATATCCACTTTACCAGAGT 
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2.5.2. Fluorescent reporter probe methods 
(Quantitation of microRNA by TaqMan assay) 
MicroRNA expression in each sample, and the cell line, was measured using 
TaqMan microRNA assays technology (Applied Biosystems) on Realplex4 
Mastercycler (Eppendorf). This qRT–PCR method specifically detects mature 
microRNA, but not precursor microRNA. The TaqMan assay was performed 
using the same amount of total RNA (5 ng) that was transcribed into cDNA 
(Applied Biosystems), and Ct-values were recorded. An internal control small 
RNA, RNU66 was used to normalise the microRNA expression data for each 
sample (Applied Biosystems). The amplification step was performed in a 
Microamp optical 96-well plate (Applied Biosystems). Each well contained 
1.33 µl of template DNA and a reaction master mix containing 10 μl TaqMan 
Universal PCR master Mix II (Applied Biosystems), 1 µl of the probe and 
7.67 μl Nuclease free water. The amplification was performed on Realplex4 
Mastercycler (Eppendorf), with a first step at 95 °C for 10 minutes and then 
40 cycles with 95 °C for 15 s, 60 °C for 1 minute with a fluorescent reading at 
the end of this step (FAM dye, 520 nM filter and VIC dye, 550 nM). The 
expression of the miRNA of interest in human samples was quantified using 
2-ΔCT method (Livak & Schmittgen 2001; Schmittgen & Livak 2008). The 
relative gene expression level in cell line was determined using the 
comparative Ct method (2 –ΔΔCT) (Livak & Schmittgen 2001; Schmittgen & 
Livak 2008), relative to the housekeeping RNU66. All qPCR assays were run 
with appropriate controls including the Non-Template Control (NTC).  
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2.6. Cell culture 
2.6.1. Thawing cells from liquid nitrogen 
Cells retrieved from liquid nitrogen were thawed by placing the cryovial in a 
37 °C water bath. The thawed cell suspension was then added to a tube 
containing 10 ml of the appropriate cell culture medium and spun at 1200 
rpm for 5 minutes, room temperature, to pellet the cells. The supernatant 
was then removed and the cell pellet was resuspended in 1 ml of fresh 
culture medium. The cell suspension was then added to a 75 cm2 tissue 
culture flasks containing 10 ml of the appropriate culture medium which had 
been pre-warmed to 37 °C.  
2.6.2. Cell maintenance 
sNF96.2 cells were grown in Dulbecco's Modified Eagle Medium (DMEM)  
(Invitrogen) supplemented with 10% Fetal bovine serum (FBS) (GIBCO), 100 
of U/ml penicillin G and 100 μg/ml streptomycin (Invitrogen). The cultures 
were maintained in a 37 °C incubator with 5% CO2 and high humidity.  
HT1080 and HEK293T cell cultures were maintained in RPMI media 
supplemented with 10% fetal bovine serum (FBS) (GIBCO), 100 of U/ml 
penicillin G and 100 μg/ml streptomycin (Invitrogen). The cultures were 
maintained in a 37 °C incubator with 5% CO2 and high humidity. 
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2.6.3. Cell trypsinisation 
Cells cultures were passaged 1 in 4 when they reached 80% - 90% 
confluence using Tyrpsin-EDTA (GIBCO). 1:3 to 1:10, depending of their 
growth rate, two to three times a week. 
2.6.4. Freezing cells in liquid nitrogen 
Cells were stored frozen in FBS supplemented with 10% DMSO at a density 
of 1 to 3 million per ml. Cells were trypsinised from 75 cm2 tissue culture 
flasks and washed in PBS, spun, then placed in cryovials containing 1 ml of 
FBS with 10% DMSO. Then the vials are placed in an alcohol-graded 
freezing container(s) and put in a -80 ºC freezer. (The isopropanol allows the 
vial temperature to decrease at 1 ºC /min) and left to freeze overnight. For 
long-term storage (> 1 month), I moved the vials to the vapour phase of liquid 
nitrogen storage. In the freezing process It is Important to use healthy cells 
that are growing in log phase and the medium is replaced 24 h before 
freezing. 
2.6.5. Trypan blue cell viability assay  
Cell viability was measured in cells treated with Trypan blue (Sigma Aldrich, 
Dorset, UK) using a Neubauer haemocytometer (Weber Scientific 
International Ltd., Middlesex, UK). The haemocytometer and coverslip were 
first thoroughly cleaned by rinsing in distilled water followed by a wash in 
70% ethanol. The haemocytometer and coverslip were allowed to dry and 
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the coverslip was then placed over the counting chamber. A 10 μl 
suspension of freshly trypsinised cells was mixed with an equal volume of 
Trypan blue stain (Sigma, UK). 10 µl of the Trypan blue mixed cells were 
pipetted onto the edge of the cover slip and allowed to run into the counting 
chamber until it was completely filled with sample. The haemocytometer was 
then examined under a light microscope using a 20 x objective lens. Dead 
cells stain blue with Trypan blue but live cells remain colourless. The total 
number of live cells in each of the 4 large corner squares plus the middle 
square was counted. Because each square has surface area of 1 mm-
squared and a depth of 0.1 mm, giving it a volume of 0.1 mm-cubed, so the 
sum of the cells (total) in the five squares represents cell count per 0.5 mm-
cubed. To determine cell count per ml the sum of cell number is multiplied by 
2 X 103. 
2.6.6. Live cell imaging using IncuCyte 
(Growth curve) 
The rate of cellular proliferation was determined during and after transfection 
using a non-invasive live cell imaging system within the incubator, the 
Incucyte FLR (Essen BioScience, Welwyn Garden City, Herts, UK) and its 
companion software version 2010A (Essen BioScience). A kinetic 
quantification of the growth of the cells was obtained by recording the 
average well confluency from at least nine points per well. The cells were 
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placed in the Incucyte and the growth was recorded for up to a week with 
measurements at least every 2 h. 
2.6.7. MTS cell viability assay 
MTS is a tetrazolium compound [3-(4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] 
which is reduced by living cells into a coloured product. sNF96.2 Cells were 
seeded in triplicate onto 96 well plates at a density of 2x103 cells in 100 µl of 
culture medium. The number of cells was then estimated at 24, 48, 72 and 
96 h using the MTS based CellTiter 96R Aqueous One Solution Cell 
Proliferation Assay (Promega) as instructed by the manufacturer. Briefly the 
culture medium was discarded and replaced with 100 µl of fresh culture 
medium. 20 µl of MTS solution was added to each well and the plate was 
then placed in an incubator at 37 °C and 5% CO2 for 1 h. The reaction was 
then stopped by adding 25 μl of 10% SDS. The plate was then placed in a 
Varioskan Flash plate-reader and the absorbance readings at 490 nm 
wavelength were measured by the SkanIt software programme (Thermo 
Scientific).  
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2.6.8. Cell migration analysis 
2.6.8.1. Scratch/wound healing assays for cell 
migration 
The scratch wound healing assay was performed using the approach 
previously described by (Liang et al. 2007). sNF96.2 cells (3X104) were 
seeded in 24-well plates containing 0.5 ml of culture medium. The cells were 
left to grow in a 37 ºC, 5% CO2 incubator for 16 – 24 h until confluent. On 
reaching confluence, a scratch was made through the central axis of the 
plate using the Essen BioScience Wound-Maker for 24-well plates. The wells 
were then washed twice with PBS and the appropriate culture medium was 
added to the cells. The growth of cells in the scratch area was then imaged 
and recorded for 6 days using the Incucyte Live imaging system (Essen 
BioScience, Welwyn Garden City, Herts, UK) (section  2.6.6). All experiments 
were performed in triplicate. 
2.6.8.2. Transwell assay 
Cell migration was assessed using 24-well transwells with 8 μm pore 
Membrane type of membrane (Corning distributed by Appeleton Woods, 
Birmingham, UK). 1 ml of complete DMEM with 10% FBS was placed in the 
bottom of the wells and sNF96.2 Cells were plated at a density of 2.5x103 
cells in 100 μl of DMEM without FBS inside each transwell. After 6 h 
incubation at 37 °C and 5% CO2, the wells were rinsed with PBS and the 
cells were fixed onto the membrane and stained with GelRed. Migrated cells 
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on the membrane were counted in four fields where the cells were evenly 
distributed (regularly spaced apart from one another). 
2.7. MiRNA microarray expression 
profiling  
MiRNA profiling of neurofibromas and MPNST samples was performed using 
the Human miRNA microarray V2 (Agilent). This microarray quantifies 723 
human miRNAs by ~15,000 probes. miRNA probe sequences were sourced 
from miRBase (http://www.mirbase.org/). Each miRNA is quantified by 20 
randomly distributed probes; 5 sequence variations per miRNA are repeated 
4 times at different locations across the chip. Probes were designed to 
distinguish miRNAs from the same family which differ by no more than one 
nucleotide.  
2.7.1. Sample preparation  
Tissue was disrupted and homogenised using the Tissue-Tearor (Biospec 
Products). RNA was extracted using the miRNeasy mini kit (quiagen) Prior to 
further processing for microarray analysis, the abundance and quality of the 
small RNA fraction was assessed using the Agilent small RNA Kit, according 
to manufacturer’s instructions. 1-20 ng of total RNA was loaded in 1 μl onto 
the small RNA chip; nucleic acid fragments were separated 
electrophorectically according to size. Samples plus the small RNA ladder 
were denatured before use by heating to 70 °C for 2 min, and then stored on 
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ice. The electrophoretic gel and sample dye were prepared and loaded onto 
the chip according to manufacturer’s instructions. RNA between 6 and 150 
nts was visualised using the Agilent 2100 Bioanalyzer (Agilent). The miRNA 
fraction was assessed by the size of the peak at 10-40 nt on the 
electrophoregram, only those samples with a sufficient miRNA content were 
used for miRNA microarray analysis. 100 ng of total RNA was incubated with 
0.7 μl Calf Intestine Alkaline phosphatase (25 unit/μl, TaKaRa) at 37 °C for 
30 min to dephosphorylate the sample according to manufacturer’s 
instructions. Dephosphorylated RNA was then denatured by treatment with 5 
μl of 100% DMSO and heating to 100 °C for 7.5 min, samples were then 
placed on ice. Fluorescent miRNA was generated by labelling the RNA with 
Cyanine 3-pCp at the 3’ end according to manufacturer’s instructions. Briefly, 
ligation master mix was prepared with the following: 2 μl 10 x T4 RNA ligase 
buffer (New England Biolabs), 2 μ RNAse-Free Water, 3 μ pCp-Cy3 
(Agilent), 1 μl NEB T4 RNA ligase (20 units/μl, New England Biolabs) giving 
a total volume of 8 μ per sample. The ligation mixture was added to the 
sample and incubated at 16 °C for 2 hrs. Labelled RNA was made up to a 
total volume of 50 μl with ddH2O, then purified by passing the sample 
through Micro Bio-spin 6 columns (BioRad), according to manufacturer’s 
instructions. These columns contain Bio-Gel P, which desalts samples and 
removes unincorporated dye, smaller RNA fragments are retained while 
larger molecules are excluded.  
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2.7.2. miRNA microarray hybridization and scanning 
Clean, labelled miRNA samples were then prepared for hybridisation 
following manufacturer’s protocol. Briefly, 10 x blocking agent (GE 
Healthcare) was reconstituted with 125 μl of nuclease-free water. Labelled 
samples were dried using a speed-vac, spinning at 45 °C for 1 h. RNA was 
re-suspended in 18 μl of DNase/RNase-free water and 4.5 μl of the 10 X GE 
Blocking Agent added to each sample. 22.5 μl of 2 x Hi-RPM Hybridization 
buffer was added and samples incubated for 5 min at 100 °C. Labelled 
miRNA was then hybridised to miRNA microarrays and scanned following 
manufacturer’s protocol. The hybridisation mixture was added to a clean 
gasket slide and loaded into the Agilent SureHyb chamber base. Samples 
were rotated and hybridised at 55 °C for a minimum of 20 hrs. After which, 
chips were washed with Gene Expression wash buffer (Agilent) containing 
Triton X-102 according to manufacturer’s protocol. Washed chips were 
scanned using the Agilent microarray scanner and data extracted with the 
Agilent Feature Extraction Software.  
2.7.3. miRNA microarray data analysis  
A quality control (QC) report was generated and assessed after scanning to 
confirm that the experimental procedure was successful. Agilent miRNA 
arrays were analysed by Dr. S. Henderson (CR-UK Viral Oncology group, 
UCL) using the 'limma' package for the R programming language and 
additional custom methods. Background subtraction was undertaken for all 
probes, negative values were given a small positive value. Sets of probes for 
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each gene were converted to log2 and a summary calculated from the 
median. Differential expression between summary probe set values was then 
calculated using the 'limma' methodology. 
2.8. MicroRNA mimics transfection of 
sNF96.2 cells 
The MPNST cells, sNF96.2 were seeded at a density of 5x104 per 6-well 16 
h prior to transfection. 100 nM of either miR-29c mimics (Dharmacon Inc., 
Lafayette, CO, USA) or scrambled oligonucleotides (Dharmacon Inc., 
Lafayette, CO, USA) were transfected in 1 ml of OPTI-MEM (Invitrogen) 
using Oligofectamine™ (Invitrogen), according to manufacturer’s 
instructions. The medium was then changed 24 h post-transfection. Cells 
were harvested after 24 h, 48 h, and 72 h following exposure to the mimics, 
after which total RNA including microRNA were extracted (Qiagen). 
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2.9. DNA methylation detection 
2.9.1. Genomic DNA extraction 
2.9.1.1. Genomic DNA extraction from fresh frozen 
tissue and cell lines 
Genomic DNA was extracted from fresh frozen tissue and cell lines using 
Qiagen’s DNeasy kit (Qiagen, Crawley, West Sussex, UK) following the 
manufacturer’s instructions. For the fresh frozen tissue, twenty frozen 
sections (20 μm thick) were used for DNA extraction from each tissue 
sample. These were cut in advance and stored at -80 ºC until ready for use. 
In the case of cell lines, DNA was extracted from cells grown in 75 cm2 size 
flasks. The cells were harvested in advance using Trypsin-EDTA as 
described in section ‎2.6.3 They were then washed twice with PBS and stored 
at -80 ºC until ready for use.  
The tissue sections or cell pellet were digested by the addition of 180 µl of 
ALT buffer mixed with 20 µl of proteinase K. The samples were mixed 
thoroughly with the lysis solution making sure the cell pellets were 
completely disrupted and that all cells and tissue were completely immersed 
in the lysis solution. The samples were then incubated in a 56 °C water bath, 
for 10 minutes in the case of cell lines and for 1 to 2 h in the case of tissue 
samples until the tissue was completely lysed. 200 µl of AL buffer were then 
added to each sample and mixed thoroughly by vortexing. 200 µl of 100% 
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ethanol were then added to each sample which was vortexed again. The 
sample was then pipetted into a DNeasy Mini spin column placed inside a 2 
ml collection tube and centrifuged at 8000 rpm for 1 minute. The flow through 
and collection tube were discarded and the spin column was placed inside a 
fresh 2 ml collection tube. 500 µl of AW1 buffer were pipetted into the spin 
column and then centrifuged at 8000 rpm for 1 minute. The flow through and 
collection tube were discarded and the spin column was placed inside a 
fresh 2 ml collection tube. 500 µl of AW2 buffer were added to the column 
and this was centrifuged again for 3 minutes at 14,000 rpm to dry the 
DNeasy membrane. The flow through and collection tube were discarded 
and the spin column was placed inside a clean 1.5 ml tube. 100 or 200 µl of 
Buffer AE (depending on the starting amount of tissue or cells in the sample) 
was pipetted directly on to the column membrane and this was left to stand 
at room temperature for 1 minute before spinning for 1 minute at 8000 rpm to 
elute the DNA. The concentration and purity of the DNA sample was then 
analysed using a Nanodrop UV spectrophotometer. A note was made of the 
A260/A280 and A260/A230 ratios as well as the DNA concentration 
readings. The DNA was samples were then stored at -20 °C. 
2.9.1.2. Genomic DNA extraction from formalin fixed 
paraffin embedded (FFPE) tissue 
Genomic DNA was extracted from formalin fixed paraffin embedded (FFPE) 
tissue using QIAamp DNA FFPE Tissue kit (Qiagen, Crawley, West Sussex, 
UK) following the manufacturer’s instructions. For the FFPE tissue, twenty 
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sections (20 μm thick) were used for DNA extraction from each tissue 
sample. These were cut in advance and stored at 4 ºC until ready for use.  
First, 1 ml xylene was added to the sections in 1.5 ml microcentrifuge tube 
and vortexed vigorously for 10 s. Then centrifuged at full speed for 2 min at 
room temperature. Then the supernatant was removed by pipetting. Then 1 
ml ethanol (96–100%) was added to the pellet, and mix by vortexing. The 
reason for adding ethanol was to extract residual xylene from the sample. 
Then centrifuged at full speed for 2 min at room temperature. Next, the 
supernatant was removed by pipetting. Then the tube was opened and 
incubated at room temperature for 10 min to evaporate all residual ethanol. 
Then the pellet was resuspend in 180 μl Buffer ATL With 20 μl proteinase K 
added, and mixed by vortexing. Next, incubate at 56 °C for 1 h (or up to 2 hrs 
until the sample has been completely lysed). Then Incubated at 90 °C for 1 h 
to reverse formaldehyde modification of nucleic acids. 200 μl Buffer AL was 
then added to the sample, and vortexed. Next 200 μl ethanol (96–100%) was 
add and mixed by vortexing to yield a homogeneous solution. The entire 
lysate was then transferred to the QIAamp MinElute column (in a 2 ml 
collection tube) and centrifuged at 8000 rpm for 1 min. Next, 500 μl Buffer 
AW1 was added and centrifuged at 8000 rpm for 1 min. Then 500 μl of Buffer 
AW2 was add centrifuged at 8000 rpm for 1 min. Finally, the QIAamp 
MinElute column was placed in a clean 1.5 ml microcentrifuge tube and 20–
100 μl Buffer ATE was applied to the centre of the membrane and incubated 
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at room temperature (15–25 °C) for 1 min, then centrifuged at full speed for 1 
min. 
The concentration and purity of the DNA sample was then analysed using a 
Nanodrop UV spectrophotometer. A note was made of the A260/A280 and 
A260/A230 ratios as well as the DNA concentration readings. The DNA 
samples were then stored at – 20 °C. 
2.9.2. Bisulphite treatment of DNA 
This technique involves treating methylated DNA with bisulfite, which 
converts unmethylated cytosines into uracil. Methylated cytosines remain 
unchanged during the treatment.  
About 500 ng DNA was treated using EZ DNA Methylation-GoldTM Kit (Zymo 
Research, Orange, CA, USA) according to the manufacturer's protocol. 
Briefly, 130 μl of CT Conversion Reagent was added to up to 20 μl of DNA 
sample and mixed, then heated to 98 °C for 10 minutes and then 64 °C for 
2.5 h and kept at 4 °C. M- Binding Buffer was added (600 μl) to a Zymo-Spin 
IC Column, then the sample was added and the column was centrifuged at 
full speed (> 10,000 rpm) for 30 s. The flow-through was discarded and 100 
μl of M-Wash Buffer was added to the column. The column was centrifuged 
for 30 s and 200 μl of M-Desulphonation buffer was added to the column and 
left for 15-20 minutes at room temperature. The column was then centrifuged 
at 10,000 rpm for 30 s. A wash step was then performed by addition of 200 μl 
of M-Wash Buffer to the column after which the column was centrifuged for 
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30 s. This wash step was repeated twice. M-Elution buffer (10 μl) was added 
directly to the column matrix and the bisulfite-treated DNA was collected in 
1.5 ml micro-tubes and stored at -20 °C.  
2.9.3. PCR and pyrosequencing of bisulphite 
treated and control samples 
Bisulfite-treated DNA was used for generating PCR-amplified templates for 
pyrosequencing using target specific primers (described in Table ‎2-7). The 
primers were designed using the PyroQ assay design software (Biotage, 
Uppsala, Sweden). A common tag was placed on either the forward or the 
reverse primer (depending on the strand to be sequenced), and a universal 
biotinylated primer was used for all reactions as described previously (Tost & 
Gut 2007). Two rounds of bisulphite-PCR cycling conditions included 
denaturation at 95 °C for 4 minutes, followed by 10 cycles of 94 °C for 15 s, 
touchdown from 60–50 °C (reducing 1 °C per cycle) for 15 s and 72 °C for 20 
s followed by a further 30 cycles at a 50 °C annealing temperature. The 
second PCR used 2 μl of a 1:10 dilution of the first PCR as template and the 
same cycling conditions. All products were confirmed to be single bands by 
agarose gel electrophoresis. Touchdown PCR is a method for expanding 
specificity of PCR reactions. Touchdown PCR utilises a cycling steps where 
the annealing temperature is continuously decreased (e.g. 1-2 °C/every 
cycle). The initial annealing temperature ought to be a few degrees over the 
specified Tm of the preparations. The annealing temperature is then steadily 
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diminished until it reaches the calculated annealing temperature of the 
primers or a few degrees beneath. Amplification is then kept using this 
annealing temperature. 
Ten microlitres of the biotinylated PCR product was sequenced according to 
the manufacturer's recommendation. Pyrosequencing was carried out on the 
PSQ HS 96 System using Pyro Gold Reagent kits (PSQ 96MA, Biotage). 
Sample preparation as follow: 2 μl streptavidin beads (GE Healthcare, 
Buckinghamshire, UK), 38 μl PyroMark binding buffer (Qiagen), 10 μl PCR 
product and 30 μl ddH2O were mixed and incubated for 10 minutes on a 
shaking table at 1500 rpm. Employing the Biotage Q96 Vacuum Workstation, 
DNA was separated, denatured and washed then 0.3 µM sequencing 
primer in 12 µl of annealing buffer is added. Then the samples are incubated 
at 80 °C for 2 minutes for primer annealing then left to cool to room 
temperature. This technique is a sequencing-by-synthesis method where a 
sequencing primer hybridises to the target DNA template. The 
deoxyribonucleotide triphosphates (dNTPs) are used by the enzyme 
polymerase to synthesise a new DNA strand. The dispensation order of 
dNTPs is according to assay design (PyroQ assay design software). When 
the complementary dNTP is dispensed, it will be incorporated into the newly 
synthesised DNA and this causes release of a pyrophosphate (PPi). The 
enzymes sulfurylase convert the released PPi into adenosine triphosphate 
(ATP). Then luciferase uses the ATP to convert luciferin to oxyluciferin, and 
this generates visible light which then captured and presented as a peak in 
P a g e  | 115 
   
  
the program). The degree of methylation of each CpG position in a sequence 
is determined from the ratio of T (thymine) and C (cytosine). All runs 
contained standard curves, which comprised a range of control methylated 
DNA (0%, 20%, 40%, 60%, 80% and 100%) to allow standardised direct 
comparisons between different primer sets. Methylation was quantified using 
Pyro Q-CpG Software (Biotage) that calculates the ratio of converted Cs (Ts) 
to unconverted Cs at each CpG and expresses this as a percentage of DNA 
methylation.  
 
Table ‎2-7: List of primer sequences used for pyrosequencing 
 
 
Gene Primer Sequence 
CDKN2A 
F TTTTATATTTTTTTGGTTTAGTAGTTAGTT 
R AACCACTAAAACTCATTATATAACACTC 
S ACTCCTTTTCTTCTTACAACCCTA 
WT1 
F GGGGATATGTTAGTTATATTGGTTTTG 
R ATTTTCCACAACCTACTTTTCTCTA 
S GTTTAGTAAGAAGGTAGGTAGTA 
S100B 
F AGGGTGGAAGGTTATAGATTTT 
R ACTAACCCCCCTATTCAAAAACTCCAATC 
S GAAGGTTATAGATTTTTAGAGT 
 
Key: F= forward; R= reverse; S= sequencing. 
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2.10. 5-aza-2′-deoxycytidine treatment of 
sNF96.2 MPNST cells 
The effects of DNA methylation on expression of various genes in sNF96.2 
cells was examined by treating this cell line with 5-aza-2′-deoxycytidine (5-
aza-dC). This compound is an epigenetic modifier which inhibits DNA 
methyltransferase activity resulting in global demethylation of DNA and 
activation of gene expression by chromatin remodelling (Claus et al., 2005; 
Hackanson & Daskalakis, 2014).  
The optimum dose of 5-aza-dC that could be used to induce global 
hypomethylation of DNA in sNF96.2 cells with minimal cytotoxic effects was 
first determined empirically. The sNF96.2 cells (2X104 ) were initially seeded 
per well in 24 well plates (7 plates were used) and grown for 1 day. The 
medium was then removed from each plate and replaced with fresh medium 
containing 5-aza-dC (Sigma-Aldrich, St. Louis, MO) at one of the following 
concentrations: 0.25 μM, 0.5 μM, 1 μM, 2 μM, 3 μM, 5 μM, and 10 μM. The 
different cell cultures were maintained in the same concentration of 5-aza-dC 
for a maximum period of 7 days. The viability of cells grown in each different 
concentration of 5-aza-dC was measured by Trypan Blue assay as described 
in section  2.6.5. Cells were incubated for 7 days with 5-aza-dC with the 
culture media being replaced every 24 h with fresh media containing 1 μM 5-
aza-dC. All experiments were carried out in triplicate.  
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2.11. Protein isolation and Western blot 
analysis  
To test protein expression by Western blotting ten sections (each 20 m) 
were cut from snap-frozen tumours as described above and placed into 
micro-tubes. A tumour lysate was produced using Radio- 
Immunoprecipitation Assay (RIPA) lysis buffer (150 mM NaCl, 1% IGEPAL® 
CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM 
Tris [pH 8.0]) containing both phosphatase and protease inhibitor cocktails 
(Sigma-Aldrich). Lysates were incubated on ice for 15 minutes and then 
centrifuged at 13,000 rpm and 4 °C for 10 minutes to remove debris. Proteins 
were quantified with BCA protein assay kit (Fisher Scientific UK Ltd, 
Loughborough, Leicestershire, UK). Thirty micrograms of protein lysate were 
resolved by SDS-8% polyacrylamide gel electrophoresis (SDS-8% PAGE) 
and transferred to a polyvinylidene fluoride (PVDF) Immobilion-P transfer 
membrane (Millipore Corporation, Bedford, MA, USA) by standard wet 
electro-transfer methods. The membrane was blocked with PBS, 0.1% 
Tween 20, 5% BSA for a minimum of 30 minutes and probed with the 
appropriate primary antibody overnight at 4 °C. Blots were washed three 
times (15 minutes each) in 1 X PBS with 0.1% Tween 20 (PBS-T) and 
incubated for 1 h at room temperature with the appropriate secondary 
horseradish peroxidise (HRP)-conjugated antibody, followed by further 
washing and enhanced using chemiluminescence (ECL) detection 
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(GEHealthcare Ltd, Amersham, Buckinghamshire, UK). The primary 
antibodies used included: mouse monoclonal (CA-4001) matrix 
metalloproteinase (MMP2), rabbit monoclonal (EP1254) MMP9 (dilution 
1 : 1000; incubation overnight at 4 °C, Abcam, Cambridge, Cambs., UK), 
MMP3 (dilution 1 : 50; incubation overnight at 4 °C, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA), rabbit monoclonal S100B 
(dilution 1:1000, incubation overnight at 4 °C, Abcam ab52642) and GAPDH 
mouse monoclonal antibody (6C5) at dilution 1 : 5000; incubation 1 h at room 
temperature (Advanced Immunochemical Inc., Long Beach, CA, USA). 
2.12. Gelatin Zymography 
Two days after siRNA transfection of sNF96.2 cells, the medium was 
changed to serum-free medium (350 μl Optimem; Invitrogen) for overnight 
incubation after which the supernatant was collected and spun to remove 
floating cells. At the same time, the cells were lysed using lysis buffer (0.1% 
Triton x-100 in 0.05 Trizma base, 0.2 M NaCl, 0.005 CaCl2) in non-reduced 
conditions (no heating or reducing reagents). The supernatants and cell 
extracts were separated using 10% acrylamide gels containing 0.1% gelatin 
type A from porcine skin (Sigma-Aldrich, Dorset, UK) with non-reducing 
conditions. The gels were incubated in a 2.5% Triton X-100 solution at room 
temperature with gentle agitation for 1 h and then soaked in reaction buffer 
(50 mM Tris-HCl (pH 7.5), 200 mM NaCl, and 10 mM CaCl2) at 37 °C 
overnight. The gels were stained with 0.5% Coomassie Blue R250 in 
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30% methanol/10% glacial acetic acid in H2O for 1 h and then de-stained 
(staining solution without Coomassie Blue) for 0.5 h after which they were 
fixed in 0.2% glacial acetic acid. Zones of gelatinolytic activity were revealed 
by negative staining. 
2.13. Sequencing of NF1 gene  
In order to detect the presence or absence of mutation in NF1 gene in our 
cell line, fifty nanograms of genomic DNA were amplified by the following 
touchdown PCR protocol. It is a method for expanding specificity of PCR 
reactions. Touchdown PCR utilises a cycling steps where the annealing 
temperature is continuously decreased (e.g., 1-2 °C/every cycle). The initial 
annealing temperature ought to be a few degrees over the specified Tm of 
the preparations. The annealing temperature is then steadily diminished until 
it reaches the calculated annealing temperature of the primers or a few 
degrees beneath. Amplification is then kept using this annealing 
temperature.  
Steps involved initial heating at 95 °C for 15 minutes. The annealing 
temperature being reduced by 1 °C per cycle, from 65 °C to 56 °C, followed 
by 35 further cycles at 56 °C. The PCR reaction was performed in a total 
volume of 50 μl containing 5 μl of 10X Hotstart buffer I, 0.2 μM dNTP, 10 pM 
of each primer, 1 U of Hotstart DNA polymerase (Qiagen). PCR products 
were purified using Qiagen PCR Purification kit (Qiagen) and sent for DNA 
direct sequencing at the Scientific Support Services at UCL Cancer 
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Institute/Wolfson Institute for Biomedical Research (WIBR). Direct 
sequencing reactions were run using GenomeLab™ DTCS Quick Start 
chemistry (Beckman Coulter UK Ltd, High Wycombe, Bucks., UK) and were 
analysed on a CEQ™ 8000 Genetic Analysis System (Beckman Coulter). 
2.14. Immunohistochemistry (IHC)  
2.14.1. Slide staining  
Three μm thick paraffin-embedded sections were de-waxed by successive 
baths of xylene, ethanol and water, pre-treated and incubated with the 
primary antibody; Anti-S100 beta antibody (ab52642; Abcam,Cambridge, 
UK). Pre-treated slides were either stained manually with the Ventana iVIEW 
DAB kit (Ventana Medical Systems, Strasbourg, France) following the 
manufacturer’s instructions. The slides were counterstained with 
haematoxylin. A positive and a negative control (e.g., no primary antibody 
added) were performed on tissue controls. An H&E was performed for each 
slide to review its histology. The slides were kindly revised to confirm the 
scoring by Dr. Nischalan Pilly (Pathologist at Department of Pathology, 
RNOH).  
2.14.2. Immunohistochemistry scoring  
Both the intensity of the staining and the number of cells stained were scored 
for each slide. For the number of cells stained per 10 contiguous HPF, a 
score of 0 was given when no or sparse tumour cells (less than 1%) were 
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stained, 1 for less than 10%, 2 for between 11 and 60% and 3 for above 
60%. For the staining intensity, a score of 0 corresponded to an absence of 
staining, 1 to a weak staining intensity (less intense than the positive control), 
2 to a medium staining intensity (comparable to the positive control) and 3 to 
a high staining intensity (above the positive control). The score of each of the 
duplicated scores for the same case were then averaged, to give a final 
score for the staining intensity and for the extent of the staining. 
Unequivocally immunoreactive cases, with a score for intensity equal or 
above 1 and a score for the % of cells stained over 1, were considered as 
expressing the protein. Cases not immunoreactive, with a score equal or 
below 1 for the extent of the immunoreactivity, were considered as negative 
for protein expression.  
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2.15. S100B expression cloning 
2.15.1. PCR cloning strategy 
The S100B cDNA was cloned using a PCR cloning strategy. The first step 
was to design 5′ and 3′ PCR primers containing different restriction enzymes. 
There were two criteria used to select restriction enzymes for cloning. Firstly, 
there had to be no restriction sites present within the region to be cloned. 
The cDNA sequence to be cloned was obtained from the NCBI GenBank 
depository of sequenced DNA: this was then entered into the web site 
http://tools.neb.com/NEBcutter2/. This program identified all user specified 
restriction enzyme sites present within the sequence; enzymes which did not 
cut the DNA could then be selected. The second criterion in selecting 
restriction enzymes was the presence of the restriction site within the 
multiple cloning site (MCS) of the vector. These were restriction enzyme 
sites included into a defined region of the vector during vector design to 
facilitate the cloning process. Primers complimentary to the beginning and 
end of the sequence to be cloned were designed using Invitrogen 
OligoPerfect primer designing tool (www.invitrogen.com). The DNA 
sequence to be cloned was entered into the program: variables including 
primer length, C/G composition, product length and primer melting 
temperature were then specified. Once complimentary primers had been 
designed and the appropriate restriction enzymes selected, a random 
sequence of junk DNA was added to the ends of both primers, this facilitated 
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restriction enzymes digestion. PCR was performed with 2 μl of 10 μM 
forward and reverse primers, 1 μl of 10 mM dNTPs (Invitrogen), 5 μl 
PfuTurbo 10 x reaction buffer (Stratagene) or 10 μl of HotStart HiFidelity 5X 
PCR Buffer (Qiagen), 1 μl of PfuTurbo DNA polymerase (2.5 units) 
(Stratagene) or 1 μl of HotStart HiFidelity DNA polymerase (2.5 units) 
(Qiagen) and 100-1000 ng of template DNA made up to a final volume of 50 
μl with ddH2O. PCR conditions were as specified by the manufacturer’s 
instructions, typically the polymerase was activated and DNA denatured by 
incubating at 95 °C for 2-5 minutes. Followed by 20-40 cycles of 95 °C for 1 
minute, 55 °C for 1 minute, 72 °C for 1 minute, during which double-stranded 
DNA is denatured, primers anneal and polymerase-mediated elongation of 
PCR produced occurs. The final step was elongation step of 7 minutes at 72 
°C; this ensured that any remaining single-stranded DNA was fully extended. 
Variables in the PCR program were cycle number, extension time and primer 
annealing temperature. Extension time was dictated by the length of the 
product, with 1 minute/1 kb of DNA, primer annealing temperature was 
governed by the base composition and length of primers. The melting 
temperature of primers was calculated using the formula 2(A/T) + 4(G/C). 
However, to determine experimentally the optimum primer annealing 
temperature, a temperature gradient PCR was performed. In this program 
the annealing temperature increases in defined increments across the PCR 
block, the products were then run on a gel and the temperature yielding the 
maximum PCR product was used for subsequent cloning. Non-template 
controls, whereby all reactions minus template DNA were run to confirm 
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reagents were uncontaminated. Amplification of the PCR product of the 
correct size was confirmed by resolving the product on an agarose gel, the 
correct sequence was then confirmed by direct sequencing. The PCR clone 
is inserted in the pENTR 4 dual selection (Invitrogen) (Figure ‎2-1) using 
appropriate restriction enzymes (New England Biolabs). Next, I performed 
the LR recombination reaction between pENTR clones and pLenti PGK 
PuroDEST (w529-2) destination vectors (Figure ‎2-2). (LR is a recombination 
reaction between an attL-containing entry clone and an attR-containing 
destination vector). LR reactions containing 300 ng destination plasmid DNA, 
300 ng pENTR plasmid DNA, 4 μl LR clonase reaction buffer and 4 μl LR 
clonase enzyme were made up to 20 μl with TE (pH 8.0). LR reactions were 
incubated at 25 °C for 1 h. Reactions were terminated by the addition of 
proteinase K (2 μg) and incubation at 37 °C for 10 minutes.  
  
P a g e  | 125 
   
  
 
 
 
Figure ‎2-1: pENTR 4 dual selection entry vector map 
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Figure ‎2-2: pLenti PGK PuroDEST destination vector map 
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2.15.2. Restriction enzyme digestion 
Restriction enzyme digestion was performed on plasmid DNA to confirm the 
presence of a cloned insert. All restriction enzyme digests were performed 
for 1 h at 37 °C with 5-10 units of each enzyme in a total volume of 15-25 μl 
Included in the restriction enzyme mix was 10 x restriction enzyme buffer and 
~1 μg of DNA. The appropriate buffer was selected by consulting New 
England Biolabs enzyme buffer compatibility chart 
(https://www.neb.com/tools-and-resources/interactive-tools/double-digest-
finder) and determining in which buffer the two enzymes had maximum 
activity. After restriction enzyme digestion, 6X DNA loading buffer 
(Fermentas) was added and the product resolved by electrophoresis on an 
agarose gel, the product was then excised and cleaned up using QIAquick 
Gel Extraction Kit (Qiagen). Alternatively, digested PCR products were 
purified directly using the QIAquick Gel Extraction Kit.  
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2.15.3. Plasmid Ligation 
Ligation reactions were performed in a total volume of 20 μl using 20 units (1 
μl) of T4 DNA ligase and 2 μl of 10X T4 DNA ligase buffer (New England 
Biolabs). Varying ratios of insert to plasmid DNA were used in ligation 
reactions, always keeping the insert at higher concentration to the plasmid 
DNA to encourage ligation and prevent vector re-ligation. Two different 
restriction enzymes were used in the cloning process, this aided cloning of 
the fragment in the correct orientation and minimised vector re-ligation. In 
addition, prior to ligation 200- 1000 ng of gel purified restriction digested 
vector was incubated with 2 μl (2 units) of shrimp alkaline phosphatase 
(Promega) as well as 10 x enzyme buffer (Promega). The enzyme-DNA 
mixture was incubated at 37 °C for 15 minutes after which the alkaline 
phosphatase was inactivated by heating to 65 °C for 15 minutes. Alkaline 
phosphatase treatment is another measure designed to minimise vector re-
ligation, promoting the uptake of cloned insert. Typically, the highest ratio of 
insert to vector was used depending on the DNA concentration of the insert. 
Ligation reactions were carried out at 16 °C overnight.  
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2.15.4. Bacterial transformation 
Plasmid DNA was amplified through chemical transformation and expansion 
of bacterial cultures. One vial of 50 μl DH5-Alpha chemically competent 
E.coli (Invitrogen) was transformed with 1-5 μl of ligation reaction or plasmid 
DNA (~100 ng). Bacteria were incubated on ice for a minimum of 5 minutes 
and then heat shocked at 42 °C for 30 s, after which they were placed on ice. 
250 μl of room temperature SOC media (Invitrogen) was added to each vial 
of bacteria and incubated at 37 °C for 1 h with shaking. After shaking, 200 μl 
was streaked on Ampicillin containing LB agar plates. Plates were incubated 
overnight at 37 °C. Successfully transformed bacteria contained an 
Ampicillin-resistant cassette, and therefore survived Ampicillin selection 
growing to form visible colonies, which were then picked for subsequent 
expansion.  
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2.15.5. Plasmid purification 
Plasmid DNA was extracted from transformed bacterial cultures using 
Qiagen miniprep or maxiprep kits according to manufacturer’s instructions. 
Minipreps were performed on 5 ml of bacterial cultures typically transformed 
with ligation reactions during the cloning process in order to test for the 
presence of a DNA insert. Minipreps yielded approximately 20 μg of plasmid 
DNA. For minipreps, a single bacterial colony was picked and placed into 5 
ml of Lysogeny Broth (LB) containing the antibiotic Ampicillin, which was 
grown overnight at 37 °C with shaking. Bacteria were pelleted by spinning at 
3000 rpm for 15 minutes in a desktop centrifuge. The bacterial pellet was re-
suspended, lysed and neutralised through an alkaline lysis method according 
to manufacturer’s instructions (Qiagen). Cellular debris and genomic DNA 
were pelted by spinning at 13000 rpm in a desktop centrifuge. The resulting 
clear solution containing the plasmid DNA was passed through a mini-prep 
column by spinning at 13000 rpm in a desktop centrifuge for 1 minute. Wash 
steps were performed according to manufacturer’s protocol and clean 
plasmid DNA solution was eluted in 50 μl of ddH2O. Maxipreps were 
performed on 300 ml of bacterial culture from which bacteria were pelleted 
through spinning at 3500 rpm for 15 minutes at 4 °C. The pellet was 
resuspended, lysed and neutralised according to manufacturer’s instructions. 
Genomic DNA was pelleted through centrifuging the solution at 3500 rpm for 
30 minutes at 4 °C. Subsequent wash steps and elution were performed 
according to manufacturer’s instructions. The culture was centrifuged at 
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4,000 rpm for 15 minutes at 4 °C. The pellets were then pooled and 
resuspended in 5 ml of buffer P1, and lysed with 10 ml of buffer P2. The 
tubes were inverted for mixing and incubated for 5 minutes at room 
temperature. Ten ml of pre-chilled buffer P3 were added to neutralise the 
reaction and the solution was incubated for 20 minutes on ice before 
centrifugation at 3,500 rpm for 30 minutes at 4 °C. The plasmid in the 
supernatant obtained was bound to the column, washed twice with 30 ml of 
QC buffer and eluted in 5 ml of QF buffer. Maxipreps typically yielded ~1 
μg/μl of plasmid DNA. Plasmid DNA concentration and purity was quantified 
by measuring the absorbance at 260 nm/230 nm and the absorbance at 260 
nm/280 nm respectively using a NanoDrop UV spectrophotometer. The 
plasmid with the S100B insert clones was sequenced confirming that it had 
the expected sequence. The primers used were: forward primer 
5′GTTGACCGAATCACCGACCT3′ and reverse primer 
5′AGAGGTTGATTGTCGAGCGG3′. 
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2.15.6. Agarose gel electrophoresis 
Gel electrophoresis was performed to visualise DNA and or for gel 
purification. Typically 1% weight/volume (w/v) agarose (Sigma) in TAE buffer 
(Tris-acetate 0.4 M, ethylenediaminetetraacetic acid (EDTA) 0.01 M) gels 
were used to resolve DNA fragments > 200 bp. For resolution of DNA < 200 
bp 2-4% agarose gels were used. DNA was visualised through the addition 
of 0.04 mg/ml of GelRed Nucleic acid stain (Biotium). Agarose gels were 
electrophoresed in TAE buffer at a voltage of 100 V. DNA bands in the gel 
were visualised using the G:BOX gel documentation system (Syngene). DNA 
ladders (Fermentas) of the appropriate size range were separated alongside 
experimental samples to estimate the size of DNA molecules.  
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2.15.7. DNA extraction from agarose gel 
Agarose gel extraction was performed on PCR products or digested 
plasmids to be used for subsequent ligation or sequencing. Gel extraction 
was performed using the QIAquick Gel Extraction Kit (Qiagen). Excised 
DNA-containing gel pieces were weighed and three times the volume of QG 
buffer added. Gel was dissolved in QG buffer by incubating at 50 °C until all 
gel was in solution. Then an equivalent volume of isopropanol was added 
and samples loaded onto the QIAquick spin column and processed 
according to manufacturer’s protocol. DNA was eluted from the column in 30 
μl of ddH2O. The QIAquick kit was also used to clean up PCR products 
which had been restriction digested, these products were not run on a gel as 
digesting the product had little effect on size and therefore electrophoresis 
was unnecessary. After restriction digest, 300 μl of QG buffer was added to 
the DNA, followed by 100 μl of isopropanol. The sample was then loaded 
onto the column and processed according to the manufacturer’s instructions. 
DNA was eluted in 30 μl of ddH2O.  
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2.15.8. Lentivirus production 
HEK293T cells were maintained in DMEM media supplemented with 10% 
FBS and 1% penicillin and streptomycin. They were split 3 times per week at 
a ratio of 1:4 using 0.05 mM trypsin/EDTA. The day before the transfection, 
the cells were seeded in a 10 cm dish at a density of 3.5 million cells in 8 ml 
of complete medium and incubated at 37 °C, 5% CO2. On the day of 
transfection, the following mixture was prepared in 1.5 ml micro-tube; 1 μg 
p8.91 (gag-pol expressor), 1 μg pMDG.2 (VSV-G expressor), 1.5 μg plasmid 
DNA containing the S100B insert and sterile TE to final volume of 15 μl. In a 
second microtube, 10 μl Fugene (Roche Diagnostics Ltd., Burgess Hill, West 
Sussex, UK) was added to 200 μl Optimem (Invitrogen) for each of the 
transfection mixtures. The DNA mix was added to the Optimem-Fugene mix 
and left at room temperature for 15 minutes. The medium was changed with 
fresh complete medium and the Optimem/DNA/Fugene mix was added to the 
cells and incubated overnight at 37 °C, 5% CO2. After 24 h, the medium was 
changed to fresh complete medium. At 48 h, the lentivirus-containing 
supernatant was collected in a 10 ml syringe (Fisher) and filtered through a 
0.45 μm filter (VWR International Ltd., Lutterworth, Leicestershire, UK) into a 
50 ml tube. The supernatant was aliquoted and stored at -80 °C.  
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2.15.9. Lentivirus titration 
The day before titration, HEK293T cells were seeded at 0.5x105 cells per 
well in 6 well plates in 2 ml of complete medium and incubated overnight at 
37 °C, 5% CO2. Different concentrations of the virus stock to be titrated were 
added together with 8 μg/ml polybrene (Sigma-Aldrich) to different wells and 
incubated for two days. The cells were detached with trypsin/EDTA 
(Invitrogen) and DNA was extracted. 
In order to determine the number of lentiviral copies per infected cell (c/c) 
qPCR was performed for glyceraldehydes 3-phosphate dehydrogenase 
(GAPDH) and the lentiviral packaging signal. Genomic DNA was extracted 
48 h post lentiviral infection. Primers (Table ‎2-8) were used at a 
concentration of 0.7 μM and probes at 0.15 μM. Reactions were performed in 
a total volume of 50 μl using the Absolute QPCR ROX and dUTP mix 
(ABgene) and 0.01 units AmpErase (Applied Biosystems). 10 μl of genomic 
DNA at a concentration of 50 ng/μl was added to the reactions. The q-PCR 
conditions used were as follows: 50 °C for 2 minutes followed by 95 °C for 15 
minutes and 40 cycles of 95 °C for 15 sec and 60 °C for 1 minute. Reactions 
were run in optical 96-Well Thermal Cycling Plates (Applied Biosystems) on 
Realplex4 Mastercycler (Eppendorf). The number of c/c was determined by 
adjusting the number of lentiviral constructs present to the number of cells 
analysed, using GAPDH. For each sample a neat and 1/10 dilution of 
genomic DNA was run, a negative control of ddH2O was performed for all 
PCRs.  
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Table ‎2-8: List of primers sequences used for Lentiviral titration 
 
 
 
 
2.15.10. Infection of sNF96.2 cells with 
Lentivirus 
Stable infected sNF96.2 cells were selected in 1 μg/ml puromycin (Sigma- 
Aldrich). A puromycin-kill curve is performed to determine the optimal 
concentration needed for selection where the minimum antibiotic 
concentration to use is the lowest concentration that kills 100% of 
untransduced cells and maximal survival transduced cells in 3-4 days. 
  
Primer Name      Primer Sequence (5′ -> 3′) 
GAPDH (Forward) GGAGTCAACGGATTTGGTCGTA 
GAPDH (Reverse) GGCAACAATATCCACTTTACCAGAGT 
GAPDH (TaqMan probe) FAM-GGCAACAATATCCACTTTACCAGAGT-TAMRA 
Lentiviral (Forward) GCACGGCAAGAGGCGA 
Lentiviral (Reverse) CGCACCCATCTCTCTCCTTCTA 
Lentiviral (TaqMan probe) FAM-CGGCGACTCTCTCCTTCTA-TAMARA 
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2.16. Statistical analysis 
All experiments were performed in independent replicates. Error bars 
correspond to the standard deviation from the calculated mean. SPSS 
(Statistical Package for the Social Sciences; Version 22.0, Chicago, IL) was 
used for all statistical analyses. Mean value and standard deviation were 
calculated using descriptive statistics. Comparison of means was performed 
by one-way analysis of variance. Two-tailed Student’s t-test (for continuous 
and normally distributed data), one-way ANOVA (for normal unpaired 
continuous data comparing more than two groups) were used where 
appropriate, and differences were considered statistically significant if p < 
0.05. The Spearman rho test was used for regression analysis to correlate 
two not normally distributed continuous sets of data and the Pearson’s 
correlation test for normally distributed continuous sets of data.  
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3. Role of miR-29c in the 
progression of neurofibroma to 
MPNST 
3.1. Introduction 
MicroRNAs (miRNAs) are small (~22 nucleotides) non-coding RNAs that can 
regulate gene expression by hybridising to complementary target mRNAs, 
resulting in either inhibition of translation or mRNA degradation (Ambros 
2001; Bartel 2004).  miRNAs can influence a wide variety of biological 
processes, including cell proliferation, differentiation and cell death (Schickel 
et al. 2008) . miRNAs are also involved in the development of cancer where 
they have been shown to act as both tumour suppressor genes, e.g., miR-
15, miR-16, miR-29 family and let-7, (Cimmino et al. 2005; S. M. Johnson et 
al. 2005; Mott et al. 2007) as well as oncogenes, e.g., miR-155 and miR-21 
(Kluiver et al. 2005; Chan et al. 2005). The mechanism by which miRNAs 
mediate their effects in cancer includes the regulation of migration and 
invasion of tumour cells (Ma et al. 2007; Yu et al. 2007). The star forms (*) of 
miRNA represent the opposite complementary strand of the guide strand; 
these are generally found to be less expressed compared with the non-star 
forms and are preferentially degraded (Schwarz et al. 2003). 
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Previous investigations into the role of miRNAs in the pathogenesis of 
MPNSTs in patients with and without neurofibromatosis type 1 are limited 
and have resulted in different miRNAs being implicated in the development 
of MPNSTs from neurofibromas. In one study of patients with and without 
neurofibromatosis type 1, using miRNA expression microarrays, 
Subramanian et al. (2010) demonstrated up-regulation of 5 micro-RNAs 
(miR-214, miR-377, miR409-3p, miR-487b, and miR-99b) and 
downregulation of 5 others (miR-517, miR-34a, miR-29a, miR-30e-5p and 
miR-27a) in MPNSTs compared to neurofibromas (Subramanian et al. 2010). 
In another study of 6 MPNSTs and 6 neurofibromas by Itani et al. 2012, the 
miRNA expression analysis demonstrated up-regulation of 6 miRNAs (miR-
21, miR-135b, miR-152, miR-130b, miR-92, and miR-15b) and down-
regulation of 3 others (miR-125b, miR-127, and miR-302d) in MPNSTs 
compared to neurofibromas. Using qRT-PCR method, they confirmed the 
miRNA profiling for the miRNAs which shows more than 2 fold difference in 
expression, namely miR-21, miR-135b, miR-125b, miR-127, and miR-302d in 
neurofibromas, MPNSTs and normal nerve. The qRT-PCR showed that only 
miR-21 which shows significantly higher expression in MPNST higher than 
that in neurofibromas and normal nerves. Accordingly, they studied miR-21 
further and showed that transfection of miR-21 inhibitor significantly 
increased apoptotic activity through increasing caspase activity, suppressed 
cell growth, and upregulated protein level of PDCD4 tumour suppressor 
which has been reported previously as a target for miR-21; indicating that 
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miR-21 inhibitor could induce cell apoptosis of MPNST cells (Itani et al. 
2012). 
Masliah-Planchon et al. (2013) examined miRNAs expression in 50 
neurofibromas and 15 MPNSTs from patients with neurofibromatosis type 1 
and reported miR-139-5p, miR-150, miR-338-3p, miR-195, miR-146a, miR-
95, let7b, miR-186, miR885-5p and miR-200c as significantly downregulated 
in MPNST relative to neurofibromas. However, 103 miRNAs were found to 
be upregulated in MPNST relative to neurofibromas (Masliah-Planchon et al. 
2013). 
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3.2. Aims 
The aims of this part of the project were threefold: 
 Determine which miRNAs may be important in development of 
MPNSTs by looking for differentially expressed miRNAs in 
neurofibromas and MPNSTs from patients with neurofibromatosis type 
1. 
 Select a potential miRNA candidate for further study and examine its 
in vitro effect(s) on cell growth and proliferation following expression of 
the selected miRNA in an MPSNT derived cell line.  
 Identify the specific targets of any putative miRNA candidate. 
 
 
 
 
P a g e  | 142 
   
  
3.3. Results 
3.3.1. miRNA microarrays demonstrate down-
regulation of miR-29 family in MPNSTs versus 
neurofibromas 
In order to identify any miRNAs that may play an important role in 
pathogenesis of MPNSTs, the miRNA microarray expression data from 10 
neurofibromas and 10 malignant peripheral nerve sheath tumours 
(MPNSTs), which had previously been generated in our lab (by Dr Nadège 
Presneau), were analysed by hierarchical clustering to look for differentially 
expressed genes. Details of the clinical samples (which are all derived from 
neurofibromatosis type 1 patients) and miRNA microarrays used are given in 
chapter 2. 
Using this approach (with a cut off value of q = 8.48E-03 for the least 
significant miRNA) 16 miRNAs were identified as significantly differentially 
expressed in MPSNTs and neurofibroma (Figure  3-1A). The majority, 
fourteen, were downregulated in MPNSTs. These included miR-30e*, miR-
29c*, miR-29c, miR-340*, miR-30c, miR-139-5p, miR-195, miR-151-5p, miR-
342-5p, miR-146a, miR-150, miR-223, let-7a and let-7g. The remaining two 
however, miR-210 and miR-339-3p, were found to be upregulated in MPNST 
compared with neurofibromas.  
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Of the 16 differentially expressed genes miR-29c was of particular interest 
since, as well as showing significant reduction in the level of expression in 
MPNSTs, this miRNA has also been implicated in a variety of other 
malignancies (Mraz et al. 2009; Stamatopoulos et al. 2009; Ding et al. 2011; 
Sengupta et al. 2008; Fabbri et al. 2007; Pass et al. 2010).  miR-29c also 
belongs to a family of miRNAs which includes miR-29a, b, c*, b-1*. All the 
miR-29 family members share a common sequence of the seed region and 
are therefore predicted to target largely overlapping sets of genes. As an 
initial step, I decided to examine whether other members of the miR-29 
family might also be differentially expressed in MPNSTs relative to 
neurofibromas. Generation of a supervised heat-map for the miR-29 family 
including miR-29a, b, c* and b-1*, demonstrated that these were also 
significantly downregulated in MPNST compared with neurofibromas with a   
p < 0.05 (Figure  3-1B).   
I next focussed my attention on miR-29c for further studies. I concentrated 
on the mature form of miR-29c since the star forms of miRNA are generally 
found to be less expressed in vivo compared with the non-star forms 
(Schwarz et al. 2003). In addition, the mature form of miRNA is the one that 
incorporate in the RNA induced silencing complex (RISC) which causes its 
stabilisation and this process is accompanied by destruction of the (*) form 
(Schwarz et al. 2003).  
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Figure  3-1: miRNA expression profiling of neurofibromas and MPNSTs 
by microarray analysis 
Microarray expression data from 10 neurofibromas and 9 MPNSTs are shown. (A) 
Unsupervised hierarchical clustering analysis representing the 16 most significant 
differentially expressed miRNAs (with a cut off of q= 8.48E-03 for the least significant 
miRNA) demonstrating up-regulation of miR-210 and miR-339-3p and downregulation of the 
remaining 14 miRNAs in MPNSTs compared to neurofibromas. (B) Supervised heat-map of 
miR-29 family demonstrating significantly reduced expression of all miR-29 family members 
in MPNSTs relative to neurofibromas (p < 0.05). The columns in each heat map represent 
individual tumour samples and the rows represent relative expression levels of individual 
miRNAs in each tumour. The yellow and orange colours indicate relatively high and low 
expression, respectively. 
(A) 
(B) 
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3.3.2. Confirmation of decreased miR-29c 
expression in MPNSTs versus neurofibromas 
by qRT-PCR  
In order to validate the results from the miRNA microarray experiments, the 
expression of the mature form of miR-29c was examined in the 10 
neurofibromas and 10 MPNSTs by quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) using a commercially available 
TaqMan reporter assay. Details of the assay and quantification methods 
used are as previously described in chapter 2. The small nucleolar RNA, 
RNU66, was used as a control for normalization of the qRT-PCR data. 
RNU66 is an ideal candidate for use as an internal control in Real time 
quantitative PCR since it exhibits abundant and constant expression across 
a wide variety of human tissues. All experiments were conducted in duplicate 
and the data was analysed using the (2^-ΔCt) method.  
The results from the miR-29c qRT-PCR experiments can be seen in 
Figure ‎3-2. These demonstrated a significant reduction in expression of miR-
29c in MPSNTs compared to that in neurofibromas (p < 0.001) thus 
confirming the previous findings from the microarray expression data. 
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Figure  3-2: Downregulation of miR-29c expression in MPNSTs 
compared to neurofibromas demonstrated by qRT-PCR 
(A) Bar graph demonstrating miR-29c expression levels in 10 neurofibromas and 10 
MPNSTs.  The qRT-PCR data was normalised to expression of RNU66 nucleolar 
RNA. Each bar represents the average results of two technical replicates from one 
experiment.  Error bars represent standard deviation. (B) Summary of the miR-29c 
qRT-PCR results.  The box plots show the median, interquartile  boxes, 95th 
percentile range for miR-29c expression in 10 neurofibromas and 10 MPNSTs 
(unpaired Student’s t-test, *p < 0.001).  
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3.3.3. NF1 mRNA expressed at low levels in 
MPNSTs and neurofibromas  
Biallelic inactivation at the NF1 gene locus is a hallmark of all neurofibromas 
and MPNSTs (Legius et al. 1993; Colman et al. 1995). In order to confirm the 
genotype of our 10 neurofibromas and 10 MPNSTs as being null for the NF1 
gene, I examined the levels of NF1 mRNA expression in these samples 
using a SYBR green-based qRT-PCR. Details of the NF1 primers and 
thermo-cycling conditions used are given in chapter 2. The sNF96.2 cell line, 
which is derived from an NF1-deficient human MPNST cell line, was used as 
a negative PCR template control for NF1 mRNA expression and the human 
embryonic kidney cell line HEK293T, which is wild-type homozygous for the 
NF1 gene, was used as a positive PCR template control. The qRT-PCR data 
was normalised to the GAPDH gene and all experiments were performed in 
duplicate. A summary of the NF1 qRT-PCR can be seen in Figure  3-3. The 
expression of NF1 mRNA in the 10 NFs and 10 MPNSTs was found to be 
extremely low compared to expression in the wild-type HEK293T cells and 
resembled more closely the data from the negative control sNF96.2 cell line. 
This finding along with loss of heterozygosity of the neurofibromin 1 locus, as 
recently reported by SNP genotyping analysis on the pooled samples from 
the same 10 neurofibromas and 10 MPNST (Feber et al. 2011), is consistent 
with functionally biallelic inactivation of neurofibromin 1 gene these tumour 
samples (Legius et al. 1993; Colman et al. 1995).   
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Figure  3-3: Low levels of NF1 mRNA expression in neurofibromas and 
MPNSTs  
qRT-PCR of NF1 mRNA expression in 10 neurofibromas and 10 MPSNTs. The 
HEK293T cell line, which is homozygous wild-type for the NF1 gene, was used as a 
positive PCR control and the sNF96.2 MPSNT-derived cell line, which is null for the 
NF1 gene, was used as a negative template control. The qRT-PCR data was 
normalised to GAPDH gene. The results shown represent the average of two 
technical replicates from one experiment. Error bars represent standard deviation.  
The data is consistent with biallelic inactivation of NF1 in all 10 neurofibromas and 
10 MPNSTs. 
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3.3.4. miR-29c expression in different types 
of sarcomas and low-grade tumours  
Having determined that miR-29c is expressed at low levels in MPNSTs 
relative to neurofibromas I decided to look at the expression of this miRNA in 
other sarcomas and low-grade tumours. I selected 35 fresh frozen tumours 
for examination including 4 Neurofibromas, 3 MPNSTs, 4 Liposarcomas, 4 
Osteosarcomas, 4 Synovial Sarcomas, 4 Rhabdomyosarcomas, 3 Solitary 
fibrous tumours, 3 Fibromatosis desmoid type, 2 Chondromas and 2 
Chondroblastomas. Total RNA was isolated from frozen sections prepared 
from each tumour, and the miR-29c qRT-PCR was carried out as previously 
described for the MPNSTs and neurofibromas using a TaqMan reporter 
assay (Chapter 2). The results from these qRT-PCR demonstrated relatively 
low levels of miR-29c expression in most of these different tumour types 
compared with expression in neurofibromas. Chondroblastomas exhibited 
relatively high levels of miR-29c compared to all the other tumours types 
followed by the solitary fibrous tumours although the error bars were fairly 
large in the latter case. These findings suggest that miR-29c could play a 
role in the pathogenesis of a wide variety of sarcomas and low-grade 
tumours in addition to MPNSTs. 
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Figure  3-4: miR-29c expression in neurofibromas and MPNSTs 
compared with other sarcomas and low-grade tumours 
qRT-PCR results demonstrating relatively low levels of miR-29c expression in 
nearly all the different sarcomas and low-grade tumours compared to expression in 
neurofibromas.  Chondroblastomas demonstrate relatively high levels of miR-29c 
expression. Box plots show the median, interquartile boxes and 95th percentile 
range for miR-29c expression.  The number of each tumour type analysed is given 
in brackets. The qRT-PCR data was normalised to expression of RNU66 nucleolar 
RNA. The results shown represent the average of two technical replicates from one 
experiment. 
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3.3.5. In vitro studies on the MPSNT- derived 
sNF96.2 cell line  
3.3.5.1. Confirmation of NF1 gene mutation in 
sNF96.2 cell line  
In order to determine what role miR-29c might play in the in pathogenesis of 
MPNSTs, functional studies were carried out in vitro using the MPNST-
derived cell line sNF96.2. This cell line was chosen because it had previously 
been shown in our lab to express very low levels of mature miR-29c (Dr 
Nadege Presneau personal communication). As a preliminary step, the 
sNF96.2 cell line was first genotyped to confirm the presence of a germline 
mutation in exon 21 (3683delC) of the neurofibromin (NF1) gene and loss of 
the remaining wild-type (WT) NF1 allele as has previously been documented 
in this cell line (Perrin et al. 2007). DNA was extracted from cultured sNF96.2 
cells and the region around exon 21 of the NF1 gene, which encompasses 
the single nucleotide deletion, was amplified by PCR and sequenced (details 
of the PCR and sequencing methods are given in chapters 2). DNA from the 
HT1080 fibrosarcoma cell line which is known to be homozygous wild-type 
for the NF1 gene was also amplified and sequenced for use as a control. The 
results of the sequencing analysis, which confirmed presence of the NF1 
gene mutation in the sNF96.2 cell line, are shown in Figure  3-5. 
. 
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Figure  3-5: Single nucleotide deletion in the NF1 gene of sNF96.2 
Sequencing of neurofibromin 1 (NF1) exon 21 confirms the homozygous deletion 
(3683delC) in exon 21 of sNF96.2 cells. The normal NF1 sequence is demonstrated 
in HEK293T cells which are wild-type for NF1. 
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3.3.5.2. Transfection of miR-29c into MPNST-derived 
cell line sNF96.2 
Having confirmed that the sNF96.2 cell line has a mutation in the NF1 gene, 
the effects of expressing miR-29c in this cell line were examined in vitro by 
transfecting synthetic miR-29c mimics into the cell line using oligofectamine 
as described in chapter 2. Control experiments in which sNF96.2 cells were 
transfected with scrambled oligonucleotides were also carried out at the 
same time. The efficiency of transfection was examined at two time points 
following the start of transfection; RNA was extracted from transfected cells 
at 24 and 48 h and the levels of miR-29c expression was then determined by 
qRT-PCR as previously described (chapter 2). The results demonstrated an 
increase of miR-29c expression in the cells transfected with synthetic miR-
29c mimics at 24 h compared to control cells transfected with scrambled 
nucleotides and the was even more marked at 48 h post-transfection 
(Figure  3-6). These findings demonstrated that the miR-29c mimics had 
successfully been transfected and were being expressed in the MPNST- 
derived sNF96.2 cell line. 
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Figure  3-6: Increased miR-29c expression following transfection of 
sNF96.2 cells 
qRT-PCR results demonstrating increased miR-29c expression in cells transfected 
with miR-29c mimics compared to control cells transfected with scrambled 
oligonucleotides at 24 and in 48 h post-transfection (paired Student’s t-test, *p < 
0.001 at 24 and 48 h).  The qRT-PCR data was normalised to expression of RNU66 
nucleolar RNA.  Bars represent the average results obtained from three 
independent experiments (three biological replicates).  Error bars represent 
standard deviation. 
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3.3.5.3. Functional effects of miR-29c transfection on 
proliferation and migration of sNF96.2 cells  
3.3.5.3.1. Cell proliferation  
Next, I wanted to examine miR-29c in vitro effects on cell proliferation. 
Following successful transfection of miR-29c into sNF96.2 cells, functional 
studies examining the effects of miR-29c expression on cell proliferation and 
migration were carried out on the transfected cells. 
Cell proliferation was assessed over a 5 day period using two different 
methods; (i) MTS assay which detects cell viability via a colorimetric assay 
and (ii)  Kinetic Live Cell Imaging by the IncuCyte™ System that gives 
updates on cell confluence in real-time. Details of both assays can be found 
in chapter 2. 
The results from the MTS assay, which are summarised in Figure ‎3-7A, 
showed no significant difference in cell proliferation following transfection of 
sNF96.2 cells with either miR-29c mimics or scrambled oligonucleotides. The 
live cell imaging data was found to be in agreement with that obtained by 
MTS assay i.e. there was no significant difference in cell proliferation 
following transfection of sNF96.2 cells with either miR-29c mimics or 
scrambled oligonucleotides (control) over a 5 day period (Figure ‎3-7B). 
These findings suggest miR-29c does not significantly alter cell proliferation 
when expressed in MPSNT–derived cells. 
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Figure  3-7: sNF96.2 cell proliferation following miR-29c transfection  
(A) MTS assay showing no significant difference in proliferation between 
sNF96.2 cells transfected with miR-29c mimics (test cells) or scrambled 
oligonucleotides (controls).  Cells were plated on Day 0 and transfected 24 h later 
(Day 1).  Cell viability was measured at five separate time points (Days 0 to 5). The 
results are expressed as units of absorbance at 490 nm wavelength vs days after 
transfection. The results shown represent the average results from three 
independent experiments (three biological replicates). Error bars represent standard 
deviation (B) Incucyte quantification of cell confluence over 50 hs showing no 
significant difference in proliferation rates between control and test cells. The data is 
expressed as percentage confluence vs number of hours. The graph show the 
results obtained from three replicate transfections from one experiment.  
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3.3.5.3.2. Cell migration 
Following the cell proliferation analyses I wanted to test the effect of miR-29c 
expression on cell migration. Cell migration was analysed in sNF96.2 cells 
using transwell plates and the scratch/wound healing assays. These assays 
are described in more detail in chapter 2. 
Figure ‎3-8 A and B demonstrates the results from the cell migration assay 
which revealed significantly fewer numbers of miR-29c-transfected sNF96.2 
cells had invaded the transwell membranes compared to control cells 
transfected with scrambled oligonucleotides.  
The scratch-wound healing assay was carried on sNF96.2 cells transfected 
with either miR-29c mimics or scrambled oligonucleotides. On reaching 
confluence, a scratch was made through the central axis of each well in cell 
culture plate, and the growth of cells in the scratch area was monitored using 
time-lapse photography. At 60 h post-transfection I found a significant 
reduction in the number of miR-29c transfected cells which had migrated into 
the wound area compared to control cells transfected with scrambled 
oligonucleotides (Figure ‎3-8C). 
The findings suggest that miR-29c expression may play an important role in 
suppressing the migratory behaviour of MPSNT- derived cells. 
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Figure  3-8: miR-29c transfection inhibits sNF96.2 cell migration  
(A) Cell migration assay showing MPSNT-derived sNF96.2 cells attached to 
transwell membranes. Around 25000 cells were transferred to individual wells 2 
days post-transfection and after 6 h incubation the cells were fixed and stained with 
GelRed. Markedly fewer numbers of miR-29c-transfected cells are visible on the 
bottom of the transwell membrane compared to controls. The migrated cells on the 
membrane were counted in four fields where the cells were evenly distributed and 
the graph (B) shows the average number of cells in each field from three 
independent experiments (three biological replicates). Horizontal bars depict mean 
number of cells (unpaired Student’s t-test, *p < 0.05). (C) In vitro scratch wound 
healing assay demonstrating fewer numbers of miR-29c transfected sNF96.2 cells 
migrating into the wound area compared to control cells 60 h post-transfection. 
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3.3.6. In silico prediction of miR-29c targets 
implicated in migration 
Following the demonstration that miR-29c expression can inhibit the 
migration of MPNST-derived cells, I next set out to identify specific mRNAs 
that may be targeted by miR-29c. Predicted targets of miR-29c were sought 
in silico using TargetScan (http://www.targetscan.org/), PicTar 
(http://pictar.mdc-berlin.de/) and MiRanda 
(http://www.microrna.org/microrna/home.do) software algorithms which are 
specifically designed for the identification of microRNA targets (Bartel 2009). 
Different prediction algorithms usually have a high degree of overlap, 
however, they are not 100% identical, and there is often a need to 
crosscheck multiple algorithms to get an additional layer of confidence for the 
true positive targets. Using these three algorithms, I identified a list of 223 
predicted gene targets for miR-29c.  
Next, I performed a functional classification of the 223 predicted targets 
using the DAVID program (http://david.abcc.ncifcrf.gov/). Based on the 
functional classification, the top category identified was extracellular matrix 
genes (Table  3-1). Table  3-2 describes the predicted miR-29c target genes 
relevant to migration in three different in silico databases (TargetScan, 
PicTar, and MiRanda); where 0 i.e. not present in database 1 i.e. present in 
database. SUM i.e. the sum of the three in silico databases. I conclude from 
this that collagen genes are predicted targets for miR-29c in all the three in 
silico databases, which make them interesting for further studies.  
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Table  3-1: Gene ontology analysis for miR-29c predicted target genes 
identified extracellular matrix genes as the top category. 
No. of 
Genes 
p-value Annotations 
13 4.10E-09 GO:0030198 :extracellular matrix organization (BP) 
49 4.96E-06 
GO:0010556 :regulation of macromolecule biosynthetic 
process (BP) 
48 4.86E-06 
GO:2000112 :regulation of cellular macromolecule biosynthetic 
process (BP) 
50 5.24E-06 GO:0031326 :regulation of cellular biosynthetic process (BP) 
25 1.03E-05 GO:0022008 :neurogenesis (BP) 
48 1.21E-05 GO:0010468 :regulation of gene expression (BP) 
24 1.04E-05 GO:0048699 :generation of neurons (BP) 
49 1.02E-05 
GO:0019219 :regulation of nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process (BP) 
6 1.90E-05 GO:0071230 :cellular response to amino acid stimulus (BP) 
6 3.24E-05 GO:0071418 :cellular response to amine stimulus (BP) 
18 5.10E-05 GO:0031175 :neuron projection development (BP) 
41 0.000266939 GO:0051252 :regulation of RNA metabolic process (BP) 
17 0.000255123 GO:0072358 :cardiovascular system development (BP) 
18 0.000263187 GO:0048666 :neuron development (BP) 
41 0.000332515 GO:0006351 :transcription, DNA-dependent (BP) 
13 0.000778813 GO:0001944 :vasculature development (BP) 
5 0.00091948 GO:0043588 :skin development (BP) 
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Table  3-2: Description of selected predicted target genes relevant to 
migration and invasion in three different in silico databases 
(TargetScan, PicTar, and MiRanda) 
 
Gene 
Symbol 
Target 
scan 
PicTar MiRanda SUM 
Collagens 
COL1A1 1 1 1 3 
COL1A2 1 1 1 3 
COL4A4 1 1 1 3 
COL4A5 1 1 1 3 
COL4A1 1 1 1 3 
COL4A3 1 1 1 3 
COL4A2 1 1 1 3 
COL5A3 1 1 1 3 
COL5A2 1 1 1 3 
COL6A3 1 1 1 3 
COL7A1 1 1 1 3 
COL11A1 1 1 1 3 
COL22A1 1 1 1 3 
Matrix metalloproteinases 
MMP2 0 1 0 1 
MMP24 0 0 0 0 
Transforming growth factor beta 
TGB3 0 1 
 
1 
Desintegrin and metalloproteases 
ADAMTS6 1 1 0 2 
ADAMTS7 1 1 0 2 
ADAMTS9 1 1 0 2 
ADAMTS10 0 0 1 1 
ADAMTS17 1 0 1 2 
ADAMTS18 1 1 1 3 
ADAM19 0 1 0 1 
Integrins 
ITGB1 0 0 1 1 
ITGA6 0 1 0 1 
ITGA11 0 1 0 1 
 
Key: 0= not present in database; 1= present in database; SUM= sum of three in silico 
databases   
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Further analysis of the data from our previous gene expression microarray 
performed on neurofibroma and MPNST (Henderson et al. 2005) showed 
that extracellular matrix genes which are predicted targets for miR-29c are 
more highly expressed in MPNST as compared to neurofibroma (Figure  3-9).  
 
 
Figure  3-9: Extracellular matrix genes are highly expressed in MPNSTs 
compared to neurofibromas 
Heat-map demonstrating high expression of ECM genes in MPSNTs using gene 
expression microarrays. Red boxes depict genes that are highly expressed. Genes 
with low levels of expression are depicted by green boxes. 
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3.3.7. miR-29c targets collagen matrix genes 
My in silico target prediction analyses identified the extracellular matrix 
(ECM) genes COL1A1, COL1A2, COL4A1, COL4A2, COL5A2 and 
COL21A1 as possible targets for miR-29c. These ECM genes have 
previously been identified in our lab by gene expression microarray analysis 
as being overexpressed in MPSNTs compared to expression in 
neurofibromas (Henderson et al. 2005). I therefore decided to examine 
whether ectopic expression of miR-29c in vitro could have an influence on 
the expression of these ECM genes. This was done by analysing the 
expression of these genes by qRT-PCR in miR-29c transfected sNF96.2 
cells and control cells transfected with scrambled oligonucleotides.  
Details of the qRT-PCR experiments including primers used are given in 
chapter 2. The results of these qRT-PCR experiments are summarised in 
Figure  3-10. A significant reduction in expression (between 65% - 85%) of all 
six ECM target genes was found the in miR-29c-transfected sNF96.2 cells 
compared to controls (Figure  3-10). These findings suggest miR-29c may 
play a role in development of MPSNTs by down-regulating expression of 
ECM genes and in particular COL1A1, COL1A2, COL4A1, COL4A2, 
COL5A2, and COL21A1. 
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Figure  3-10: Down-regulation of collagen gene expression in miR-29c 
transfected sNF96.2 cells 
qRT-PCR results demonstrating reduced expression of 6 collagen genes in miR-
29c-transfected sNF96.2 cells relative to expression in control cells transfected 
with scrambled oligonucleotides (which are all given the value 1), (paired 
Student’s t-test, *p < 0.001). The qRT-PCR data was normalised to GAPDH 
gene.  Bars represent the average results from three independent experiments 
(three biological replicates). Error bars represent standard deviation. 
  
P a g e  | 165 
   
  
3.3.8. miR-29c directly influenced MMP2 but 
indirectly inhibits MMP9 activity  
The reduced migration of sNF96.2 cells following transfection with miR-29c 
mimics led me to speculate as to whether this could be a result of decreased 
proteolytic activity in these cells. Previous analyses in our lab using 
zymography have shown that sNF96.2 cells transfected with miR-29c mimics 
have reduced proteolytic activity. Specifically, the bands corresponding to 
Matrix metalloproteinases 2 and 9 (MMP2 and MMP9) were shown to be 
absent in zymographs of supernatants taken from miR-29c-transfected 
sNF96.2 cells (Figure 3-11A). In order to throw more light on these findings I 
decided to examine the expression of MMP2 and MMP9 in miR-29c-
transfected sNF96.2 cells at both the mRNA and protein level by qRT-PCR 
and Western blot analysis. Details of the qRT-PCR and Western blot 
techniques used are described in Chapter 2. 
Western blots were prepared using extracts from sNF96.2 cells transfected 
with miR-29c mimics or scrambled nucleotides and probed using antibodies 
for MMP2 and MMP9 antibodies. The results from the Western blot analysis 
demonstrated clear expression of the 92 KDa MMP9 protein in miR-29c- 
transfected sNF96.2 cells as well as in the control cells (Figure 3-11B). 
Expression of MMP9 mRNA transcripts was also confirmed by qRT-PCR in 
both test and control sNF96.2 transfected cells. MMP2 protein (72 KDa) 
however was not detectable in miR-29c-transfected sNF96.2 cells, although 
it was expressed in control sNF96.2 cells. In addition, a significant reduction 
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of MMP2 mRNA expression was demonstrated by qRT-PCR in miR-29c 
transfected sNF96.2 cells compared to control cells. 
These findings demonstrate that the inhibition of MMP9 proteolytic activity in 
miR-29c-transfected SNP96.2 cells is not due to direct abrogation of MMP9 
mRNA or protein expression but may be brought about indirectly through an 
as yet unknown mechanism (I will investigate this in the next section). MMP2 
activity on the other hand appears to be directly influenced by expression of 
miR-29c in sNF96.2 cells; expression of miR-29c leads to reduced 
expression of MMP2 mRNA, which in turn leads to diminished MMP2 protein 
expression thus reducing MMP2 enzyme activity in these cells.  
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Figure  3-11: MMP2 and MMP9 activity & expression in miR-29c 
transfected sNF96.2 cells  
(A) Zymograph of supernatants from sNF96.2 cells transfected with miR-29c mimics (test) or 
scrambled oligonucleotides (control). Zones of gelatinolytic activity are visualised as 
transparent bands against a dark background. The MMP2 and MMP9 bands are visible in 
control cells but absent in the test cells. MMP3 expression is visible in all samples. (B) 
Western blots demonstrating expression of MMP9 and MMP3 protein in all cultures. MMP2 
protein is clearly visible in control cells but is absent in miR-29c transfected cells. (C) qRT-
PCR data demonstrating significantly reduced MMP2 mRNA (paired Student’s t-test, *p < 
0.01) but no significant alteration of MMP9 mRNA expression in miR-29c-transfected 
sNF96.2 cells compared to that in control cells. The qRT-PCR data was normalised to 
GAPDH gene. The bars represent the average results from three independent experiments 
(three biological replicates). Error bars represent standard deviation. Zymograph image 
courtesy of Dr. Malihe Eskandarpour. 
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3.3.9. miR-29c partially inhibits MMP9 activity 
through influencing TGFB3  
Another predicted target of miR-29c predicted by my in silico analysis is 
Transforming Growth Factor Beta3 (TGFB3). This gene is particularly 
interesting as a link between MMPs and the TGFB gene family has 
previously been demonstrated in breast cancer (Wiercinska et al. 2010). I 
therefore decided to investigate whether TGFB3 is a target of miR-29c in 
MPSNT-derived cells by examining the expression of this gene in miR-29c-
transfected cells by qRT-PCR. Details of the TGFB3 primers and qRT-PCR 
protocol used are described in more detail in chapter 2. The results from 
these experiments demonstrated a significant reduction in TGFB3 mRNA 
expression at 24 h following transfection of sNF96.2 cells with miR-29c-
mimics compared to expression in control cells transfected with scrambled 
oligonucleotides, and by 48 h, the expression of TGFB3 mRNA was reduced 
by almost 50% in the miR-29c-transfected cells (Figure ‎3-12). These findings 
suggest miR-29c expression may have an important influence on the 
expression of TGFB3 as well as affecting the expression of MMP2 in 
MPNSTs. 
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Figure ‎3-12: Downregulation of TGFB3 mRNA is induced by miR-29c  
qRT-PCR data demonstrating down-regulation of TGFB3 mRNA expression in sNF96.2 cells 
transfected with miR-29c mimics at 24 and 48 h following transfection with miR-29c mimics 
compared to expression in control cells transfected with scrambled oligonucleotides (paired 
Student’s t-test, *p < 0.01 after 48 h). The qRT-PCR data was normalised to GAPDH gene. 
Bars represent the average results from three independent experiments (three biological 
replicates).  Error bars represent standard deviation. 
 
I next investigated a possible link between TGFB3 and MMP2 or MMP9 by 
reducing the expression of TGFB3 in sNF96.2 cells and examining the 
effect(s) this might have on the expression of MMP2 and MMP9. TGFB3 
mRNA expression was inhibited by transfecting anti-TGFB3 siRNA into wild-
type sNF96.2 as described in chapter 2. The cells were harvested 24 and 48 
h following transfection and the mRNA expression of TGFB3 in the siRNA 
transfected cells was measured by qRT-PCR and compared to expression of 
TGFB3 in control sNF96.2 cells, which had been transfected with scrambled 
oligonucleotides. The results of the TGFB3 qRT-PCRs are shown in 
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TGFB3 mRNA expression was reduced by more than 50% in the anti-TGFB3 
siRNA transfected cells. Having demonstrated successful inhibition of 
TGFB3 mRNA expression by siRNA the MMP2 and MMP9 mRNA and 
protein expression were examined in the anti-TGFB3 siRNA treated cells, as 
well as control cells, by qRT-PCR and western blot analysis as previously 
described (Chapter 2). The results from these experiments demonstrated no 
significant alteration in the expression of MMP2 or MMP9 at either the mRNA 
transcript or protein level following inhibition of TGFB3 mRNA expression in 
sNF96.2 cells (Figure  3-13 B & C respectively).  
The MMP9 and MMP2 enzyme activity in the supernatant of anti-TGFB3 
siRNA-treated cultures and control sNF96.2 cells was then examined by 
gelatine zymography as described in chapter 2. The results of these 
experiments are shown in Figure  3-13D. Inhibition of MMP9 and MMP2 
activity was clearly demonstrated in the supernatants of anti-TGFB3 siRNA 
treated cells compared to that in supernatants of control cells, as 
demonstrated by reduced intensity of the MMP2 and MMP9 transparent 
bands on the zymography gel.  
My findings suggest that TGFB3 does not have a direct influence on the 
expression of MMP9 and MMP2 mRNA or protein but may indirectly bring 
about partial inhibition of MMP9 and MMP2 activity by an as yet unknown 
mechanism. Since TGFB3 expression was also shown to be under the 
influence of miR-29c, my findings suggest that miR-29c may influence the 
activity of MMP2 and MMP9 through targeting TGFB3. 
P a g e  | 171 
   
  
  
 
  
 
 
Figure  3-13: Down-regulation of TGFB3 mRNA expression partially inhibits 
MMP9 and MMP2 activity  
(A) qRT-PCR demonstrating down-regulation of TGFB3 mRNA expression in sNF96.2 
cells 48 h after transfection with anti-TGFB3 siRNA compared to expression in control 
cells transfected with scrambled oligonucleotides (SC), (paired Student’s t-test, *p < 0.05 
and **p < 0.01 at 24 and 48 h, respectively).  (B) qRT-PCR demonstrating no alteration in 
MMP2 or MMP9 mRNA levels in anti-TGFB3 siRNA treated sNF96.2 cells compared to 
expression in control cells. The qRT-PCR data in (A) and (B) was normalised to GAPDH 
gene.  Bars represent the average results from three independent experiments (three 
biological replicates).  Error bars represent standard deviation. (C) Western blot 
demonstrating no significant change in MMP2 or MMP9 protein expression in sNF96.2 
cells transfected with anti-TGFB3 siRNA compared to expression in control cells.  (D) 
Gelatin zymography of supernatants from sNF96.2 cells showing decreased activity of 
MMP2 and MMP9, but not MMP3, in cells treated with anti-TGFB3 siRNA compared to 
control cells transfected with scrambled oligonucleotide as demonstrated by reduced 
intensity of the transparent bands on the gel. 
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3.3.10. Suppression of ROBO1 expression by 
miR-29c  
Another interesting gene which I identified in-silico as a potential target of 
miR-29c is ROBO1. This gene has been reported to be involved in cancer 
cell migration and invasion in gliomas as well pancreatic cancer and breast 
cancer (Dontula et al., 2013; Hang et al., 2014; Yang et al., 2012). Closer 
inspection of previous microarray data from our laboratory (Henderson et al. 
2005) also revealed ROBO1 to be significantly highly expressed in MPNSTs 
compared to neurofibromas (p < 0.01).  
In order to determine whether ROBO1 is a target for miR-29c, I examined the 
expression of ROBO1 by qRT-PCR in sNF96.2 cells, which had previously 
been transfected with miR-29c mimics or scrambled oligonucleotides. Details 
of the cell transfection and ROBO1 qRT-PCR protocols are given in chapter 
2. The qRT-PCR results demonstrated a significant reduction in ROBO1 
mRNA levels at 24 h following transfection of miR-29c into sNF96.2 cells 
compared to expression in control cells transfected with scrambled 
oligonucleotides. At 48 h post-transfection, the expression of ROBO1 mRNA 
was further reduced to approximately 50% of that in the control cells (p < 
0.05) (Figure  3-14A). The findings demonstrate that miR-29c can influence 
and down-regulate the expression of ROBO1 transcript in MPNST-derived 
cells. 
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In order to confirm these findings at the protein level, the expression ROBO1 
protein was examined in the transfected cultures by Western blot analysis. 
The HEK293T cell line was used as a positive control for ROBO1 protein 
expression and GAPDH was used as a control for protein loading onto the 
western blot gels. The results of the Western blot analysis can be seen in 
Figure ‎3-14B. A strong 180 KDa ROBO1 protein signal was clearly visible in 
control HEK293T cells. However only a very weak ROBO1 protein signal 
was seen in control cells transfected with scrambled oligonucleotides and 
there was no evidence of ROBO1 protein expression in the cells transfected 
with miR-29c. These findings suggest that despite ROBO1 mRNA being 
expressed in sNF96.2 cells, the transcript is not translated into ROBO1 
protein at any detectable level.  
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(B) 
 
Figure  3-14: Downregulation of ROBO1 expression following 
transfection of sNF96.2 cells with miR-29c  
(A) qRT-PCR data demonstrating significant reduction in ROBO1 mRNA 
expression in sNF96.2 cells at 24 and 48 h following transfection with miR-29c 
mimics compared to expression in control cells transfected with scrambled 
nucleotides (paired Student’s t-test, *p < 0.05).  The qRT-PCR data was normalised 
to GAPDH gene. Bars represent the average results from three independent 
experiments (three biological replicates).  Error bars represent standard deviation.  
(B) Western blot demonstrating very weak expression of the 180 KDa ROBO1 
protein at 48 h following transfection of sNF96.2 cells with scrambled nucleotides 
and no visible ROBO1 protein in cells transfected with miR-29c mimics.  Strong 
expression of ROBO1 can be seen in the HEK293T positive control cells.  GAPDH 
was used as a protein loading control. 
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3.4. Summary of results 
Using microRNA microarray analysis of 10 MPNSTs and 10 neurofibromas 
16 differentially expressed genes were identified. Of these, miR-29c was of 
particular interest since, as well as showing a significant reduction in levels of 
expression in MPNSTs; this miRNA has also been implicated in a variety of 
other malignancies. Other members of the miR-29 family were examined 
using the same microarrays and showed that expression of miR-29a, b, c* 
and b-1*, as well as miR-29c, were also significantly downregulated in 
MPNSTs relative to neurofibromas. I then focussed my attention on miR-29c 
for further studies. Using qRT-PCR, I confirmed decreased expression of 
miR-29c in MPNSTs and also demonstrated relatively low levels of miR-29c 
expression in a variety of other sarcomas and low-grade tumours compared 
to expression neurofibromas.  
In order to determine what role miR-29c might play in the pathogenesis of 
MPNSTs, in vitro functional studies were carried out using the MPNST-
derived cell line sNF96.2, which had previously been shown to express very 
low levels of mature miR-29c. The sNF96.2 cell line was first sequenced to 
confirm presence of a germline mutation in exon 21 (3683delC) of the 
neurofibromin (NF1) gene as well as loss of the remaining wild-type NF1 
allele. The effects of miR-29c expression on cell proliferation and migration 
were then examined by transfecting the sNF96.2 cell line with miR-29c 
mimics. Using the MTS assay and Incucyte kinetic live cell imaging, I found 
miR-29c expression does not significantly alter the proliferation of sNF96.2 
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cells. However, using transwell plates and the scratch/wound healing assays 
I showed that miR-29c expression could inhibit the migration of sNF96.2 
cells. 
Predicted targets of miR-29c were sought in silico using TargetScan, PicTar 
and MiRanda databases. I identified a list of 223 predicted gene targets for 
miR-29c. Functional classification of these 223 predicted targets using the 
DAVID programme, identified the top category was extracellular matrix 
genes.  
The collagen genes COL1A1, COL1A2, COL4A1, COL4A2, COL5A2, and 
COL21A1 were identified as possible targets for miR-29c in all three data 
databases. These ECM genes had also previously been identified in our lab 
by gene expression microarrays as being overexpressed in MPSNTs 
compared neurofibromas. Using qRT-PCR, I showed that the expression of 
all six collagen genes was significantly reduced in the miR-29c expressing 
sNF96.2 cells. 
Previous analyses have demonstrated reduced MMP2 and MMP9 proteolytic 
activity miR-29c-transfected sNF96.2 cells. I examined expression of MMP2 
and MMP9 at both the mRNA and protein level in these cells by qRT-PCR 
and Western blot analysis. I showed that expression of MMP2 mRNA and 
protein is significantly inhibited in miR-29c-transfected sNF96.2 cells. 
However, MMP9 mRNA and protein remained largely unaltered. 
Transforming Growth Factor Beta3 (TGFB3) is another target of miR-29c 
predicted by my in silico analysis. I showed TGFB3 mRNA expression is 
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significantly downregulated in miR-29c- transfected sNF96.2 cells. However, 
I found no significant alteration in expression of MMP2 or MMP9 at either 
mRNA transcript or protein level following anti-TGFb3 siRNA treatment of 
wild-type sNF96.2 cells, although inhibition of MMP9 and MMP2 activity was 
observed in the supernatants of these cells by gelatine zymography.  
Another potential target of miR-29c identified in-silico is ROBO1. Closer 
inspection of previous microarray data from our laboratory revealed ROBO1 
to be significantly highly expressed in MPNSTs compared to neurofibromas. 
Western blot analysis demonstrated no visible ROBO1 protein in cells 
transfected with miR-29c mimics. However, only very weak ROBO1 protein 
expression was detected in control cells transfected with scrambled 
nucleotides. 
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4. Relationship between miR-29c 
and DNMT3A and 3B 
4.1. Introduction  
The relationship between microRNAs and DNA methyltransferases (DNMTs) 
has been studied in several types of cancer including lung, breast and 
hepatocellular (Fabbri et al. 2007; Kogure et al. 2014). DNMT3A and -3B 
have the ability to introduce methyl groups onto CpG sites that were 
previously unmethylated on the parental template strands of DNA, hence 
called “de novo” methyltransferases (Okano et al. 1999). On the other hand, 
DNMT1 is responsible for maintenance of methylation; hence, it is called the 
“maintenance methyltransferase”. It prefers to target the hemimethylated 
DNA (with methylation of only one DNA strand) 10 fold more than the 
unmethylated strand. The function of DNMT1 in the cell is to keep the DNA 
methylation status stable throughout cell division (Jones & Liang 2009). 
The expression of the miR-29 family of microRNAs has been shown to be 
inversely correlated with the expression of DNMT3A and -3B in lung cancer, 
and the miR-29s have been shown to directly target both these genes 
(Fabbri et al. 2007). Another study showed that miR-29a regulates TGFB 
induced epithelial-mesenchymal transition (EMT) by altering its DNA 
methylation state via the suppression of DNMT3B (Kogure et al. 2013). 
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Sandhu (2012) examined the expression of microRNAs which are predicted 
to regulate DNMT3B (miR-29a, miR-29b, miR-29c, miR-148a, miR-148b, 
miR-26a, miR-26b, miR-203, miR-222) among 10 hypermethylator (express 
DNMT3B at high levels) and 6 non-hypermethylator (express DNMT3B at 
low levels) breast cancer cell lines. Results showed that hypermethylator cell 
lines express lower levels of miR-29c, miR-148a, miR-148b, miR-26a, miR-
26b, and miR-203 compared to non-hypermethylator cell lines (Sandhu et al. 
2012). The microRNA expression pattern was also shown to correlate 
inversely with methylation-sensitive gene expression (CEACAM6, CDH1, 
CST6, ESR1, GNA11, MUC1, MYB, TFF3 and SCNN1A) (Roll et al. 2008) 
and correlates directly with the methylation status of these genes (Sandhu et 
al. 2012). 
The methylome profile of neurofibroma and MPNST from patients with 
Neurofibromatosis type 1 have been published and it has been shown that 
there are hundreds of genes that are differentially methylated between 
neurofibroma and MPNST (Feber et al. 2011). The samples used in this 
methylome study were the same tumours analysed in the microRNA array 
analysis (Chapter 3). As described in chapter 3, the expression of miR-29c is 
significantly lower in MPNSTs compared to neurofibromas, and because 
DNMT3A and DNMT3B are known targets for miR-29c (Fabbri et al. 2007) in 
lung cancer, I hypothesised that a relationship between them might exist in 
nerve sheath tumours.  
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4.2. Aims 
The main objectives of this part of the thesis were twofold: 
 
 To determine the relationship between the expression of miR-29c and 
expression of DNA methyltransferases DNMT3A and DNMT3B in 
MPNSTs and neurofibromas. 
 To identify any differentially methylated genes in neurofibromas and 
MPNSTs that may play an important role in the progression of these 
tumours. 
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4.3. Results 
4.3.1. DNMT3B mRNA expression is higher in 
MPNSTs compared to neurofibromas and 
inversely correlates with miR-29c expression 
I previously demonstrated in chapter 3 that expression of miR-29c is 
significantly lower in MPNSTs compared to neurofibromas. In order to 
determine if any relationship exists between the expression of miR-29c and 
the DNA methyltransferases DNMT3A and DNMT3B, I decided to examine 
the same set of neurofibromas and MPNSTs used in chapter 3 for 
expression of these two DNA mehtyltransferases. Of the 20 tumour samples 
previously examined, sufficient RNA was available from nine MPNSTs and 
nine neurofibromas for analysis of DNMT3A and DNMT3B mRNA expression 
by qRT-PCR. Details of the primers and PCR conditions as well as clinical 
samples used for the DNMT3A and DNMT3B qRT-PCR analysis are given in 
chapter 2. 
The results from the DNMT3A and DNMT3B mRNA qRT-PCR expression 
data are presented in Figure ‎4-1. These demonstrated no significant 
difference in the DNMT3A mRNA expression levels between neurofibromas 
and MPNSTs (unpaired Student’s t-test, p = 0.748). However, DNMT3B 
mRNA expression was found to be significantly higher in the MPNSTs 
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compared to that in neurofibromas (unpaired Student’s t-test, p < 0.05; 
Figure ‎4-2).  
I then compared the DNMT3A and DNMT3B mRNA expression with the miR-
29c expression level in each of the individual tumour samples. The results 
demonstrated no correlation between the expression of DNMT3A and miR-
29c (Pearson’s correlation test, p = 0.748 and correlation coefficient of -
0.081; Figure ‎4-3). However, I found an inverse correlation between the 
expression of DNMT3B mRNA and miR-29c expression in the MPNSTs and 
neurofibromas (Pearson’s correlation test, p < 0.05 and correlation coefficient 
of -0.469; Figure ‎4-4). These findings suggest that miR-29c expression may 
have an important influence on the gene methylation pattern in MPNSTs and 
NFs through regulation of DNMT3B expression. 
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Figure ‎4-1: No significant difference in DNMT3A mRNA expression 
between MPNSTs and neurofibromas 
qRT-PCR analysis of DNMT3A mRNA expression in 9 neurofibromas and 9 MPNST 
samples demonstrating no significant differences in DNMT3A mRNA expression 
levels between MPNSTs and NFs.  The bar graph (A) shows the DNMT3B mRNA 
expression level in each individual tumour.  The qRT-PCR data was normalised to 
GAPDH gene.  Bars represent the average results of two technical replicates from 
one experiment. .  Error bars represent standard deviation.  The box plot (B) shows 
a summary of the DNMT3B qRT-PCR expression data in the 9 neurofibromas and 9 
MPNSTs (unpaired Student’s t-test, p = 0.748). 
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Figure ‎4-2: DNMT3B mRNA expression is significantly higher in the 
MPNSTs compared neurofibromas  
qRT-PCR analysis of DNMT3B mRNA expression in 9 neurofibroma and 9 MPNST 
samples demonstrating significantly higher levels of DNMT3B mRNA expression in 
the MPNSTs compared to neurofibromas. The bar graph (A) shows the DNMT3B 
mRNA expression level in each individual tumour. The qRT-PCR data was 
normalised to GAPDH gene. Bars represent the average results of two technical 
replicates from one experiment. Error bars represent standard deviation. The box 
plot (B) gives a summary the DNMT3B qRT-PCR expression data in the 9 
neurofibromas and 9 MPNSTs (unpaired Student’s t-test, *p < 0.05).   
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Figure ‎4-3: No correlation between miR-29c and DNMT3A mRNA 
expression in MPNSTs and neurofibromas  
The graph shows the qRT-PCR data from 9 neurofibromas and 9 MPNSTs. The 
DNMT3A mRNA expression is plotted against the miR-29c expression level in each 
individual tumour. The expression of DNMT3A mRNA is not correlated with miR-29c 
expression in MPNSTs and NFs (Pearson’s correlation test: p = 0.748 and 
correlation coefficient of -0.081). 
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Figure ‎4-4: Inverse correlation between miR-29c and DNMT3B 
expression in MPNSTs and neurofibromas  
The graph shows the qRT-PCR data from 9 neurofibromas and 9 MPNSTs. The 
DNMT3B mRNA expression is plotted against the miR-29c expression level in each 
individual tumour. The expression of DNMT3B mRNA is negatively correlated with 
miR-29c expression in MPNSTs and NFs (Pearson’s correlation test: p < 0.05 and 
correlation coefficient of -0.469). 
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4.3.2. miR-29c inhibits DNMT3A and DNMT3B 
expression in sNF96.2 cells 
Having demonstrated an inverse correlation between the expression of miR-
29c and DNMT3B in our tumour samples, I next examined the in vitro effects 
that miR-29c might have on the expression of DNMT3A and DNMT3B. For 
this purpose, I employed the use of the MPNST-derived cell line sNF96.2 
which was previously had been shown to express very low levels of miR-29c 
mRNA (Dr Nadège Presneau personal communication). To this end, I 
transfected the sNF96.2 cell line with miR-29c mimics (test samples) or 
scrambled oligonucleotides (control cells) as previously described in chapter 
2. The DNMT3A and DNMT3B mRNA expression levels were then 
determined in sNF96.2 test and control cells by qRT-PCR. See chapter 2 for 
details of the primers and PCR conditions used.  
The results from the DNMT3A and DNMT3B qRT-PCR experiments are 
shown in Figure ‎4-5. These demonstrated a significant reduction in the 
DNMT3A and DNMT3B mRNA expression levels following transfection of 
miR-29c into sNF96.2 cells compared to their expression in control cells. The 
level of DNMT3A mRNA expression at 24 and 48 h following transfection 
with miR-29c was reduced by approximately 40% (paired Student’s t-test; p < 
0.05) and 50% (paired Student’s t-test; p < 0.01) respectively. The level of 
DNMT3B mRNA expression at the same time points was reduced by 
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approximately 30% (paired Student’s t-test; p < 0.05) and 45% (paired 
Student’s t-test; p < 0.01) respectively. These findings demonstrate that 
DNMT3A and DNMT3B are both targets of miR-29c in MPNST derived cells 
and lend further support to the idea that miR-29c may have an important 
influence on gene methylation in MPNSTs by regulating DNMT3A and 
DNMT3B expression in these tumours.  
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 (A)     DNMT3A 
                 
 
 (B)     DNMT3B 
       
 
 
Figure ‎4-5: Down-regulation of DNMT3A and DNMT3B mRNA 
expression in miR-29c-transfected sNF96.2 cells 
qRT-PCR expression data for DNMT3A (A) and DNMT3B (B) at 24 and 48 h following 
transfection of sNF96.2 cells with miR-29c (test samples) or scrambled oligonucleotides 
(controls).  The data is presented as fold difference in DNMT3A or DNMT3B mRNA levels in 
test samples compared to that in controls (the control was given the value 1 at both 24 and 
48 h). The graphs demonstrate a significant reduction in expression of DNMT3A and 
DNMT3B at 24 and 48 h (paired Student’s t-test; *p < 0.05 and **p < 0.01 for DNMT3A at 24 
and 48 h, respectively; *p < 0.05 and **p < 0.01 for DNMT3B at 24 and 48 h, respectively).  
The qRT-PCR data was normalised to GAPDH gene. Bars represent the average results 
from three independent experiments (three biological replicates). Error bars represent 
standard deviation. 
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4.3.3. Identification of candidate genes that 
may be targets for DNMTs in MPNSTs and 
Neurofibromas 
Following my demonstration that DNMT3A and DNMT3B are downregulated 
by miR-29c in vitro, I next decided to look for candidate genes that may be 
differentially methylated between neurofibromas and MPNSTs. I first derived a 
list of possible candidates from the results of the methylome analysis by Feber 
et al. 2011 and identified a long list of 607 genes. In order to narrow down this 
list further, I compared it with the list of 1551 genes previously reported by the 
gene expression microarray studies of Subramanian et al. 2010 as 
differentially expressed between neurofibromas and MPNSTs. I found 41 
genes in common between the two studies of Feber et al (2011) and 
Subramanian et al. (2010) (Table ‎4-1). I then examined the literature in order 
to determine where any of these genes had been proven to be differentially 
expressed between neurofibromas and MPNSTs. I finally decided to focus my 
studies on 3 genes S100B, CDKN2A, and WT1, which I thought were strong 
candidates as possible targets of DNMTs in MPNSTs. As well as being 
differentially methylated these genes had previously been verified as being 
differentially expressed between MPNSTs and neurofibromas (Feber et al. 
2011; Subramanian et al. 2010; Karamchandan et al., 2012; Parenti et al. 
2014). In addition they have been reported to play a role in other types of 
cancer (Fang et al. 2009; Fraizer et al. 2004; van Dieck et al. 2010).
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Table ‎4-1: Genes which are differentially methylated and differentially 
expressed in MPNSTs compared to neurofibromas 
Serial 
Gene 
symbol 
Gene description 
1 ADAM23  ADAM metallopeptidase domain 23 
2 AIF1  Allograft inflammatory factor 1 
3 AIG1  Androgen-induced 1 
4 AKAP6  A kinase (PRKA) anchor protein 6 
5 ALDH3A2  Aldehyde dehydrogenase 3 family, member A2 
6 ANK2  Ankyrin 2, neuronal 
7 APOD  Apolipoprotein D 
8 ARHGEF10  Rho guanine nucleotide exchange factor (GEF) 10 
9 AZGP1  Alpha-2-glycoprotein 1, zinc 
10 C13orf18  Chromosome 13 open reading frame 18 
11 C13orf23  Chromosome 13 open reading frame 23 
12 C2  Complement component 2 
13 CAMSAP1L1  Calmodulin regulated spectrin-associated protein 1-like 1 
14 CHML  Choroideremia-like (Rab escort protein 2) 
15 EP300  E1A binding protein p300 
16 FAM63B  Family with sequence similarity 63, member B 
17 FXYD3  FXYD domain containing ion transport regulator 3 
18 GFM1  G elongation factor, mitochondrial 1 
19 ID4  Inhibitor of DNA binding 4 
20 KLF4  Kruppel-like factor 4 (gut) 
21 LETMD1  LETM1 domain containing 1 
22 LY96  Lymphocyte antigen 96 
23 MAP3K2  Mitogen-activated protein kinase kinase kinase 2 
24 OCLN  Occludin 
25 PCMTD2  Protein-L-isoaspartate O-methyltransferase domain containing 2 
26 PLXDC2  Plexin domain containing 2 
27 PTK2  PTK2 protein tyrosine kinase 2 
28 RDH13  Retinol dehydrogenase 13 (all-trans/9-cis) 
29 S100B  S100 calcium binding protein, beta (neural) 
30 SERBP1  SERPINE1 mRNA binding protein 1 
31 SOAT1  Sterol O-acyltransferase  1 
32 SORBS1  Sorbin and SH3 domain containing 1 
33 SOX10  SRY (sex determining region Y)-box 10 
34 TARDBP  TAR DNA binding protein 
35 TMEM18  Transmembrane protein 18 
36 TXNIP  Thioredoxin interacting protein 
37 VANGL1  Vang-like 1 (van gogh, Drosophila) 
38 VKORC1L1  Vitamin K epoxide reductase complex, subunit 1-like 1 
39 ZNF33A  Zinc finger protein 33A 
40 ZNF516  Zinc finger protein 516 
41 ZNRF2  Zinc and ring finger 2 
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4.3.4. Hypermethylation of CDKN2A, WT1 and 
S100B is frequent in MPNSTs compared to 
neurofibromas in human samples 
The methylation status of CDKN2A, WT1 and S100B was examined in our 
10 neurofibromas and 10 MPNSTs by bisulfite pyrosequencing analysis 
covering 5 to 7 CpG sites within each gene (Figure ‎4-6 to Figure ‎4-8). The 
CpG sites chosen for study were selected from previously available 
methylome data (Feber et al. 2011) based on the fact they were clustered 
within regulatory regions of the genes and exhibited differential methylation 
between neurofibromas and MPNSTs. Details of protocol used for 
pyrosequencing can be found in chapter 2. 
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Figure 4-6: CDKN2A gene as depicted by ensemble showing location of the regulatory feature area (transcription factor binding site), 
which was examined by pyrosequencing. The zoom box shows the DNA sequence within this area and location of the 7 CpG sites 
which are highlighted in red. 
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Figure 4-7: WT1 gene as depicted by ensemble showing location of the regulatory feature area (open chromatin), which was examined 
by pyrosequencing. The zoom box shows the DNA sequence within this area and location of the 5 CpG sites which are highlighted in 
red. 
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Figure 4-8: S100B gene as depicted by ensemble showing location of the regulatory feature area (enhancer), which was examined by 
pyrosequencing. The zoom box shows the DNA sequence within this area and location of the 6 CpG sites which are highlighted in red. 
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The CDKN2A, WT1, and S100B pyrosequencing data obtained from all 10 
NFs and 10 MPNSTs analysed are shown in Figure  4-9, Figure  4-10 and 
Figure  4-11 respectively. Each box in the figures represents an individual 
pyrogram from a single tumour sample. The shaded bars indicate the 
positions of the CpGs analysed and the level of methylation at each CpG site 
is expressed as a percentage in the blue boxes on top of the bars.  
The results from each pyrogram are summarised in Table  4-2. The average 
level of gene methylation in each sample was calculated by adding the % 
methylation at each CpG site and dividing this by the total number of CpG 
sites within each pyrogram. Any gene with an average methylation value of 
greater than 50% was considered to be hypermethylated.  
The results demonstrated hypermethylation of CDKN2A and WT1 in 6 
MPNSTs compared to only 1 neurofibroma (unpaired Student’s t-test, p < 
0.05 and < 0.01 respectively) and S100B was hypermethylated in 7 MPNSTs 
compared to only 2 neurofibromas (unpaired Student’s t-test, p < 0.01). The 
overall data suggests that methylation of CDKN2A WT1 and S100B is more 
frequent in MPNSTs compared to neurofibromas and may play a role in the 
pathogenesis of MPNSTs from neurofibromas. 
 
 
P a g e  | 197 
   
  
               
               
               
               
               
 
                
               
               
               
               
 
 
17% 18% 8% 15% 10% 19% 30%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
200
400
600
-200
F5 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
25% 29% 12% 26% 16% 32% 43%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
100
200
300
400
500
600
-100
D4 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
13% 10% 3% 13% 8% 13% 24%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
200
400
600
-200
F4 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
28% 23% 6% 25% 12% 30% 45%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
100
200
300
400
500
600
-100
F6 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
26% 20% 10% 25% 16% 29% 36%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
100
200
300
400
500
-100
D5 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
56% 51% 19% 47% 29% 59% 69%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
200
400
600
D2 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
23% 17% 7% 20% 15% 26% 38%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
100
200
300
400
500
600
D3 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
80% 75% 64% 64% 70% 76% 78%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
100
200
300
400
F1 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
18% 12% 4% 18% 6% 19% 30%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
200
400
600
-200
F3 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
21% 20% 8% 21% 11% 28% 54%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
200
400
600
F2 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
73% 68% 64% 70% 69% 70% 76%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
100
200
300
400
500
-100
D7 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
21% 18% 14% 19% 15% 15% 21%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
100
200
300
400
500
-100
D6 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
92% 87% 82% 89% 84% 90% 90%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
200
400
600
800
-200
F11 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
23% 22% 10% 22% 11% 26% 38%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
200
400
600
800
-200
F8 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
79% 73% 74% 73% 73% 77% 77%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
100
200
300
400
500
600
-100
D9 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
88% 88% 73% 88% 82% 89% 88%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
200
400
600
-200
F9 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
28% 27% 7% 22% 16% 29% 39%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
100
200
300
400
500
-100
F7 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
11% 14% 11% 6% 6% 14% 21%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
100
200
300
400
-100
F10 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
83% 78% 79% 80% 78% 83% 82%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
100
200
300
400
500
-100
D8 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
62% 58% 55% 58% 56% 64% 64%
E S A C A G A
5
T C G A T
10
C G A T C
15
A G A T A
20
C G A T C
25
G A C T C
30
T C T A G
35
C T A C G
40
A
0
200
400
600
800
1000
-200
F12 : CRAACCRCRCRATCRCRCTTTCTCTACCCTCCRCCRAATAAACCTAAAACRCTTAAACRATCRACRCRCCTAAAACAACCAAAC
Figure 4-9: Methylation analysis of CDKN2A in Neurofibromas and MPNSTs 
Each box is the pyrogram from a single neurofibroma (A) or MPNST (B). Each shaded column indicates a CpG 
dinucleotide examined and the percentage methylation at that CpG dinucleotide is indicated above. The yellow 
shaded boxes are internal bisulfite modification control assessments. The results demonstrate that CDKN2A is 
hypermethylated in MPNSTs compared to neurofibromas. 
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E7 : TTTTTATTYGTYGYGGAYGATAGGYGTTTTTTTGTATTTTTTTTAGTTYGYGAGGTTYGTTTTTYGYGAGGTTTTAGAGAAAAGTAGGTTGT
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G12 : TTTTTATTYGTYGYGGAYGATAGGYGTTTTTTTGTATTTTTTTTAGTTYGYGAGGTTYGTTTTTYGYGAGGTTTTAGAGAAAAGTAGGTTGT
Figure 4-10: Methylation analysis of WT1 in Neurofibromas and MPNSTs 
Each box represents the pyrogram from a single neurofibroma (A) or MPNST (B). Each shaded column indicates a 
CpG dinucleotide examined and the percentage of methylation at that CpG dinucleotide is indicated above. The 
yellow shaded boxes are internal bisulfite modification control assessments. The results demonstrate that WT1 is 
hypermethylated in MPNSTs compared to neurofibromas. 
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C11 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
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C12 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
50% 51% 63% 57% 54% 57%
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C10 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
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D2 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
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C7 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
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C8 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
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C9 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
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D3 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
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D8 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
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92% 87% 92% 93% 80% 90%
E S G T G T A
5
T C G A T
10
G T C T A
15
G A G A T
20
A G T T C
25
T G T C G
30
T A T C G
35
T G T T A
40
C T A G A
45
T G T C G
50
T G T G T
55
A T C G T
60
G
0
200
400
600
800
1000
-200
D12 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
37% 37% 49% 46% 55% 64%
E S G T G T A
5
T C G A T
10
G T C T A
15
G A G A T
20
A G T T C
25
T G T C G
30
T A T C G
35
T G T T A
40
C T A G A
45
T G T C G
50
T G T G T
55
A T C G T
60
G
0
200
400
600
800
-200
D5 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
92% 87% 96% 91% 81% 88%
E S G T G T A
5
T C G A T
10
G T C T A
15
G A G A T
20
A G T T C
25
T G T C G
30
T A T C G
35
T G T T A
40
C T A G A
45
T G T C G
50
T G T G T
55
A T C G T
60
G
0
200
400
600
800
1000
-200
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D6 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
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D9 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
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D10 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
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E1 : TGGAYGATGTTTTAGAGATGTTTYGTTYGAAYGTTGTTTTATAGAGGYGTGTGGAYGGTGTGTTTTTTTGTTGAAGTTTTT
Figure 4-11: Methylation analysis of S100B in Neurofibromas and MPNSTs 
Each box represents the pyrogram from a single neurofibroma (A) or MPNST (B). Each shaded column indicates a 
CpG dinucleotide examined and the percentage of methylation at that CpG dinucleotide is indicated above. The 
yellow shaded boxes are internal bisulfite modification control assessments. The results demonstrate that S100B is 
significantly hypermethylated in MPNSTs compared to neurofibromas. 
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Tumour  
CpG methylation levels % 
CDKN2A  WT1       S100B  
NF1 17 12 24 
NF2 26 13 24 
NF3 12 13 55 
NF4 24 10 41 
NF5 23 12 30 
NF6 47 32 31 
NF7 21 16 67 
NF8 72 40 50 
NF9 15 11 21 
NF10 23 80 50 
MPNST1 70 69 56 
MPNST2 17 17 38 
MPNST3 88 92 89 
MPNST4 22 10 48 
MPNST5 75 85 89 
MPNST6 85 33 88 
MPNST7 24 18 37 
MPNST8 12 90 78 
MPNST9 80 85 61 
MPNST10 60 78 72 
 
 
Table  4-2: Hypermethylation of CDKN2A, WT1, and S100B in MPNSTs 
vs Neurofibromas 
Each box represents the average level of CpG methylation in each gene 
individual pyrogram. The results demonstrate a significantly higher level of 
CDKN2A, WT1, and S100B gene methylation in MPSNTs compared to 
neurofibromas (unpaired Student’s t-test, p < 0.05 for CDKN2A; p < 0.01 for 
WT1; p < 0.01 for S100B).  
  
Colour code: 
Methylation % 
0-25% 
26-50% 
51-75% 
76-100% 
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4.3.5. Increased expression of WT1 and 
S100B in 5-aza-dC-treated sNF96.2 cells 
Having shown that CDKN2A, WT1, and S100B are hypermethylated in 
MPNSTs compared to neurofibromas, I next wanted to determine whether 
this methylation within the regulatory regions of these genes has any bearing 
on their expression. In order to test this, I decided to examine the expression 
of CDKN2A, WT1, and S100B mRNA in the sNF96.2 cell line following 
treatment with 5-Aza-2′-deoxycytidine (5-aza-dC). This drug is an epigenetic 
modifier which inhibits DNA methyltransferase activity and leads to 
progressive global demethylation of DNA during replication in proliferating 
cells (Claus et al., 2005; Hackanson & Daskalakis, 2014) thus resulting in 
activated gene expression. Before I could begin these experiments, however, 
it was necessary to determine the optimum dose of 5-aza-dC that could be 
used to treat the sNF96.2 cells and allow a reasonable level (≥ 50%) of cell 
viability over a 7 day period. In order to do this, an optimisation step was 
performed whereby sNF96.2 cells were grown in culture medium treated with 
various concentrations of 5-aza-dC (0.25 μM, 0.5 μM, 1 μM, 2 μM, 3 μM, 5 
μM and 10 μM) and allowed to grow for a period of a week after which cell 
viability was measured using the Trypan Blue assay as described in chapter 
2.  
The results from these experiments demonstrated the optimum dose of 5-
aza-dC that sNF96.2 cells could tolerate over 7 days of treatment was 1 μM. 
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Following this, a fresh batch of cell cultures then was grown for a period 4 
and 7 days in culture medium containing 1 μM 5-aza-dC, replacing the 
culture medium every 24 h with fresh media containing 1 μM 5-aza-dC. The 
cells were harvested on days 4 and 7. DNA and RNA were then extracted 
from each of these as well as from a batch of control sNF96.2 cells, which 
had been grown without 5-aza-dC treatment. All experiments were carried 
out in triplicate.  
The treated and untreated control sNF96.2 cells were analysed for 
methylation of S100B by pyrosequencing as described in the previous 
section. The results of these experiments which are summarised in 
Figure  4-12 demonstrated a significant reduction of S100B gene methylation 
(by approximately 15% at each of the 6 CpG sites examined) in the 5-aza-
dC-treated cells compared to that in control cells (paired Student’s t-test, p < 
0.01). I did not examine the methylation status of CDKN2A and WT1 in the 5-
aza-dC treated and untreated cells but since 5-aza-dC is a global inhibitor of 
DNA methylation, the S100B pyrosequencing data were considered a good 
indicator that the whole sNF96.2 genome had been successfully 
demethylated following treatment with 5-aza-dC.  
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Figure  4-12: Decreased S100B gene methylation in 5-aza-dC-treated 
sNF96.2 cells 
Pyrosequencing data demonstrating percentage methylation at 6 CpG 
islands in the S100B gene of sNF96.2 cells which had been grown in culture 
medium containing 1 µM 5-aza-dC and in control cells grown without 5-aza-
dC for 1 week. The graph demonstrates a reduction of S100B gene 
methylation by approximately 15% at each of the 6 CpG sites examined 
(paired Student’s t-test, p < 0.01). 
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I next examined the effects that hypomethylation might have on the 
expression of S100B and WT1 in the sNF96.2 cell line. This was done by 
qRT-PCR analysis of the gene transcripts at days 4 and 7 following the start 
of 5-aza-dC treatment in sNF96.2 cells. Details of these experiments 
including qRT-PCR primers and protocols used are as described in chapter 
2. The results of these qRT-PCR experiments demonstrated a significant 
increase in expression of both S100B and WT1 mRNA at both time points in 
5-aza-dC treated cells compared to untreated control cells (Figure  4-13A). 
The expression WT1 mRNA increased by approximately 50% in sNF96.2 
cells after 4 days of 5-aza-dC treatment (paired Student’s t-test, p < 0.05 and 
at 7 days the WT1 mRNA expression in 5-aza-dC treated cells was more 
than double the level of expression in the control untreated cells (p < 0.01). 
S100B mRNA transcript was not detectable in control untreated sNF96.2 
cells but 5-aza-dC treatment resulted in detectable levels of S100B mRNA 
expression on day 4 and (p < 0.05) on 7 day the level of S100B mRNA 
expression was increased by another 70% approximately (p < 0.05 
(Figure  4-13B). The WT1 mRNA expression is presented in Figure  4-13A as 
relative expression (2^-ddCt), however, the S100B mRNA expression is 
presented in Figure  4-13B as (2^-dCt) because there was no detectable 
mRNA in the untreated cells so I was not able to calculate the relative 
expression. 
I was unable to obtain any data from the CDKN2A gene or transcript in the 
sNF96.2 cell line as both the bisulfite converted DNA and the cDNA from this 
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cell line failed to give any amplifiable PCR product. It is possible that the 
CDKN2A gene has been deleted in this cell line. 
My findings indicate that hypermethylation of CpG sites of S100B and WT1 
can lead to inhibition of gene transcription and suggest that DNA methylation 
may provide an important epigenetic mechanism for controlling the 
expression of WT1 and S100B within MPNST-derived cells. 
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Figure  4-13: Increased expression of WT1 and S100B mRNA in 5-aza-dC 
treated sNF96.2 cells 
qRT-PCR results demonstrating (A) 1.5 fold and > 2 fold increase in WT1 mRNA expression 
at 4 days and 7 days, respectively, following treatment of sNF96.2 cells with 5-aza-dC (1 
µM) compared to that in untreated control cells (paired Student’s t-test, *p < 0.05 and **p < 
0.01 at 4 and 7 days, respectively).  Expression of WT1 in control cells remained constant at 
both time points and was given the value 1.  (B) S100B mRNA was not detectable in control 
untreated sNF96.2 cells but its’ expression was significantly increased at day 4 (paired 
Student’s t-test, *p < 0.05 and **p < 0.01 at 4 and 7 days, respectively). Expression of 
S100B mRNA on day 7 was approximately 70% higher than on day 4. The WT1 expression 
is presented as relative expression (2^-ddCt) but the S100B mRNA expression is presented 
as 2^-dCt because there was no detectable mRNA in the untreated cells. The qRT-PCR 
data was normalised to GAPDH gene. Bars represent the average results obtained from 
three independent experiments (three biological replicates). Error bars represent standard 
deviation. 
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4.3.6. S100B and WT1 DNA methylation is 
frequent in high grade MPNST as compared 
with low grade MPNST and Neurofibromas 
Having demonstrated that demethylation of sNF96.2 MPNST cells results in 
re-expression of S100B mRNA and increased the expression of WT1 mRNA, 
I wanted to test whether there any relationship between methylation of these 
genes and tumour grade. I first tested the level of S100B and WT1 gene 
methylation in a cohort of 80 MPNSTs and 80 neurofibromas using bisulfite 
pyrosequencing. The MPNST samples include high grade (grade 3; n = 56), 
intermediate (grade 2; n = 20) and low grade (grade 1; n= 4) tumours. I 
examined the DNA methylation state of 6 and 5 CpGs within the regulatory 
regions of S100B and WT1 respectively and the average DNA methylation 
level across the CpGs within these areas was measured.  
My results demonstrated that methylation of S100B is significantly higher in 
MPNSTs compared to neurofibromas (Table  4-3). The average percentage 
of S100B methylation is 75% in MPNST compared to 34% in neurofibroma 
(Figure ‎4-14; unpaired Student’s t-test, p < 0.001). In addition, analysis of 
different grades of MPNST showed that S100B is significantly 
hypermethylated in grade 3 compared to grade 1 (unpaired Student’s t-test, 
p < 0.001) and grade 2 tumours (p < 0.05). Hypermethylation of S100B was 
also significantly higher in grade 2 compared grade 1 tumours (p < 0.001; 
one-way ANOVA test between all groups, p < 0.001; Table  4-5). The average 
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S100B percentage methylation was 75% in grade 3, 62% in grade 2 and 
22% in grade 1 tumours (Figure ‎4-16). 
WT1 DNA methylation was also found to be significantly higher in MPNSTs 
compared to neurofibromas (Table ‎4-4). The WT1 average percentage 
methylation was 49% in MPNST compared to 11% in neurofibromas 
(unpaired Student’s t-test, p < 0.001; Figure ‎4-15). In addition, WT1 was 
significantly hypermethylated in grade 3 compared to grade 1 tumours (p < 
0.05) and WT1 in grade 2 tumours was significantly hypermethylated 
compared to grade 1 tumours (p < 0.05). However there was no significant 
difference in methylation levels between grade 2 and grade 3 MPNSTs (p = 
0.835; One-way ANOVA test between all groups, p = 0.111; Table ‎4-6). The 
WT1 average percentage methylation was 49% in grade 3, 48% in grade 2 
and 23% in grade 1 (Figure ‎4-17).  
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84 34 83 91 
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43 31 33 6 
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54 51 35 26 
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37 56 68 22 
 
44 86 33 89 
67 37 21 39 
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33 43 9 49 
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80 12 88 86 
49 21 51 25 
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33 32 6 22 
 
83 84 43 87 
42 21 34 36 
 
76 60 100 88 
 
 
 
 
 
 
 
 
 
Table  4-3: S100B DNA methylation is significantly higher in MPNSTs 
compared to neurofibromas 
Methylation of the S100B gene was examined by pyrosequencing in 80 
neurofibromas (A) and 80 MPNSTs (B). Each box represents the average 
methylation level (expressed as percentage) of 6 CpG dinucleoides within the gene 
regulatory area in a single tumour. The results demonstrate a significantly higher 
level of S100B gene methylation in MPSNTs (average= 75%) compared to 
neurofibromas (34% average) (unpaired Student’s t-test, p < 0.001).  
 
 
Colour code: 
Methylation % 
0-25% 
26-50% 
51-75% 
76-100% 
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Figure  4-14: Hypermethylation of S100B in MPNSTs vs Neurofibromas 
Box plot shows the mean methylation level of 6 CpG sites within the regulatory area 
of S100B gene in 80 neurofibromas and 80 MPNSTs. The average level of S100B 
gene methylation is significantly higher in MPNSTs (75%) compared to that in 
neurofibromas (34%) (unpaired Student’s t-test, *p < 0.001). Error bars represent 
standard deviation. 
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NFs (N=80) 
   
MPNSTs (N=80) 
 
         10 14 26 14 
 
52 51 17 16 
12 9 20 5 
 
45 58 91 89 
11 26 14 5 
 
58 39 88 66 
2 11 3 4 
 
8 57 51 74 
14 21 4 17 
 
5 97 20 37 
8 2 11 9 
 
85 61 27 76 
12 11 11 15 
 
62 68 21 70 
3 4 10 22 
 
24 18 26 62 
2 21 10 6 
 
2 74 54 31 
6 14 15 11 
 
12 32 90 79 
59 8 10 2 
 
85 85 59 16 
7 13 5 6 
 
90 73 43 57 
1 8 4 9 
 
23 78 88 30 
2 9 8 3 
 
40 63 75 87 
16 1 4 9 
 
76 17 74 63 
28 9 1 18 
 
5 10 38 82 
8 37 10 12 
 
66 46 8 95 
17 7 12 11 
 
62 24 15 25 
7 15 11 12 
 
59 38 71 17 
9 12 15 23 
 
52 20 18 34 
 
 
 
 
 
 
 
 
 
Table  4-4: WT1 gene methylation level is significantly higher in 
MPNSTs compared to neurofibromas 
Methylation of WT1 gene regulatory area was analysed by pyrosequencing in 80 
Neurofibromas (A) and 80 MPNSTs (B). Each box represents the average 
methylation level of 5 CpG dinucleoides within a single tumour. The results 
demonstrate a significantly higher level of WT1 gene methylation in MPSNTs 
(average = 49 %) compared to neurofibromas (11 % average) (unpaired Student’s t-
test, p < 0.001).  
 
 
Colour code: 
Methylation % 
0-25% 
26-50% 
51-75% 
76-100% 
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Figure  4-15: Hypermethylation of WT1 in MPNSTs vs Neurofibromas 
Box plot shows the mean methylation level of 5 CpG sites within the WT1 gene 
regulatory area of 80 neurofibromas and 80 MPNSTs. The average level of WT1 
gene methylation is significantly higher in MPNSTs (49%) compared to that in 
neurofibromas (11%) (unpaired Student’s t-test, *p < 0.001). Error bars represent 
standard deviation. 
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Grade 1  Grade 2 
 
Grade 3 
        
 
  
    
28 
 
90 45 
 
80 85 48 76 91 71 
18 
 
37 79 
 
77 86 80 80 30 77 
29 
 
49 77 
 
83 66 48 86 39 92 
12 
 
34 44 
 
76 85 78 43 81 84 
  
71 17 
 
88 77 33 100 97 87 
  
69 63 
 
60 87 85 60 89 88 
  
84 72 
 
34 88 30 98 69 
 
  
79 80 
 
72 79 81 23 76 
 
  
84 87 
 
93 90 88 67 91 
 
  
69 48 
 
70 83 90 79 86 
  
 
 
 
 
Table  4-5: S100B is significantly hypermethylated in high grade 
MPNSTs compared to lower grades 
Methylation of the S100B gene regulatory region was analysed by pyrosequencing 
in 80 MPNSTs. Each box represents the average methylation level of 6 CpG 
dinucleoides within a single tumour. The average S100B gene methylation level in 
grade 1 MPNSTs = 22% (4 cases); grade 2 = 65% (20 cases); and grade 3 = 81% 
(56 cases). Unpaired Student’s t-test, grade 1 vs. grade 2, p < 0.001; Grade 1 vs. 
grade 3, p < 0.001; grade 2 vs. grade 3, p < 0.05. One-way ANOVA test between all 
groups, p < 0.001. 
 
 
 
 
Colour code: 
Methylation % 
0-25% 
26-50% 
51-75% 
76-100% 
(N=4)  (N=20)     (N=56) 
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Figure  4-16: Hypermethylation of S100B with increasing grade of 
MPNST  
Box plot demonstrating the mean methylation level of 6 CpG sites within the S100B 
gene regulatory area from 80 MPNSTs of different grades (4 grade 1, 20 grade 2, 
and 56 grade 3 tumours). The results demonstrate significantly higher levels of 
S100B gene methylation with increasing grade of MPNST. Unpaired Student’s t-
test, grade 1 vs. grade 2, p < 0.001; Grade 1 vs. grade 3, p < 0.001; grade 2 vs. 
grade 3, p < 0.05. One-way ANOVA test between all groups, p < 0.001. 
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Grade 1 Grade 2 
 
Grade 3 
        
 
  
    
24 
 
5 76 
 
51 75 74 87 51 85 
38 
 
85 5 
 
20 17 37 63 58 73 
20 
 
62 66 
 
27 38 76 82 39 78 
8 
 
24 62 
 
21 8 70 95 57 63 
  
2 59 
 
26 15 62 25 97 34 
  
12 52 
 
54 71 31 74 61 10 
  
85 17 
 
90 18 79 52 68 
  
  
90 91 
 
59 16 16 45 18 
 
  
23 88 
 
43 89 57 58 74 
 
  
40 51 
 
88 66 30 17 32 
  
 
 
Table  4-6: WT1 is significantly hypermethylated in high grade MPNSTs 
compared to lower grades 
Methylation of the WT1 gene regulatory area was analysed by pyrosequencing in 80 
MPNSTs. Each box represents the average methylation level of 5 CpG dinucleoides 
within a single tumour. The average level of WT1 methylation in grade 1 MPNTs = 
23% (4 tumours); grade 2 = 48% (20); and grade 3 = 49% (56). Grade 1 vs. grade 
2, unpaired Student’s t-test (p < 0.05). Grade 1 vs. grade 3 (p < 0.05). Grade 2 vs. 
grade 3 (p = 0.835). One-way ANOVA test between all groups p = 0.111. 
 
 
 
Colour code: 
Methylation % 
0-25% 
26-50% 
51-75% 
76-100% 
(N= 4)   (N= 20)      (N= 56) 
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Figure  4-17: Hypermethylation of WT1 with increasing grade of MPNST  
Box plot shows the mean methylation level of 5 CpG sites within the WT1 gene 
regulatory area from 80 MPNSTs of different grades (4 grade 1; 20 grade 2; and 56 
grade 3). The results demonstrate significantly higher levels of WT1 gene 
methylation in grade 2 and grade 3 MPNSTs compared to that in grade 1 tumours 
(unpaired Student’s t-test, p < 0.05). However there is no significant difference in 
levels of WT1 methylation between grade 2 and grade 3 MPNSTs (unpaired 
Student’s t-test, p = 0.835). Comparison between all groups showed no significant 
difference (one-way ANOVA test, p = 0.111). 
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4.4. Summary of Results 
In this chapter, I examined fresh frozen tissue from 9 MPNSTs and 9 
neurofibromas by q-RT-PCR and demonstrated a significantly higher level of 
DNMT3B mRNA expression in MPNSTs compared to that in neurofibromas. 
However, I found no significant difference in DNMT3A mRNA expression 
between the benign and malignant nerve sheath tumours.  
I showed that miR-29c expression inversely correlates with DNMT3B mRNA 
expression in MPNSTs and neurofibromas. However, no correlation was 
found between miR-29c and DNMT3A mRNA expression in MPNSTs and 
neurofibromas. 
My in vitro analyses demonstrated a significant reduction in DNMT3A and 
DNMT3B mRNA levels following transfection of miR-29c into sNF96.2 cells.  
From my examination of the in silico data and published literature I identified 
S100B, CDKN2A and WT1 as differentially methylated and differentially 
expressed between MPNSTs and neurofibromas. I therefore considered 
these as potential targets of DNMTs in MPNSTs.  
Pyrosequencing analysis of CDKN2A, WT1, and S100B in a larger cohort of 
80 MPNSTs and 80 neurofibromas FFPE tissue samples revealed 
hypermethylation of these three genes is more frequent in MPNSTs 
compared to neurofibromas. In addition, S100B and WT1 DNA methylation 
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was found to be higher in high grade MPNST as compared with low grade 
MPNST. 
I next looked at the expression of WT1 and S100B by qRT-PCR following 
global demethylation of sNF96.2 cells by treatment with 5-Aza-2′-
deoxycytidine (5-aza-dC) and showed that this leads to a significant increase 
in levels of WT1 and S100B mRNA expression in this cell line. 
My findings suggest miR-29c may have an important influence on gene 
methylation in MPNSTs and neurofibromas by regulating the expression of 
DNMT3B. In addition, the inhibition of S100B and WT1 expression by 
hypermethylation may play an important role in the pathogenesis of MPNSTs 
from neurofibromas and in the progression of MPNSTs from low grade to 
high-grade tumours. 
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5. Analysis of S100B and WT1 
candidates as potential tumour 
regulators in nerve sheath 
tumours  
5.1. Introduction 
S100 protein immunoreactivity in formalin-fixed paraffin-embedded material 
was first suggested as a diagnostic tool for diagnosis in a range of tumours 
(Nakajima et al. 1982). Nakajima et al. showed that S100 was expressed in 
the cells of eosinophilic granuloma, Hand-Schüller-Christian disease and 
Letterer-Siwe disease as well as in epidermal Langerhans cells 
and interdigitating reticulum cells in the lymph node, spleen and thymus 
(Nakajima et al. 1982). Subsequently, additional studies identified the 
expression of S100 in further tumour types including rhabdomyosarcoma, 
Ewing sarcoma, and synovial sarcoma (Coindre et al. 1988; Shimada et al. 
1988; Fisher & Schofield 1991).  
The known human S100 protein family consists of twenty-one members. 
They are small proteins of molecular weight between 9 kDa and 14 kDa 
(Marenholz et al. 2004; Donato 2003; Zimmer et al. 2013). They have been 
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shown to regulate different cellular functions using a calcium-dependent 
mechanism and  they have also been shown to have a potential role in 
tumour formation and metastasis (Böni et al. 1997; Petersson et al. 2009; 
Keijser et al. 2006; Maelandsmo et al. 1997).  
S100B protein is most abundant in neural tissue and it is commonly used by 
pathologists as a marker to indicate glial cell and Schwann cell differentiation 
(Hachem et al. 2005). S100B protein functions through intracellular and 
extracellular mechanisms and depending on its concentration, 
secreted S100B protein exerts either cytotrophic or cytotoxic effects (Astrand 
et al. 2013). Lévy et al. showed that S100B mRNA is significantly 
downregulated in MPNST as compared to neurofibromas(Lévy et al. 2004). 
WT1 was first discovered as a tumour suppressor in the paediatric kidney 
malignancy, nephroblastoma, or Wilms’ tumour (WT) (Gessler et al. 1990; 
Call et al. 1990; Little & Wells 1997). WT1 can function as an oncogene in 
addition to its tumour suppressor function. It has been shown in a mouse 
model that WT1 can suppress growth and tumour formation (Smith et al. 
2000; Fraizer et al. 2004; Luo et al. 1995). A study on acute myeloid 
leukaemia showed that 10-15% of cases studied had WT1 mutation (King-
Underwood et al. 1996). In contrast, an oncogenic role for WT1 in acute 
myeloid leukaemia has been suggested (McMaster et al. 1995; Barragán et 
al. 2004) where increased level of WT1 was associated with a poor response 
to therapy. In another study on acute myeloid leukaemia, a group of patients 
with poor prognosis showed high expression of WT1 and Bcl-2 (Karakas et 
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al. 2002). The methylation of WT1 CpG islands has been detected in 
squamous cell carcinomas of the uterine cervix, suggesting it can be used for 
cervical cancer screening (Lai et al. 2008). WT1 expression has been 
identified in various neural crest tumours including peripheral nerve sheath 
tumours e.g. neurofibromas and schwannomas (Schittenhelm et al. 2010; 
Singh et al. 2012). WT1 overexpression has been detected also in MPNST 
using real-time RT-PCR (Ueda et al. 2003). A recent study has shown that 
silencing of WT1 in sNF96.2 MPNST cell line Inhibits cell proliferation 
(Parenti et al. 2014). 
In chapter 4, I have shown that S100B and WT1 are frequently 
hypermethylated in MPNST compared to neurofibromas and the methylation 
is higher with the higher grade of tumour. I have also shown that 
demethylation of sNF96.2 MPNST cells cause re-expression of S100B 
mRNA and increased the expression of WT1 mRNA (Chapter 4). Here, I 
focus on S100B and WT1 as they have shown response to demethylation in 
sNF96.2 MPNST cells.  
Although there are some studies in the literature that have discussed the 
expression of WT1 (Schittenhelm et al., 2010; Parenti et al., 2014) or S100B 
protein in MPNST (Lévy et al. 2004; Nonaka et al. 2008), my work is the first 
to shed light on the possible regulatory mechanism of those genes through 
DNA methylation in MPNST.  
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5.2. Aims 
The aims of this chapter were threefold: 
 Examine the S100B and WT1 mRNA expression pattern in MPNSTs 
and neurofibromas and determine whether there is any correlation 
between expression of these genes and their DNA methylation status. 
 Test the protein expression using any of these two genes that might 
demonstrate a significant correlation between gene expression and 
methylation. 
 Carry out functional studies in an MPNST-derived cell line of the 
selected potential regulator(s). 
 
 
  
P a g e  | 223 
   
  
5.3. Results 
5.3.1. S100B mRNA expression is low in 
MPNST compared to neurofibromas and 
inversely correlated with DNA methylation. 
In chapter 4, I have shown that the S100B and WT1 genes are frequently 
hypermethylated in MPNST compared to neurofibromas and also 
demonstrated that the level of their DNA methylation is elevated in higher 
grade tumours. I have also shown that global DNA demethylation of sNF96.2 
MPNST-derived cells results in re-expression of S100B mRNA and increases 
expression of WT1 mRNA (Chapter 4). In order to determine whether any 
relationship exists between the expression of S100B and WT1 mRNA 
transcripts and their DNA methylation status, I decided to examine our fresh 
frozen human MPNSTs and neurofibromas by pyrosequencing and qRT-
PCR as described in the previous chapter. However only 9 samples from 
each of the 10 MPNSTs and 10 neurofibromas was available for analysis this 
time. 
The results of the WT1 qRT-PCR data from the two different groups of 
tumour are summarised in Figure ‎5-1. These demonstrated no significant 
difference in WT1 mRNA expression between MPNSTs and Neurofibromas 
(unpaired Student’s t-test, p = 0.694; Figure ‎5-1). However, expression of 
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S100B mRNA was found to be significantly lower in MPNSTs compared to 
neurofibromas (unpaired Student’s t-test, p < 0.01) as shown in (Figure ‎5-3) 
I next compared the WT1 and S100B mRNA expression levels with the 
S100B and WT1 gene methylation levels in these tumour samples. The CpG 
methylation for the same samples has been analysed previously in 
section ‎4.3.4.  
I observed a significant inverse correlation between the level of S100B 
mRNA expression and the level of S100B gene methylation in these tumours 
as demonstrated in Figure ‎5-4 (Pearson’s correlation coefficient of -0.590, p 
< 0.01). However, I found no correlation between the level of WT1 mRNA 
expression and the level of WT1 gene methylation (Pearson’s correlation 
coefficient of -0.051, p = 0.841), see Figure ‎5-2. 
.  
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Figure ‎5-1: WT1 mRNA expression shows no significant difference 
between MPNSTs and neurofibromas 
Box plot shows qRT-PCR results of WT1 mRNA expression levels in 9 
neurofibromas and 9 MPNSTs. The WT1 mRNA levels were normalised to 
expression of GAPDH gene. The results shown are representing the average of 2 
technical replicates from one experiment.  Error bars correspond to standard 
deviation. Neurofibromas vs. MPNSTs, unpaired Student’s t-test, p = 0.694. 
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Figure ‎5-2: WT1 mRNA expression does not correlate with the level of 
WT1 gene methylation  
qRT-PCR and pyrosequencing analysis demonstrates no correlation between WT1 
mRNA expression and methylation of the corresponding WT1 DNA in MPNSTs and 
neurofibromas (Pearson’s correlation test, p = 0.841, correlation coefficient of -
.051). 
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Figure ‎5-3: S100B mRNA expression is significantly lower in MPNSTs 
compared to neurofibromas 
Box plot shows qRT-PCR analysis of S100B mRNA expression level in 9 
neurofibromas and 9 MPNSTs. The S100B mRNA levels were normalised to 
expression of the GAPDH gene. The results shown are representing the average of 
2 technical replicates from one experiment.Error bars correspond to standard 
deviation.  Neurofibromas vs. MPNSTs, unpaired Student’s t-test, *p < 0.01. 
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Figure ‎5-4: S100B mRNA expression inversely correlates with level of 
S100B gene methylation 
qRT-PCR and pyrosequencing data demonstrates a significant inverse correlation 
between S100B mRNA expression and DNA methylation status of the 
corresponding S100B gene in MPNSTs and neurofibromas (Pearson’s correlation 
test , p < 0.01, correlation coefficient of -0.590). 
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5.3.2. S100 IHC staining inversely correlates 
with CpG methylation 
Having demonstrated that S100B mRNA expression is significantly lower in 
MPNSTs compared to Neurofibromas and significantly correlates with 
methylation of CpG sites within the S100B gene regulatory region 
(Figure ‎5-4); I next examined the expression of S100B protein in human 
MPNSTs and neurofibromas. IHC staining of S100B protein was performed 
on FFPE tissue samples from a selected cohort of 15 MPNSTs and 15 
neurofibromas. 10 of the 15 MPNSTs chosen were highly hypermethylated 
at the S100B regulatory region (> 75% methylation), 10 of the neurofibromas 
were hypomethylated (< 25% methylation), and 5 each of the MPNSTs and 
neurofibromas chosen were intermediate-methylated (25 - 75% methylated). 
Details of the IHC staining protocol are described in chapter 2.  
Table ‎5-1 gives a summary of the S100B IHC results obtained from the 15 
MPNSTs and 15 neurofibromas. The IHC staining intensity was scored as 0 
for no staining; 1 for weak staining; 2 for moderate staining; and 3 for strong 
staining of S100B protein. The percentage of tumour cells stained positive 
within each tumour sample was also scored as 0 for < 1% of tumour stained; 
1 for 1 – 10% of tumour stained; 2 for 11 – 60% of tumour stained; and 3 for 
> 60% of tumour stained. A combined score was then calculated for each 
tumour sample by adding together the score for intensity of staining and 
score for percent of tumour cells stained.  
P a g e  | 230 
   
  
The results of the IHC analysis demonstrated negative or focal weak staining 
of S100B protein in 7 out of the 10 hypermethylated MPNST samples. Focal 
strong staining of S100B was also seen in 3 of the hypermethylated 
MPNSTs. In the neurofibromas, diffuse strong staining of S100B protein was 
seen in 9 out of 10 hypomethylated cases. Diffuse moderate staining of 
S100B protein was seen in only one of these cases. In the 10 intermediate-
methylated tumour samples different patterns of S100B protein staining was 
observed; 1 sample was S100B negative, 2 cases showed focal weak 
staining, 2 showed diffuse moderate staining and 5 cases demonstrated 
diffuse strong staining for S100B.  
I next compared the S100B protein staining pattern with the corresponding 
S100B DNA methylation level in each of the 15 MPNSTs and 15 
neurofibromas. The results of this analysis, which are summarised in 
Figure ‎5-5 showed that tumours which are negatively stained or show focal 
weak or focal strong staining of S100B protein are largely hypermethylated 
(MPNSTs). The hypomethylated tumours (neurofibromas) mainly exhibited 
diffuse moderate or diffuse strong IHC staining for S100B (Figure ‎5-5). In 
other words there is a significant inverse correlation between the expression 
of S100B protein and methylation of CpG sites within the regulatory region of 
the corresponding S100B gene in MPNSTs and neurofibromas (Pearson’s 
correlation test, correlation coefficient of -0.716, p < 0.001; Figure ‎5-6). 
Examples of the of different types of S100B IHC staining patterns obtained 
can be seen in Figure ‎5-7. 
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Table ‎5-1: S100B gene methylation level and protein staining score in 
Neurofibromas and MPNSTs  
 
Tumour 
Diagnosis 
S100B 
% methylation 
Staining 
pattern 
Extent of 
Staining 
Staining 
intensity 
Combined 
Staining score 
MPNST 1 79 F 1 1   2 
MPNST 2 79 F 1 1  2 
MPNST 3 80 F 1 1 2 
MPNST 4 84 F 1 1 2 
MPNST 5 87 F 1 1 2 
MPNST 6 90 - 0 0 0 
MPNST 7 84 F 1 3 4 
MPNST 8 80 F 2 3 5 
MPNST 9 88 F 1 1 2 
MPNST 10 93 F 1 3 4 
MPNST 11 63 F 1 1 2 
MPNST 12 60 - 0 0 0 
MPNST 13 60 F 1 1 2 
MPNST 14 37 D 2 2 4 
MPNST 15 49 D 3 2 5 
NF 1 58 D 3 3 6 
NF 2 55 D 3 3 6 
NF 3 54 D 2 3 5 
NF 4 50 D 3 3 6 
NF 5 49 D 3 3 6 
NF 6 8 D 3 3 6 
NF 7 11 D 3 3 6 
NF 8 9 D 3 3 6 
NF 9 16 D 3 3 6 
NF 10 5 D 3 2 5 
NF 11 9 D 3 3 6 
NF 12 6 D 3 3 6 
NF 13 1 D 3 3 6 
NF 14 6 D 3 3 6 
NF15 14 D 3 3 6 
 
 
 
 
 
Key: F= focal; D= diffuse.  
Extent of staining refers to percentage of tumour cells which are positive: 0= < 1%; 1= 1-
10%; 2= 10-60% and 3= > 60%. 
Staining intensity is scored as 0= none; 1= weak; 2= moderate; and 3= strong. 
The combined staining score represents the sum of the scores for extent and intensity of 
staining in each individual tumour. 
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Figure ‎5-5: S100B gene methylation level versus protein expression 
pattern in NFs and MPNSTs 
Box plot shows the average S100B DNA methylation percentage in tumours with 
different patterns of S100B protein expression. The samples exhibiting no 
expression or focal (weak, moderate or strong) expression of S100B protein were all 
MPNSTs (13 cases) with hypermethylated S100B gene. A significant correlation 
between hypomethylation of S100B gene and diffuse (moderate or strong) 
expression of S100B protein was also demonstrated in the tumour samples. All 
cases exhibiting diffuse, strong S100B protein expression were neurofibromas (n= 
14); the cases demonstrating diffuse, moderate protein expression comprised two 
MPNSTs and one neurofibroma.  
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Figure ‎5-6: S100B protein expression inversely correlates with level of 
S100B gene methylation  
Graph shows the methylation level (expressed as a percentage) of 6 CpG islands 
within the S100B gene regulatory region plotted against the combined 
immunostaining score of S100B protein in 30 individual tumours (15 MPNSTs and 
15 NFs). The results demonstrate a significant inverse correlation between the level 
of S100B gene methylation and S100B protein expression (Pearson’s correlation 
test, p < 0.001, correlation coefficient of -0.716). 
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Negative S100B immunostaining in 2 MPNSTs: 
   
 
Focal weak S100B immunostaining in 2 MPNSTs: 
           
 
Focal strong S100B immunostaining in 3 MPNSTs: 
     
 
Diffuse moderate S100B immunostaining in 2 MPNSTs and 1 neurofibroma: 
     
 
Diffuse strong S100B immunostaining in 3 neurofibromas: 
       
 
Figure ‎5-7: S100B protein expression in MPNSTs and neurofibromas 
Representative examples of different S100B immunostaining patterns. S100B 
protein, which appears as brown staining, is expressed in both cytoplasm and nuclei 
of cells. The highest intensity and extent of staining is seen in the 3 neurofibromas 
(bottom panel).  
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5.3.3. Cloning of S100B into lentivirus 
expression vector 
Having demonstrated that S100B protein expression is decreased in 
MPNSTs compared to neurofibromas, I next examined the role that S100B 
might play in the pathogenesis of MPNSTs. This was done by carrying out 
functional studies using the sNF96.2 cell line that is known not to express 
endogenous S100B protein or mRNA transcript. I aimed to re-express S100B 
in this cell line by transducing it with an S100B lentivirus expression vector 
(pLenti PGK PuroDEST) and examine any observable effects that S100B 
expression might have on cell proliferation and migration.  
I used a standard cloning technique to insert S100B cDNA into an 
expression vector (pLenti PGK PuroDEST) using a PCR cloning strategy as 
described in chapter 2. Briefly, S100B cDNA was first amplified by RT-PCR 
and the resulting amplicon was then checked by agarose gel electrophoresis 
and direct sequencing to confirm the correct product had been amplified. The 
S100B RT-PCR product was then inserted into the pENTR 4 dual selection 
vector using appropriate restriction enzymes and then recombined into a 
PGK PuroDEST (w529-2) destination vector as described in chapter 2. The 
destination vector containing S100B cDNA was then transfected into 
lentivirus which was then used to infect the sNF96.2 cells. Lentivirus 
containing empty vector was also prepared and used to transfect a separate 
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culture of sNF96.2 cells for use as a control. Stably transduced cells were 
then selected by growing them in the presence of Puromycin (see chapter 2 
for details).  
The expression of S100B in the transduced sNF96.2 cells was then 
examined at both the mRNA and protein level by qRT-PCR and Western blot 
analysis. The results of the qRT-PCR demonstrated no detectable S100B 
mRNA transcript in sNF96.2 cells transduced with empty viral vector but a 
significant level of S100B mRNA expression was detected in the sNF96.2 
cells transduced with S100B expressing vector (unpaired Student’s t-test, p < 
0.001; Figure  5-8A).  
The Western blot analysis also demonstrated clear expression of S100B 
protein in sNF96.2 cells transduced with S100B expressing viral vector. 
However in the sNF96.2 cells transduced with empty vector there was no 
evidence of any S100B protein expression on the Western blot (Figure  5-8B). 
The data from the qRT-PCR and Western blot analysis indicated that I had 
managed to successfully transduce S100B cDNA into the sNF96.2 cells and 
that S100B was successfully being transcribed into mRNA and translated 
into protein at significant levels in this cell line. 
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Figure ‎5-8: S100B mRNA & protein expression following transduction of 
sNF96.2 cells with S100B expression vector  
(A) qRT-PCR demonstrating S100B mRNA expression in sNF96.2 cells 
transduced with S100B expressing lentiviral vector but not in control cells 
transduced with lentivirus containing empty vector (unpaired Student’s t-test, *p < 
0.001).  The qRT-PCR data was normalised to GAPDH gene. Bars represent the 
average results obtained from three independent experiments (three biological 
replicates).  Error bars represent standard deviation. (B) Western blot demonstrating 
expression of S100B protein in sNF96.2 cells transduced with S100B expressing 
viral vector but not in control cells transduced with virus containing empty vector.  
GAPDH was used as a protein loading control. 
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5.3.1. Re-expression of S100B in sNF96.2 
MPNST cells causes reduced cell proliferation 
Following successful transduction of S100B cDNA into sNF96.2 cells, 
functional studies were carried out in order to determine the effects(s) if any, 
that S100B expression might have on the proliferation and migration of these 
MPNST-derived cells. Cell proliferation was assessed using the MTS assay 
and Incucyte  Kinetic Live Cell imaging ™ System (details of which can be 
found in chapter 2). Results from the Incucyte live imaging system can be 
seen in Figure  5-9. Cells were imaged every 2 h for a total period of 96 h and 
the IncuCyte Analyser software was used to obtain real-time updates on cell 
confluence changes over the experimental time.  
Figure ‎5-10 shows the proliferation curves obtained over the four day growth 
period. The results demonstrated a significant decrease in proliferation of 
sNF96.2 cells transduced with S100B expressing viral vector compared to 
that in control cells transduced with empty viral vector. The differences in 
proliferation between test and control cells became evident very early on, at 
around 10 h into the experiment, and by 50 h, there was a greater than 20 % 
difference in confluence levels between test and control sNF96.2 cells. The 
difference in growth is highly significant at 72 h (p < 0.001).  
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 Figure 5-9: Incucyte imaging of lentivirus transduced sNF96.2 cells  
Differences in confluency between S100B expressing sNF96.2 cells (test cases) and cells transduced 
with empty viral vector (controls). The images demonstrate a significant decrease in proliferation of test 
cells compared with control cells. 
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Figure ‎5-10: Decreased proliferation of S100B expressing sNF96.2 cells  
Incucyte live imaging proliferation assay showing percentage confluence of sNF96.2 
cells transduced with S100B expressing lentiviral vector and control cells 
transduced with virus containing empty vector over a 96-h period. The data points 
represent the averages of three technical replicates from one representative 
experiment. Error bars represent standard deviation. There is a significant reduction 
in proliferation of sNF96.2 cells expressing S100B compared to control cells, p < 
0.001 at 72 h). 
   
P a g e  | 241 
   
  
The results from the MTS proliferation assay are shown in Figure ‎5-11. This 
assay was conducted over a total period of 4 days and absorbance 
measurements were taken at 0, 2, and 4 days following the start of the 
experiment. There was no significant difference in absorbance 
measurements between the test and control cells at the start of the 
experiment (day 0) but at day 2 there was a significant (> 50%) reduction in 
absorbance readings from S100B expressing cells compared to that in 
control cells. By day 2, the absorbance readings from the MTS assay began 
to plateau for both the test and control cell lines (paired Student’s t-test, p < 
0.01 at day 2). 
 
Figure ‎5-11: Decreased viability of S100B expressing sNF96.2 cells  
Cell viability was measured by MTS assay in sNF96.2 cells transduced with S100B 
expressing vector (test cells) or with empty viral vector (controls) at 0, 2 and 4 days 
following seeding of 2x103 cells in 100 µl of culture medium into each well of 96 well 
plates. Data points represent the mean absorbance measurements from three 
independent experiments (three biological replicates). Error bars represent standard 
deviation. By day 2 there was a significant reduction in viability of test cells 
compared to controls (paired Student’s t-test, p < 0.01 at day 2). 
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The result from the Incucyte live cell imaging and MTS assay demonstrate 
that S100B expression in sNF96.2 cells has an inhibitory effect on cell 
proliferation and suggests a tumour suppressor role for S100B in MPNSTs. 
Following the cell proliferation and viability assays the effect of S100B 
expression on migration of sNF96.2 cells was assessed using the scratch-
wound healing assay, details of which can be found in chapter 2. Briefly, the 
test and control sNF96.2 cells were seeded in triplicate into 24-well plates 
and left to grow until confluency was reached overnight. A scratch was then 
made through the central axis of the plate using the Essen BioScience 
Wound-Maker and images of the scratch area were recorded every 2 h for a 
total of 30 h using the IncuCyte™ live cell imaging system. The results 
demonstrated no significant differences in migration rates between S100B 
expressing sNF96.2 cells or control cells transduced with empty vector 
(Figure ‎5-12).  
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Figure ‎5-12: Cell motility rate unaltered in S100B expressing sNF96.2 
cells 
Scratch wound-healing motility assay showing sNF96.2 cells transduced with 
S100B expression vector (test cells) and control cells transduced with empty vector. 
Images were taken using the Incucyte live cell imaging system immediately after a 
scratch was made through the central axis of each plate at 0 h, and 30 h later. The 
number of cells, which had migrated into the scratch area, was found to be 
comparable in both test and control cells.   
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5.3.2. S100B gene methylation unaltered by 
miR-29c expression in sNF96.2 cells  
Having demonstrated that S100B expression can affect the proliferation of 
MPNST-derived sNF96.2 cells I next set out to determine whether S100B 
gene methylation might be influenced by the expression of miR-29c in this 
line. I therefore examined the methylation status of the S100B gene 
regulatory region in sNF96.2 cells transfected with miR-29c mimics (test 
cells) and in control cells transfected with scrambled oligonucleotides. DNA 
was extracted from test and control cells 48 h following transfection and 
examined by bisulfite pyrosequencing as previously described. The results 
from these experiments demonstrated no significant differences in the level 
of methylation at 6 CpG sites within the S100B gene regulatory region 
between the test and control sNF96.2 cells (unpaired Student’s t-test, p = 
0.375) (Figure  5-13). Although these results show that ectopic expression of 
miR-29c has no influence on the methylation status of S100B in this cell line, 
the findings do not rule out the possibility that S100B gene methylation could 
still be influenced by miR-29c during the early stages of MPNST 
development via its effects on expression of the de novo methylators 
DNMT3A and DNMT3B. 
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Figure ‎5-13: S100B gene methylation unaltered by miR-29c expression 
in sNF96.2 cells 
Bisulfite pyrosequencing of the S100B gene regulatory region in sNF96.2 
cells transfected with miR-29c mimics (test cells) or with scrambled 
oligonucleotides (controls) demonstrates no significant differences in the 
level of methylation at 6 CpG sites between test and control cells (paired 
Student’s t-test, p = 0.375). 
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5.4. Summary of results 
In this chapter, I have shown that S100B mRNA expression is significantly 
lower in MPNST compared with neurofibromas and inversely correlates with 
the level of methylation at CpG sites within the S100B gene regulatory 
region. 
However, I observed no significant difference in the level of WT1 mRNA 
expression between MPNSTs and neurofibromas and no correlation was 
found between the level of WT1 mRNA expression and methylation status of 
the WT1 gene. 
I then compared the S100B IHC staining pattern with the corresponding 
S100B DNA methylation pattern in each of 15 MPNSTs and 15 
neurofibromas and demonstrated a significant inverse correlation between 
S100B protein expression and the level of methylation at S100B gene 
regulatory region. 
In order to examine the role that S100B might play in the pathogenesis of 
MPNSTs functional studies were carried out using sNF96.2 cells that had 
been transduced with a S100B expressing lentiviral vector. I found that 
S100B expression in sNF96.2 cells had an inhibitory effect on cell 
proliferation and viability but had no effect on the migratory behaviour of 
these cells. 
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I next set out to determine whether S100B gene methylation might be 
influenced by the expression of miR-29c in this line. However, an 
examination of the methylation status of the S100B gene regulatory region in 
sNF96.2 cells that had been transfected with miR-29c mimics demonstrated 
no significant alteration in the level of methylation at the S100B gene 
regulatory region in response to miR-29c expression.  
My findings suggest that S100B functions as a tumour suppressor and its 
expression is epigenetically controlled by methylation in MPNSTs. 
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6. Discussion 
6.1. Role of miR-29c in the progression 
of neurofibroma to MPNST 
The underlying mechanisms by which neurofibromas transform to MPNST 
remain largely unknown but increased understanding of these processes 
could potentially provide novel opportunities for early diagnosis and/or 
therapy in patients. Much evidence has accumulated in recent years 
highlighting the important influence of microRNAs on various physiological 
and pathological processes, including tumour biology where they mediate 
their effect as either tumour suppressor genes or oncogenes (Calin & Croce 
2006; Di Leva & Croce 2010; Esquela-Kerscher & Slack 2006; Garzon et al. 
2006; Pasquinelli et al. 2005). 
Previous investigations into the role of miRNAs in the pathogenesis of 
MPNSTs in patients with and without neurofibromatosis type 1 are limited 
and have resulted in different miRNAs being implicated in the development 
of MPNSTs from neurofibromas. In the earliest of these studies Subramanian 
et al. (2010) carried out miRNA expression profiling for 482 known and 
predicted human miRNAs on 23 peripheral nerve sheath tumours (6 
MPNSTs, 11 neurofibromas and 6 schwannomas) and reported distinct 
miRNA expression profiles for MPNSTs and benign tumours. In comparison 
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with benign tumours, five miRNAs (miR-214, miR-377, miR409-3p, miR-487b 
and miR-99b) were relatively upregulated and five (miR-517, miR-34a, miR-
29a, miR-30e-5p and miR-27a) were downregulated in MPNSTs. All the 
MPNSTs, which were reported as demonstrating a significant downregulation 
of miR-34a by Subramanian et al. (2010), were also described as exhibiting 
a TP53 inactivation gene expression signature. They demonstrated that 
exogenous expression of p53 in MPNST cells induces miR-34a and other 
miRNAs, a finding that is consistent with published data showing that miR-
34a expression is regulated by p53 (Chang et al. 2007; He et al. 2007).  
miR-34a was not found to be significantly differentially expressed in our 
MPNSTs compared to neurofibromas although we did show that 6 out of the 
9 MPNST showed lower expression of miR-34a, whereas lower expression 
was detected in only three neurofibromas. It is noteworthy that the TP53 
gene expression signature of our 10 MPNSTs was unknown. In this context it 
is of interest that all of our patients had neurofibromatosis type 1, whereas it 
is not known if this were the case for the six patients in Subramanian's study. 
This is relevant as TP53 mutations are reported to occur in ∼25% of 
MPNSTs, and that the minority of these (36%) are found in tumours from 
patients with neurofibromatosis type 1 (Verdijk et al. 2010). Hence, it is 
interesting to speculate that the different genetic background on which 
MPNSTs arise provide an explanation for the discrepant miR-34a results. An 
alternative explanation for the discrepancy between the two studies is that 
different miRNA microarray platform were used, and the small numbers of 
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cases included in the studies could have compounded this. Nonetheless, it is 
reassuring that we reproduced the finding published by Subramanian et al 
(2010) that miR-29a was significantly downregulated in MPNST. None of the 
other miRNAs mentioned in Subramanian’s study however, were found to be 
amongst our list of differentially expressed genes in MPNSTs and 
neurofibromas. 
In a more recent study, Masliah-Planchon et al. (2012) examined 9 dermal 
neurofibromas, 41 plexiform neurofibromas, and 15 MPNSTs from 
neurofibromatosis type 1 patients using the TaqMan Low Density Array, 
which included 377 highly characterised human miRNAs. They reported 113 
miRNAs as differentially expressed between plexiform neurofibromas and 
MPNSTs. Of these 103 were significantly upregulated in MPNSTs and 10 
were downregulated. This finding is in sharp contrast to the findings in our 
study where the majority of miRNAs (14/16) were downregulated in MPNST 
relative to neurofibromas. It is of interest that miR-210 and miR-339-3p, 
which we found to be upregulated in our study, are also upregulated in 
Masliah-Planchon et al. study. The downregulated genes reported by 
Masliah-Planchon et al. (2012) included miRNAs (miR-139-5p, miR-150, 
miR-195 and miR-146a) that were also among our list of significantly 
downregulated miRNAs thus suggesting they may play an important role in 
the pathogenesis of MPNSTs and should perhaps be singled out for further 
study in these tumours. It is also interesting that a member of the lethal 7 
(let7) family (let7b) was amongst the list of relatively downregulated miRNAs 
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in MPNSTs by Masliah-Planchon et al. (2012) as two members of this family, 
let-7a and let-7g were also amongst our list of downregulated genes in 
MPNSTs. let-7 miRNAs regulate key differentiation processes during 
development. In addition, the expression of let-7 members has previously 
been reported to be significantly low in human cancers where it is thought 
they may play an important role as tumour suppressors by targeting RAS. 
(Grosshans et al. 2005; Takamizawa et al. 2004; Peter 2009). 
Itani et al. (2012) tested 6 neurofibromas and 6 MPNSTs and reported that 
miR-21, miR-135b, miR-152, miR-130b, miR-92, and miR-15b were 
upregulated in MPNST compared to neurofibromas, whereas the expression 
levels of miR-125b, miR-127, and miR-302d were downregulated in MPNST 
compared to neurofibromas. In our cohort, we did not observe these 
particular differences to statistical significance. An explanation for the 
discrepancy between our study and the other studies is that different 
microRNA microarray platforms were used, and the small numbers of cases 
included in the studies could have compounded this. In addition using 
samples from different genetic background or possible different ethnic group 
might contribute to this discrepancy between results. 
We have also demonstrated that all members of the miR-29 family, that is 
miR-29a, b, c, c* and b-1* are significantly downregulated in MPNSTs 
compared to neurofibromas. The involvement of these miRNAs in MPNSTs 
is perhaps not surprising since these miRNAs have previously been reported 
to be aberrantly expressed in a wide variety of cancers (Castilla et al. 2011; 
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Nguyen et al. 2014; Fabbri et al. 2007; Iorio et al. 2005; Li et al. 2011; 
Sengupta et al. 2008; Xiong et al. 2010; Zhao et al. 2010; Calin et al. 2005). 
The miR-29 family of miRNAs have extensive sequence homology at the 5’ 
seed region, which is important for RNA target recognition and specificity 
(Bartel, 2004). This, coupled with the fact that an mRNA can be 
simultaneously repressed by more than one miRNA species (Doench & 
Sharp 2004), makes it conceivable that the miR-29 family members might be 
acting on the same target, or may be regulating multiple genes within the 
same or related pathways in neurofibromas and MPNSTs. I found the miR-
29 family interesting to be studied further because all the members of the 
family are differentially expressed between neurofibromas and MPNSTs. 
I next focussed my attention on miR-29c specifically for further analysis. This 
particular miR-29 was chosen for a number of important reasons. Firstly this 
miRNA was more significantly differentially expressed compared to the other 
miR-29 family members in neurofibromas and MPNSTs. Secondly it has 
been implicated in a variety of other cancers including chronic lymphocytic 
leukaemia (Mraz et al. 2009; Stamatopoulos et al. 2009), oesophageal 
squamous cell carcinoma (Ding et al. 2011), nasopharyngeal carcinoma 
(Sengupta et al. 2008), lung cancer (Fabbri et al. 2007) which made it an 
attractive molecule to study. I concentrated on the mature form of miR-29c 
since the star forms (*) of miRNA are generally found to be less expressed in 
vivo compared with the non-star forms (Schwarz et al. 2003). In addition the 
mature form of miRNA is the one that incorporate in the RNA-induced 
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silencing complex (RISC) which causes its stabilisation and this process is 
accompanied by destruction of the (*) form (Schwarz et al. 2003). In addition 
I conveniently had available to me an MPNST-derived cell line, sNF96.2, 
which had previously been shown to be NF1 mutant (Perrin et al. 2007) and I 
verified this NF1 mutation using direct sequencing. We also found previously 
in our lab sNF96.2 cells to express very low levels of miR-29c, therefore 
suitable for functional studies involving transfection of miR-29c. 
I have shown that the ectopic expression of miR-29c (using synthetic miR-
29c mimics) leads to reduced migration of MPNST-derived cells but does not 
significantly affect their proliferation. These findings are consistent with 
previous reports that proliferation and migration are often mutually exclusive 
cellular phenomena (Zheng et al., 2009). The inhibitory actions of miR-29c 
expression on cell migration has previously been demonstrated in other 
cancers such as nasopharyngeal carcinoma, gastric cancer, bladder cancer 
and pancreatic cancer (Cui et al. 2015; Jiang et al. 2015; Fan et al. 2014; 
Sengupta et al. 2008). However, in glioma and gastric cancer miR-29c was 
found to have an inhibitory effect on both proliferation and migration (Fan et 
al. 2013; Y. Wang et al. 2013; Han et al. 2015) On the other hand, it has 
been demonstrated that miR-29c suppresses cell proliferation and induced 
apoptosis in oesophageal carcinoma, bladder cancer and hepatocellular 
carcinoma (Wang et al. 2011; Fan et al. 2014; Ding et al. 2011). Its possible 
miR-29c expression could have different effects on cell proliferation and 
migration depending on the cell context. 
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The migratory behaviour of mammalian cells is known to be influenced by a 
variety of factors including the extracellular matrix. The extracellular matrix is 
composed of a complex set of molecules which are secreted by cells and 
plays an important role in maintaining tissue integrity by providing structural 
as well as well as biochemical support to surrounding cells. It can also act as 
a reservoir for a variety of growth factors/cytokines e.g., adhesion molecules 
and receptor tyrosine kinases. The function of the ECM is brought about by a 
finely tuned remodelling process achieved through breakdown and 
replacement of tissue and involves MMPs, which degrade various collagens 
and non-collagenous ECM glycoproteins (Patterson et al., 2001). Alterations 
of the constituent elements of ECM can have been shown to have profound 
effects on the proliferation, survival, and migration of surrounding cells often 
seen in various disease states (Russo et al. 2005; Newby 2006; Daley et al. 
2008).  
In order to throw more light on the mechanism(s) by which miR-29c exerts its 
effects in MPNST cells I examined several ECM genes whose expression is 
known to be affected by this molecule. I demonstrated reduced expression of 
the collagen genes COL1A1, COL1A2, COL4A1, COL4A2, COL5A2 and 
COL21A1 as well as the matrix metalloproteinase MMP2 in response to miR-
29c expression. High levels of extracellular collagens have previously been 
associated with increased invasiveness of many types of tumour cells in vitro 
and with increased metastasis in animal models (Menke et al. 2001; Koenig 
et al. 2006; Shintani et al. 2006; Chintala et al. 1996; Kaufman et al. 2005) as 
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well as an increased likelihood of metastasis in several types of human solid 
tumours (Ramaswamy et al. 2003). Overexpression of MMP2 has also been 
shown to be involved in cell migration and is associated with the metastatic 
potential of malignant tumours (Xu et al. 2005).  
It is of interest that the collagens types that are targeted by miR-29c are 
those that are also degraded by MMP2, and that both sets of genes are 
upregulated in MPNST as shown in our previously published GEM study 
(Henderson et al. 2005). 
My findings of increased expression of some collagens and MMP2, together 
with reduced migration of MPNST cells after introducing of miR-29c, argue 
that miR-29c acts as a tumour suppressor gene in MPNST and mediates it 
effect through modifying tumour migration by mediating its effect through 
both collagens and MMP2. As MMP2 is a confirmed target of the miR-29 
family (Steele et al. 2010), the MMP2 inactivation in the miR-29c-transfected 
sNF96.2 cells can be explained as a post transcriptional regulatory event. 
Alternatively, MMP9 inactivation by miR-29c could be through an indirect 
pathway.  
Amongst the numerous molecules known to be targeted by microRNAs is 
Transforming growth factor beta (TGFB). This protein exists as three 
isoforms, TGFB 1-3, which share more than 97% sequence identity in 
mammalian tissue. The 3 isoforms are secreted cytokines involved in 
regulation of many processes including embryogenesis, differentiation, 
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proliferation, motility, ECM production and homeostasis in nearly all types of 
cells and tissues (Watabe & Miyazono 2009; Huang & Huang 2005; Li et al. 
2010; Sugiyama et al. 2013; Wu & Hill 2009). The TGFB pathway has also 
been shown to play an important role in tumourigenesis exerting differential 
effects on cancer cells depending on the stage of disease; TGFB has been 
shown to act as tumour suppressor in normal cells and early stage cancers 
whereas in the later stages of many cancers TGFB can behave as a tumour 
promoter by virtue of its ability to induce epithelial to mesenchymal transition 
(EMT), promote angiogenesis and degradation of the ECM all of which assist 
tumour invasion and metastasis (Tang et al. 2003; Wakefield & Roberts 
2002; Siegel et al. 2003). Although most members of the TGFB family are 
targeted by one or more miRNAs the relationship between these two classes 
of molecules is a complex one since miRNAs production can also be 
influenced either directly or indirectly by TGFB. An association between 
various miR-29 family members and TGFB has previously been 
demonstrated in animal models of renal lung and cardiac fibrosis (Ramdas et 
al. 2013; Qin et al. 2011; Y. Zhang et al. 2014; Winbanks et al. 2011). Within 
the context of cancer Jiang et al. (2014) recently showed that TGFB/Smad3 
regulated miR-29c expression negatively by binding to the MIR29C 
promoter, leading to the loss of miR-29c in PANC cells (Jiang et al. 2014). 
Downregulation of miR-29b has also been shown to enhance TGFB 
signaling in breast cancer cells (Chou et al. 2013).  
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I have identified TGFB3 as a potential target for miR-29c in MPNST derived 
cells and also showed that TGFB3, in addition to MMP2, is downregulated in 
response to ectopic expression of miR-29c in MPNST-derived cells. 
However, I failed to identify any direct links between TGFB3 expression and 
the expression of MMP2 or MMP9 since silencing of TGFB3 had no 
significant effects of on expression of MMP2 or MMP9 at either the mRNA or 
protein level in MPNST derived cells. However, using zymography I 
observed a reduction in MMP2 and MMP9 proteolytic activity in the 
supernatants of miR-29c transfected MPNST-derived cells which would 
suggest that MMP2 and MMP9 may be indirect targets of TGFB3. As far as I 
am aware there are no reported studies looking at TGFB3 expression in 
MPNSTs. However, Watanabe et al. (2001) examined 8 cases of MPNST 
arising within a neurofibroma associated with neurofibromatosis type 1 and 
demonstrated higher expression of transforming growth factor β1 (TGFB1) in 
the areas of MPNST than in the neurofibromatous areas (Watanabe et al. 
2001). Although one cannot directly extrapolate the findings with TGFB1 to 
the other TGFB isoforms, the possibility that all 3 isoforms may under the 
influence of miR-29c or indeed other microRNAs in MPNSTs is something 
that will need to be determined empirically in future studies. However, my 
findings so far would seem to support the hypothesis that TGFB3 expression 
is negatively influenced by miR-29c expression in MPNST-and that the loss 
of miR-29c in MPNSTs may lead to overexpression of TGFB3 with possibly a 
concomitant increase in tumour promoting signals. 
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Roundabout 1 (ROBO1) belongs to a family of highly conserved 
transmembrane cell surface receptors that in humans also includes ROBO2, 
ROBO3 and ROBO4. ROBO proteins were first identified in the 1990s as 
axon guidance molecules in the fruit fly Drosophila (Murray & Whitington 
1999). ROBO proteins act as receptors for the Slit family of secreted proteins 
and together the Slit/ROBO1 axis has been shown to be important 
development of a various vital organs such as kidneys, lungs breasts and 
liver (Macias et al. 2011; Piper et al. 2000; Liu et al. 2003). In addition to 
organogenesis, Slit/ROBO1 signalling has been implicated in a variety of 
cellular processes including cell proliferation, cell motility, cell adhesion and 
angiogenesis (Prasad et al. 2004; Huang et al. 2015; Yeh et al. 2014; Chen 
et al. 2010). Aberrant expression of Slits and ROBOs has over the last 
decade also been shown to play an important role in a variety of human 
diseases including cancer (Legg et al. 2008; London & Li 2011; London et al. 
2010; Wu et al. 2001). ROBOs have been shown to be both up-regulated or 
downregulated in a variety of human cancers {reviewed by (Ballard & Hinck 
2012)} which suggests that they can act as both tumour suppressors, 
providing negative growth signals to cancers or as oncogenes, promoting 
cancer progression. I have identified ROBO1 as a potential target of miR-29c 
in MPNSTs by in silico prediction analysis and demonstrated using 
microarray expression data that ROBO1 is significantly highly expressed in 
MPNSTs compared to neurofibromas. Furthermore, I provided in vitro 
evidence that ROBO1 mRNA expression is significantly downregulated in 
response to ectopic expression of miR-29c in MPNST-derived sNF96.2 cells. 
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These findings suggest ROBO1 over-expression in MPNSTs is acting as an 
oncogene and that miR-29c acts as tumour suppressor by targeting ROBO1 
expression in neurofibromas. However, the lack of any detectable ROBO1 
protein in sNF96.2 cells despite the expression of ROBO1 mRNA would 
seems to contradict the view that ROBO1 is acting as an oncogene in this 
cell line. My findings suggest that despite ROBO1 mRNA being expressed in 
sNF96.2 cells, the transcript is not being translated into ROBO1 protein at 
any significant level which would be more in line with ROBO1 acting as a 
tumour suppressor in this cell line. However, one must bear in mind the 
possibility that this cell line may not representative of the situation in the 
fresh tumour samples. At this stage, it is not possible to reach any 
conclusions about the role of ROBO1 in MPNSTs pathogenesis other than to 
say that its transcription appears to be under the control of miR-29c. Another 
miRNA that known to target ROBO1 is miR-218. miR-218 has been shown to 
behave as a tumour suppressor, inhibiting the invasion and migration of 
glioma, pancreatic, nasopharyngeal and gastric cancer cells through the 
ROBO1 signalling pathway (Tie et al. 2010; Alajez et al. 2011; Gu et al. 
2015; Rheinheimer et al. 2013). In order to throw more light on the role of 
ROBO1 in MPNST pathogenesis the expression of ROBO1 mRNA and 
protein will need to be examined in the fresh frozen neurofibromas and 
MPNSTs by qRT-PCR and western blot analysis, respectively, in addition to 
carrying out functional studies which target ROBO1 expression directly using 
siRNA. 
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In conclusion, I provide data suggesting that miR-29c is a tumour suppressor 
the loss of which plays a pivotal role in the progression of nerve sheath 
tumours by increasing their invasive/migratory properties.  
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6.2. Relationship between miR-29c and 
DNA methyltransferases 3A and 3B 
DNA methylation at the 5-position of cytosine plays an important role in 
maintaining chromatin structure and regulating gene transcription and is 
essential for mammalian development (Jin et al. 2011). The pattern of DNA 
methylation in mammalian cells is generated de novo by DNA 
methyltransferases DNMT3A and DNMT3B, which are highly expressed 
during embryogenesis but are downregulated in differentiated adult somatic 
cells (Okano et al. 1999). DNMT1 is the most abundant DNA 
methyltransferase in adult cells and is responsible for the maintenance of 
DNA methylation (Robertson et al. 1999). Disruptions in the pattern of DNA 
methylation have been implicated in the pathogenesis of a variety of human 
diseases including cancer (Jones & Baylin 2007; Berdasco & Esteller 2010). 
Human cancers generally exhibit global hypomethylation of their DNA which 
is also accompanied by region-specific DNA hypermethylation (Wild & 
Flanagan 2010). Silencing of tumour suppressor genes by hypermethylation 
of their promoters regions is a common feature in many human malignancies 
and cancer cell lines and is thought to arise in part from the increased levels 
of DNMTs expression in these tumours (Baylin 2005) e.g., overexpression of 
DNMT1, DNMT3A and DNMT3B has been reported in liver cancer (Saito et 
al. 2001). There is also much evidence to suggest that repression of gene 
transcription by DNA methylation has a causal role in cancer pathogenesis 
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rather than just being a bystander effect e.g., alterations of DNA methylation 
have been shown in early precancerous conditions and in some cases 
histologically normal appearing tissue in association with chronic 
inflammation or infection with pathogens (Kanai & Hirohashi 2007). 
Increasing levels of DNMT1, DNMT3A, and DNMT3b expression, along with 
increasing numbers of methylated genes, have also been demonstrated in 
the advancement of normal tissue to malignancy such as the case with 
progression from normal liver to chronic hepatitis/cirrhosis to hepatocellular 
carcinomas (Sceusi et al. 2011). In addition, a significant association 
between aberrant DNA methylation or elevated DNMT3A/DNMT3B 
expression and poorer tumor differentiation, increased tumor aggressiveness 
and poor prognosis has also been demonstrated in some cancers e.g., 
increased DNA methylation in renal cell carcinomas has been shown to 
significantly correlate with higher histological grade, an infiltrating growth 
pattern and vascular involvement (Arai et al. 2006) and overexpression of 
DNMT3B has been shown to correlate with poor prognosis in breast cancer 
and cutaneous melanoma (Roll et al. 2008; Nguyen et al. 2014). Patients 
with low levels of DNMT1 expression have also been reported to 
demonstrate a better response to chemotherapy and overall survival than 
those with higher levels of DNMT1 expression in their tumours (Mutze et al. 
2011). Furthermore, the inhibition of DNA methyltransferase expression has 
been to be associated with an increase in tumour suppressor gene 
expression and reduction in tumorigenicity (Brueckner et al. 2005).  
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There have are few reported studies on DNA methylation in MPNSTs and 
the number of clinical samples examined in each has also been very small 
(Bradtmöller et al. 2012; Danielsen et al. 2015; Lee et al. 2014) Feber et al. 
(2011) carried out a whole-genome comparative methylome analysis of 
MPNSTs and benign neurofibromas and reported a complex pattern of 
epigenetic changes during disease progression. In contrast to other tumour 
types, significant global hypomethylation was not observed in MPNSTs. 
However, the predominant targets of aberrant methylation in the MPNST 
genome were found to be the satellite regions, promoters and CpG islands 
(Feber et al. 2011). 
The role of DNMTs in human neurofibromas and MPNSTs has not previously 
been investigated. I examined the expression of DNMT3A and DNMT3B 
expression in these tumours and showed that DNMT3B mRNA expression is 
significantly higher in MPNSTs compared to neurofibromas. However, I 
found no significant difference in DNMT3A mRNA expression between the 
benign and malignant nerve sheath tumours. Although our tumour numbers 
were small (only 9 MPNSTs and 9 neurofibromas), these findings are not 
unusual since DNMT3B is found to be frequently expressed in cancer tissues 
compared to DNMT3A and DNMT1 which are expressed at lower 
frequencies (Robertson et al. 1999) e.g., overexpression of DNMT3B but not 
DNMT3A has been reported in breast cancer (Sandhu et al. 2012) and 
Burkitt lymphoma (Robaina et al. 2015) among others e.g., primary 
leukaemia (Ostler et al. 2007). However since both enzymes can methylate 
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most genomic targets, it is possible that increased expression of just one of 
these DNMTs will be sufficient to bring about DNA hypermethylation in 
cancers. Conversely, the absence of either can lead to decreased 
methylation that would not be the case if they were functionally redundant. 
The lack of any observable increase in DNMT3A expression in our tumour 
samples does not rule out the possibility that this DNMT is involved in 
MPNST pathogenesis. It is still possible DNMT3A could exert some effect via 
its interaction with DNMT3B. DNMT3A and DNMT3B are known to form a 
complex in mammalian cells and have been shown to mutually stimulate one 
another as a result of this direct interaction (Li et al. 2007). The majority of 
DNMT3B transcripts in cancer encode catalytically active protein but over 20 
splice variants of DNMT3B have been identified in cancer cell lines and 
primary leukaemias, many of which are catalytically inactive (Ostler et al. 
2007). Some of these inactive DNMT3B isoforms have been shown to 
modulate the activity of DNMT3A–DNMT3L complexes so it’s possible the 
genomic methylation pattern could be altered as a result of this interaction 
(Van Emburgh & Robertson 2011; Jurkowska et al. 2011; Li et al. 2013; 
Shah et al. 2010) One also cannot rule out the possibility that mutations in 
DNMT3A, as well as DNMT3B could also play a role in MPNST 
pathogenesis since carcinogen-related mutations have been shown to occur 
in the catalytic and non-catalytic domains of these DNMTs (Wang et al. 
2006; Ley et al. 2010). 
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The regulation of DNMTs is thought to be one of the mechanisms by which 
microRNAs exert their tumour suppressor activities in cells. The miR-29 
family members possess complementary sequences to the 3′-UTRs of 
DNMT3A and DNMT3B and the regulation of these DNMTs by miR-29s, as 
well as by other miRNA family members, is well documented in the literature. 
For example, the expression of DNMT3A and DNMT3B in lung cancer has 
been shown to be directly targeted by, and inversely correlates with, 
expression of miR-29 family members (Fabbri et al. 2007). In addition, re-
expression of miR-29s has been shown to reduce DNMT3B mRNA levels in 
hypermethylator breast cancer cell lines and to restore normal patterns of 
DNA methylation in lung cancer cell lines by targeting DNMT3A and 
DNMT3B (Sandhu et al. 2014; Fabbri et al. 2007). These findings give 
support to the hypothesis that expression of miR-29s can contribute to the 
epigenetic DNA modifications in cancer. 
DNMT3A and DNMT3B were identified by my in silico data as potential 
targets of miR-29c. Having shown that miR-29c expression is altered in 
MPNSTs compared to neurofibromas I wished to establish whether any 
relationship exists between the expression of miR-29c and the DNA 
methylation status of these tumours. My findings showed that DNMT3B 
mRNA expression is higher in MPNSTs compared to neurofibromas and 
inversely correlates with miR-29c expression. However, I found no significant 
difference in DNMT3A mRNA expression between the benign and malignant 
nerve sheath tumours and there was no correlation between DNMT3A and 
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miR-29c expression in our tumour samples. This finding suggested that miR-
29c expression may contribute to epigenetic DNA modification in MPNSTs 
by targeting DNMT3B. I decided to test hypothesis by examining the effect of 
exogenous miR-29c expression in the MPNST-derived sNF96.2 cell line and 
found that this induced down-regulation of endogenous DNMT3A and 
DNMT3B expression in these cells. These findings are consistent with 
previous reports on the negative influence of miR-29c on the expression of 
DNMT3A and DNMT3B in other malignancies including lung cancer, 
malignant melanoma, Burkitt lymphoma, breast cancer and gastric cancer 
(Fabbri et al. 2007; Nguyen et al. 2014; Robaina et al. 2015; Sandhu et al. 
2014; Cui et al. 2015; Sandhu et al. 2012). 
Although I managed to demonstrate in vitro that DNMT3A mRNA is 
downregulated in response to ectopic expression of miR-29c, I found no 
correlation between miR-29c and DNMT3A expression in our tumour 
samples. However, this doesn’t rule out the possibility that DNMT3A could 
still be targeted by miR-29c and play a role in MPNST pathogenesis since 
DNMTs are known to be regulated by a variety of factors e.g., at the post-
transcriptional level by other miRNAs (such as miR-148a, miR-148b, miR-
26a, miR-26b, miR-203 and miR-222) (Duursma et al. 2008; Sandhu et al. 
2014) or at the level of gene transcription by modification of the primary DNA 
sequence through gene amplification or activating gene mutations or via the 
influence of transcription factors (Shen et al. 2002; Singal et al. 2005; 
Montgomery et al. 2004; Cebrian et al. 2006; Im et al. 2014). Also since 
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DNMT3B is known to directly associate with DNMT3A (Li et al. 2007), it is 
possible that that miR-29 could indirectly affect DNMT3A activity via its 
influence on the expression of DNMT3B.  
Carcinogenesis related mutations in the catalytic and non-catalytic domains 
of DNMT3A and DNMT3B have previously been described in a variety of 
diseases and cancers including colorectal cancer, MDS, AML, T-cell 
lymphoma, ICF syndrome (Immunodeficiency, Centromere instability, Facial 
abnormalities) , breast and lung (Couronné et al. 2012; Ley et al. 2010; 
Walter et al. 2011; Weemaes et al. 2013; Xu et al. 1999). The possibility that 
mutations in DNMT3A and DNMT3B could somehow contribute to MPNST 
pathogenesis, therefore, cannot be ruled out. However, the mechanism by 
which DNMT3B is over-expressed in cancer is not thought to result from 
mutation, amplification or increased trans-activation but rather through post-
transcriptional regulation by microRNAs (Veeck & Esteller 2010; Sandhu et 
al. 2012). 
The results from our microRNA microarray expression data revealed that 
expression of miR-29a, b, c* and b-1* as well as miR-29c, are also 
significantly downregulated in MPNSTs relative to neurofibromas. The 
possibility that DNMT3A and DNMT3B might also be regulated by other miR-
29 family members or even other microRNAs in MPNSTs also cannot be 
ruled out at this stage since. 
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 Although I have not examined the relationship between miR-29c and 
DNMT1, the involvement of this DNMT in MPNST pathogenesis cannot be 
ruled out since miR-29 family members have been shown to influence the 
expression of DNA methyltransferases DNMT1, DNMT3A, and DNMT3B at 
both RNA and protein levels in acute myeloid leukaemia cells (Garzon et al. 
2009).  
As well as inhibiting DNMTs, miR-29 family members have also been 
reported to repress the activities of two major factors involved in DNA 
demethylation, namely thymine DNA glycosylase (TDG) and the ten-eleven 
translocation protein 1 (TET1). It is therefore conceivable that the 
methylation status of a cells’ genome may be influenced by miR-29s not only 
through their effects on DNMTs but also via their actions on DNA 
demethylases (Morita et al. 2013). 
Following my in vitro demonstration that DNMT3A and DNMT3B are 
downregulated by miR-29c, my next goal was to identify any candidate 
genes that could be targets of DNMTs in MPNSTs. I compared the 
methylome data of Feber et al (2011) with the gene expression microarray 
data of Subramanian et al (2010) and searched the literature for reports of 
any genes proven to be differentially expressed in neurofibromas and 
MPNSTs. I finally settled on 3 genes for further study, S100B, CDKN2A and 
WT1, which had previously been verified as differentially methylated (Feber 
et al. 2011) and differentially expressed between MPNSTs and 
neurofibromas; (Subramanian et al. 2010; Karamchandani et al. 2012; 
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Parenti et al. 2014) In addition, these genes had also been shown to play a 
role in other types of human cancers (Fang et al. 2009; Fraizer et al. 2004; 
van Dieck et al. 2010). 
Pyrosequencing analysis of CDKN2A, WT1, and S100B in 10 MPNSTs and 
10 neurofibromas fresh frozen tissue samples revealed hypermethylation of 
these three genes is more frequent in MPNSTs compared to neurofibromas 
which suggested these genes were potential targets of gene silencing by 
methylation during pathogenesis of MPNSTs from neurofibromas. 
CDKN2A is an important tumour suppressor gene, which is frequently 
inactivated by mutations, deletions, or methylation in a wide variety of human 
malignancies. The gene codes for three distinct proteins known which are 
generated by alternative splicing of an overlapping set of exons in the gene 
(Quelle et al. 1995). The most well studied of these are the p16 (INK4a) and 
the p14 (ARF) proteins. These play an important role in regulating the G1 to 
S phase transition of the cell cycle; p16 functions by inactivating the cyclin-
dependent kinases, CDK4 and CDK6, which phosphorylate the 
retinoblastoma protein and p14 stabilises the p53 tumour suppressor protein 
by sequestering and inhibiting MDM2 which is responsible for the 
degradation of p53 (Stott et al. 1998; Stein et al. 1999).  
Loss of function of the CDKN2A gene has been reported to occur in around 
half to nearly all cases MPNSTs (Nielsen et al. 1999; Perrone et al. 2003; 
Endo et al. 2011; Lee et al. 2014; Kourea et al. 1999; Menon et al. 1990) The 
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majority of these inactivations have been reported to occur as a result of 
homozygous deletions of the CDKN2A gene (Lee et al. 2014; Endo et al. 
2011; Carter et al. 2001) Inactivation of the CDKN2A gene via gene 
mutations and epigenetic silencing by methylation of the 5′ CpG island of the 
p16 promoter region are known to occur in variety of human malignancies 
(Kawaguchi et al. 2003; O’Riain et al. 2009; Merlo et al. 1995; Baur et al. 
1999), but they have rarely been described in MPNSTs (Nielsen et al. 1999; 
Endo et al. 2011). Endo et al. (2011) and Nielsen et al. (1999) examined 
MPNSTs that were without homozygous deletion of CDKN2A but were 
unable to detect any mutation in the exons of CDKN2A gene and no 
methylation was found in either the p14ARF or p16INK4a promoter (Nielsen et 
al. 1999; Endo et al. 2011). However, Nielsen el al (1999) did not rule out the 
possibility that methylation outside of the assayed region of the promoter or 
alterations in noncoding regions of the CDKN2A gene could potentially affect 
protein expression (Nielsen et al. 1999).  
I carefully examined the whole methylome data generated from the study by 
Feber et al. (2011) and also found no evidence of alteration in the 
methylation status of the CDKN2A gene promoter in MPNSTs compared with 
neurofibromas. However, I did find a differentially methylated region (DMR) 
of CpGs near the 3′ end of CDKN2A gene. CpG islands are often located at 
the 5' region of gene promoters but several CpG islands have been shown to 
be located at the 3’ end of known genes. The latter have received less 
attention than CpG islands of gene promoters but in recent years they have 
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been shown to perform important functions and have also been implicated in 
cancer development (Shiraishi et al. 2002; Medvedeva et al. 2010).  
I examined the differentially methylated region (DMR) near the 3′ end of 
CDKN2A by pyrosequencing in our cohort of 10 MPNSTs and 10 
neurofibromas and found that hypermethylation of this region was more 
frequent and more extensive in MPNSTs compared to the neurofibromas. 
One can speculate that if methylation of this region leads to silencing of the 
CDKN2A gene this could offer a possible explanation for the loss of CDKN2A 
expression in MPNSTs that do not harbour homozygous deletions or 
mutations of the CDKN2A gene. I tried to examine the possibility that 
expression of CDKN2A is controlled by methylation in the 5-aza-dC- treated 
and untreated sNF96.2 cell line but I was unable to amplify the CDKN2A 
gene for pyrosequencing and were also unable to get CDKN2A mRNA 
transcript by RT-PCR. The most likely explanation for this was that the 
CDKN2A gene may be deleted in this cell line. Since I was unable to 
demonstrate that CDKN2A is regulated by methylation, I therefore decided 
not to pursue this gene for any further in my study. 
The WT1 gene resides on 11p13 and codes for a zinc-finger transcription 
factor, which plays an important role in cellular growth and development. 
This gene was originally identified as a tumour suppressor in a paediatric 
cancer of the kidney known as Wilms tumour (Gessler et al. 1990; Call et al. 
1990; Little & Wells 1997). However over-expression of the WT1 gene has 
been demonstrated in a variety of solid cancers including those of the brain 
P a g e  | 272 
   
  
(Schittenhelm et al. 2010) lung (Oji et al. 2002), breast (Domfeh et al. 2008), 
colon (Koesters et al. 2004), pancreas (Oji et al. 2004) and melanoma 
(Wagner et al. 2008) in addition to haematologic malignancies such as 
leukaemia (Kerst et al. 2008) which is more compatible with its function as an 
oncogene rather than a tumour suppressor. Moreover, silencing of the WT1 
using RNAi has been shown to inhibit cell proliferation, induce apoptosis and 
decrease resistance to chemotherapeutic agents in a variety of malignant 
cell cultures (X. Wang et al. 2013; Chen 2001; Clark et al. 2010; Zamora-
Avila et al. 2007; Zapata-Benavides et al. 2002; Navakanit et al. 2007). The 
role of the WT1 gene therefore is very much context driven its dual 
functionality is thought in part to be due to the existence of at least 36 WT1 
transcript isoforms (Lee & Haber 2001; Ellisen 2002; Hohenstein & Hastie 
2006). Both the sense (WT1) and antisense transcripts (WT1-AS) of WT 
gene have been shown to be transcribed and CpG hypermethylation has 
been shown to be an important mechanism of WT1 and WT-AS gene 
inactivation in cancer e.g., decreased methylation in the enhancer region of 
the WT1 gene has been described in two-thirds of tumours from WT1 
patients (Mares et al. 2001) and hypermethylation at a CTCF binding site 
downstream of the WT1 gene is associated with elevated WT1 
transcriptional activity (Zitzmann et al. 2014). Methylation of CpG islands in 
the 5' region of WT1 gene is also significantly increased in NSCLC (Bruno et 
al. 2012) and hypermethylation of the WT1 promoter was demonstrated in 
human breast cancer to be associated with lack of expression of WT1 (Laux 
et al. 1999). In ovarian clear cell adenocarcinoma, both the WT1 and WT1-
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AS genes have been reported to be inactivated by promoter methylation 
(Kaneuchi et al. 2005). 
The WT1 gene has been reported to be expressed in neurofibromas and 
schwannomas but not in normal glial cells (Schittenhelm et al. 2010; Singh et 
al. 2012). In MPNSTs the WT1 gene transcript has been demonstrated to be 
over expressed in MPNSTs (Ueda et al. 2003) which suggests it functions as 
an oncogene in this type of malignancy. This is supported by a recent study 
in which silencing of WT1 by siRNA in MPNST-derived sNF96.2 cells 
resulted in inhibition of cell proliferation (Parenti et al. 2014). This was shown 
to be associated with a decrease in the levels of PI3K, pAKT and Cyclin D1 
proteins which play an important role in regulating the cell cycle, cell survival 
and proliferation (Parenti et al. 2014). 
I confirmed that expression of the WT1 gene is influenced by methylation in 
MPNST-derived cells by showing WT1 mRNA transcript is elevated in 
response to treatment of sNF96.2 cells with the demethylating agent 5-aza-
dC. In addition, my pyrosequencing data demonstrated not only a significant 
difference in the level of methylation between neurofibromas and MPNSTs in 
the DNA region examined but DNA methylation of this region was also found 
to be higher in high grade MPNST as compared with low-grade tumours. 
However, I found no correlation between expression of the WT1 gene and 
the methylation status of this region. This suggests that expression of the 
WT1 gene is not influenced by methylation of this DNA region. Furthermore, I 
found no significant differences in the level of WT1 mRNA expression 
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between our neurofibromas and MPNSTs, which suggests that expression of 
the WT1 gene does not play a significant role in the pathogenesis of 
MPNSTs from neurofibromas. My findings are consistent with those of 
Inagak et al. (2011) who examined WT1 protein and mRNA transcript in 
normal nerve root, neurofibromas, schwannomas and MPNST and reported 
WT1 expression is not higher in peripheral nerve tumours than in normal 
peripheral nerves (Inagaki et al. 2011). Similarly Schittenhelm et al. (2010) 
examined WT1 expression by immunohistochemistry in both neurofibromas 
and MPNSTs and reported the expression of the WT1 protein was 
independent of tumour malignancy or grade of malignancy (Schittenhelm et 
al. 2010).  
S100B expression was found in my study to be influenced by DNA 
methylation as demonstrated by the increased expression of its mRNA 
transcript in 5-aza-dC-treated sNF96.2 cells. The increased methylation of 
the S100B DNA region examined in our MPNSTs compared with that in our 
neurofibromas and the fact that levels of DNA methylation were found to 
increase with increasing grade of MPNST suggested S100B was a strong 
candidate for epigenetic regulation during development of MPNSTs. My 
findings with S100B are discussed in more detail in the following section. 
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6.3. S100B as a potential tumour 
regulator in nerve sheath tumours 
S100B belongs to a family of homologous calcium binding proteins known as 
S100 proteins of which there are twenty-one members known in humans 
(Zimmer et al. 2013). The genes coding for the majority of S100 reside in a 
cluster on human chromosome 1q21. They are normally expressed in cells 
derived from the neural crest (Schwann cells, and melanocytes), 
chondrocytes, adipocytes, myoepithelial cells, macrophages, Langerhans 
cells, dendritic cells, and keratinocytes and some breast epithelial cells 
(Marenholz et al. 2004; Wilson et al. 1991; Coppola et al. 1998; Heizmann et 
al. 2002).  
Despite the structural similarities (Elder & Zhao 2002; Pedrocchi et al. 1994; 
Cross et al. 2005; Donato et al. 2013; Heizmann et al. 2002; Marenholz et al. 
2004; Roth et al. 2003) proteins are involved in a variety of intracellular and 
extracellular functions that regulate many processes such as cell growth, 
differentiation, proliferation, migration, survival, cell cycle regulation and 
(Donato 2001; Donato 2007; Heizmann et al. 2002; Marenholz et al. 2004; 
Roth et al. 2003; Leukert et al. 2006) expression of S100 proteins has been 
found in a variety of human diseases including chronic inflammation, 
neurodegeneration, cardiomyopathies, atherosclerosis as well as a wide 
variety of human malignancies (Pietzsch 2010; Salama et al. 2008).  
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Unlike the majority of S100 genes, the S100B gene is located on 
chromosomes 21q22.3. S100B is normally expressed at high levels in 
astrocytes, oligodendrocytes and Schwann cells and its expression has been 
reported to be elevated in anaplastic astrocytomas and glioblastomas 
(Camby et al. 1999) as well as melanomas (Salama et al. 2008). Because of 
its high levels of expression in neural tissue, S100B is commonly used in 
pathology as a marker for glial cell and Schwann cell differentiation (Hachem 
et al. 2005). In MPNSTs S100B has been reported to be downregulated by a 
number of investigators e.g., in a study of 14 neurofibromas and 9 MPNSTs 
Lévy et al. (2004) demonstrated S100B mRNA expression was significantly 
downregulated in malignant tumours compared to expression in benign 
tumours (Lévy et al. 2004). Nonaka et al. (2008) examined S100B 
expression in 86 neurofibromas and 77 MPNSTs by immunohistochemistry 
and demonstrated diffuse staining of S100B in all neurofibromas examined 
but less than one-third of MPNSTs showed focal staining of S100B (Nonaka 
et al. 2008). A similar finding was reported by Karamchandani et al. (2012) 
whereby S100B protein staining was seen in 52 of 55 neurofibroma but only 
15 of 78 MPNSTs (Karamchandani et al. 2012). Despite the very striking 
differences in S100B protein and transcript expression between MPNSTs 
and neurofibromas, I have found no reports investigating S100B regulation 
and function in PNSTs. 
In this thesis, I have shown that S100B expression in MPNST-derived cells is 
influenced by DNA methylation as demonstrated by the increased expression 
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of its mRNA transcript in 5-aza-dC-treated sNF96.2 cells. Furthermore, I 
have shown that the level of methylation in the S100B regulatory region 
examined (an enhancer area) is higher in MPNSTS than in neurofibromas. In 
addition, the level of methylation in the S100B regulatory region (enhancer) 
was shown to increase with increasing grade of MPNST. These findings 
suggest that S100B expression is epigenetically regulated by methylation 
during MPNST pathogenesis. My demonstration of an inverse correlation 
between methylation of the S100B regulatory region and expression of its 
mRNA transcript and protein adds support to this hypothesis. In addition, 
epigenetic regulation of S100B has previously been demonstrated in animal 
studies e.g., methylation of the S100B promoter was reported to play a role 
in expression of the S100B gene during embryonic development of the 
mouse brain (Namihira et al. 2004; Shimozaki et al. 2005). In the study by 
Namihera et al. (2004), the expression of S100B was shown to be 
associated with the demethylation of one of four methylated cytosine 
residues in the S100B promoter. The loss of methylation at this one CpG site 
was accompanied by a decrease in binding of MECP2 (methyl CpG binding 
protein 2) to the S100B gene promoter which suggested that it was the 
binding of MeCp2 to the methylated CpG site that inactivated the S100B 
gene (Namihira et al. 2004). Another study by Malup et al. (2007) revealed a 
tissue specific pattern of S100B gene methylation in BALB/cLac mice. 
Hypomethylation of the S100B gene was demonstrated in the brain of these 
mice in comparison that in tissues from other organs (Malup et al. 2007). 
These findings are consistent with the known effects of methylation on gene 
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expression and with the pattern of S100B gene expression in different 
organs. In addition, demethylation of S100B has been shown to be 
influenced by binding of nuclear factor I to the S100B gene promoter, which 
occurs in response to activation of the Notch I signalling pathway. This is 
thought to bring about activation of S100B and other astrocyte specific genes 
during development of astrocytes from mammalian neural precursors 
(Namihira et al. 2009). 
Epigenetic regulation by methylation has also reported in other S100 family 
members in connection with various human malignancies e.g., re-expression 
of S100A4 was demonstrated in lymphoma cells after treatment with the 
DNA methyltransferase inhibitor, 5-aza-cytidine (Tulchinsky et al. 1995). 
Similarly, re-expression of S100A2 was reported after 5-aza-cytidine 
treatment of mammary carcinoma epithelial cells (Lee et al. 1992) and 
S100A6 was re-expressed following the 5-aza-cytidine treatment of 
hepatoma cells (Leśniak et al. 2000). Furthermore, S100A10, S100A3, 
S100A11, and S100P were shown to re-expressed in different 
medulloblastoma cell lines following 5-aza-cytidine treatment (Lindsey et al. 
2007). In other studies, expression of S100P was found to depend on 
hypomethylation of the S100P gene in prostate carcinoma (Wang et al. 
2007), pancreatic cancer (Sato et al. 2004) and cervical carcinoma cells 
(Jakubícková et al. 2005). S100A2 is downregulated in many cancers, and 
its repression has been shown to mediated by site-specific hypermethylation 
in breast cancer (Wicki et al. 1997). Chen et al. (2009) reported an apparent 
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association between S100A4 protein expression and integrin signalling in 
cancer cells. They showed that 5 of 7 CpGs in the intronic area examined 
were mostly unmethylated in MDA-MB-435 cells that stably expressed 
integrin (Chen et al. 2009). 
Although I have shown a significant association between methylation of the 
S100B regulatory region and expression of this gene in PNSTs, the S100B 
gene promoter was not found to be methylated when I examined the 
previous methylome data of Feber et al. (2011). The position of the S100B 
regulatory area, as determined by the Ensembl database, suggests that it 
may function as a gene enhancer. Although DNA methylation of enhancer 
sites have not been studied as much as those of promoters, the relationship 
between enhancer methylation and gene expression in cancer has, 
interestingly, been shown to be significantly greater than the relationship 
between promoter methylation and changes in gene expression (Aran et al. 
2013). Also in a review of genome-wide studies of DNA methylation in 
hematopoietic cells, it was concluded that enhancers, CGI shores, and 
canyon edges were the most active sites of de novo methylation and 
demethylation in the genome and were more common than in CGIs with high 
CpG density (Jeong & Goodell 2014). 
In order to determine the role that S100B might play in the pathogenesis of 
MPNSTs I carried out functional studies using sNF96.2 cells that had been 
transduced with an S100B expressing lentiviral vector. I found that S100B 
expression in sNF96.2 cells had an inhibitory effect on cell proliferation and 
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viability. Although there was no effect on the migratory behaviour of sNF96.2 
cells, these findings suggested a tumour suppressor role for the S100B in 
MPNST cells. This is consistent with my finding that S100B is 
hypermethylated in malignant peripheral nerve sheath tumours compared to 
neurofibromas as it is well established that most tumour suppressors are 
hypermethylated in many types of cancer (Luczak & Jagodziński 2006). A 
tumour suppressor role for S100B has previously been suggested by Van 
Dieck et al. (2010) who showed that S100B might promote p53 tumour 
suppressor activities through interacting with MDM2 and MDM4. More 
support for S100B as a tumour suppressor comes from a study on the PC12 
cell line that is derived from a pheochromocytoma of the rat adrenal medulla 
and has an embryonic origin from the neural crest. Arcuri et al 2005 showed 
that overexpression of S100B in this cell line increased cell proliferation, 
reduced apoptosis, enhanced cell survival and decreased responsiveness to 
the differentiating effect of Nerve growth factor (NGF) (Arcuri et al. 2005). 
However, other reports suggest S100B functions as an oncogene e.g., 
S100B has been shown to interact with and inhibit p53 phosphorylation and 
activity (Baudier et al. 1992; Rustandi et al. 1998; Lin et al. 2001) and in 
malignant melanoma cells p53 levels were found to be restored after 
Inhibiting S100B expression (Lin et al. 2004). In addition it was demonstrated 
that when p53 levels increase, this up-regulates the transcription of S100B 
as part of a negative feedback mechanism that contributes to p53 
degradation thus leading to unchecked cell proliferation (Lin et al. 2004). 
Furthermore S100B protein in serum has been shown to correlate with 
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clinical stage of malignant melanoma and is an independent prognostic 
marker in stages II and III (Mårtenson et al. 2001; Andrés et al. 2004; Smit et 
al.; Tarhini et al. 2009). 
The question as to whether S100B works as tumour suppressor or an 
oncogene is still unresolved (van Dieck et al. 2010; Baudier et al. 1992; 
Rustandi et al. 1998; Lin et al. 2001) but It’s possible that S100B may act as 
both a tumour suppressor or oncogene depending on the cell context as is 
found to be the case with the WT1 gene. This would not be unusual since 
another S100 protein, S100A7, has been shown to function as both an 
oncogene and tumour suppressor gene; Deol et al. (2011) demonstrated that 
S100A7 over-expression acts as a tumour suppressor in estrogen receptor-
positive {ERα(+)} breast cancer cells through down-modulation of the β-
catenin/TCF4 pathway both in vitro and in vivo. However expression of 
S100A7 in ERα(-) cells enhances tumorigenicity and is associated with a 
worse prognosis in patients. The increased expression of different S100B 
proteins in a wide variety of human malignancies would suggest that they 
have an oncogenic role. A number of these proteins, e.g., S100A2, S100A4 
and S100A6 have been shown to interact with p53 but in some cases they 
have a a stimulatory effect on p53 whilst in others they have been shown to 
have an inhibitory effect (Lin et al. 2001; Mueller et al. 2005; Grigorian et al. 
2001; Scotto et al. 1999; Fernandez-Fernandez et al. 2008; Fernandez-
Fernandez et al. 2005; van Dieck et al. 2009). These studies demonstrate 
that the function of S100 proteins as tumour suppressors or oncogenes 
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cannot be directly inferred from their up-regulated or downregulated status in 
malignancies and, therefore, must be determined empirically for each 
individual protein. 
In my final experiment, I set out to determine whether methylation of the 
S100B gene regulatory region might be influenced by expression of miR-29c 
in MPNST-derived cells. However, an examination of sNF96.2 cells that had 
been transfected with miR-29c mimics demonstrated no significant alteration 
in the methylation status of the S100B gene regulatory region. It’s highly 
likely methylation of S100B is being maintained by DNMT1 in this line which 
means any influence miR-29c expression might have on the de 
novo methylators, DNMT3A and DNMT3B, will not affect S100B methylation. 
However, my findings do not rule out the possibility that S100B gene 
methylation could still be influenced by miR-29c during the early stages of 
MPNST development via its effects on DNMT3A and DNMT3B. Although 
DNMT1, in addition to DNMT3A and DNMT3B, has previously been reported 
to be influenced by expression of miR-29 members, (Garzon et al. 2009) my 
results do not support the idea that DNMT1 is being influenced by miR-29c 
expression in sNF96.2 cells. 
In conclusion, I have demonstrated that miR-29c may play an important role 
in the progression of nerve sheath tumours by influencing the expression of 
DNMT3A and DNMT3B. I also suggest a tumour suppressor role for S100B 
in MPNST cells and open the gate for further studies on the mechanism by 
which S100B perform its effect on MPNSTs. 
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7. Future work 
The data presented here provides a basis for several new projects. One area 
that needs more investigation is the relationship between epigenetic and 
genetic changes. I showed here that CDKN2A is hypermethylated in our 
MPNSTs compared to neurofibromas. It has been reported previously that 
the tumour suppressor CDKN2A shows lower expression in most of MPNST 
samples compared to neurofibromas but this loss of expression cannot be 
explained by genetic changes in all the cases (Nielsen et al. 1999; Endo et 
al. 2011). A study investigating CDKN2A genetic modification and DNA 
methylation can highlight the interplay between genetics and epigenetics in 
nerve sheath tumours.  
Other epigenetic changes like histone modifications might also have a role of 
progression of neurofibroma to MPNST. Recently a study showed a role of 
Polycomb repressive complex 2 (PRC2) components (EED or SUZ12) in 
progression of neurofibroma to MPNST through loss of trimethylation at 
lysine 27 of histone 3 (H3K27me3) (Lee et al. 2014). This raises the interest 
to study further the role of PRC2 and histone methylation in the context of 
the methylome and pyrosequencing data that I highlighted in this study. We 
started in our lab to test EED and SUZ12 expression in neurofibromas and 
MPNSTs and compare its expression with the differentially methylated 
genes. 
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Another appealing research worth pursuing is to investigate the link between 
S100B and p53. My findings suggest a tumour suppressor role for S100B in 
MPNST cells and open the gate for further studies on the mechanism by 
which S100B performs its’ effect in MPNSTs. A possible mechanism for 
S100B function has been suggested by Van Dieck et al (2010) who proved 
experimentally that S100B may promote p53 tumour suppressor activity 
through interacting with MDM2 and MDM4 (van Dieck et al. 2010). It is worth 
testing the link between S100B and p53 in nerve sheath tumours.  
   
P a g e  | 285 
   
  
8. Reference list 
Abramowicz, A. & Gos, M., 2014. Neurofibromin in neurofibromatosis type 1 - 
mutations in NF1gene as a cause of disease. Developmental period medicine, 
18(3), pp.297–306. 
Adams, E.G. et al., 2011. Multiple, unilateral lisch nodules in the absence of other 
manifestations of neurofibromatosis type 1. Case reports in ophthalmological 
medicine, 2011, p.854784. 
Akbarnia, B.A. et al., 1992. Prevalence of scoliosis in neurofibromatosis. Spine, 17(8 
Suppl), pp.S244–8. 
Alajez, N.M. et al., 2011. MiR-218 suppresses nasopharyngeal cancer progression 
through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer 
research, 71(6), pp.2381–91. 
Alizadeh, S. et al., 2014. Mir-55 inhibition can reduce cell proliferation and induce 
apoptosis in Jurkat (Acute T cell Leukemia) cell line. Iranian journal of 
pediatric hematology and oncology, 4(4), pp.141–50. 
Allison, K.H. et al., 2005. Superficial malignant peripheral nerve sheath tumor: a 
rare and challenging diagnosis. American journal of clinical pathology, 124(5), 
pp.685–92. 
Alwan, S. et al., 2007. Associations of osseous abnormalities in Neurofibromatosis 
1. American journal of medical genetics. Part A, 143A(12), pp.1326–33. 
Ambros, V., 2001. microRNAs: tiny regulators with great potential. Cell, 107(7), 
pp.823–6. 
P a g e  | 286 
   
  
Andrés, R. et al., 2004. Prognostic value of serum S-100B in malignant melanoma. 
Tumori, 90(6), pp.607–10. 
Angelov, L. et al., 1998. Neurogenic sarcoma: experience at the University of 
Toronto. Neurosurgery, 43(1), pp.56–64. 
Aoki, Y. et al., 2005. Germline mutations in HRAS proto-oncogene cause Costello 
syndrome. Nature genetics, 37(10), pp.1038–40. 
Arai, E. et al., 2006. Regional DNA hypermethylation and DNA methyltransferase 
(DNMT) 1 protein overexpression in both renal tumors and corresponding 
nontumorous renal tissues. International journal of cancer. Journal 
international du cancer, 119(2), pp.288–96. 
Aran, D., Sabato, S. & Hellman, A., 2013. DNA methylation of distal regulatory 
sites characterizes dysregulation of cancer genes. Genome biology, 14(3), 
p.R21. 
Arcuri, C. et al., 2005. S100B increases proliferation in PC12 neuronal cells and 
reduces their responsiveness to nerve growth factor via Akt activation. Journal 
of Biological Chemistry, 280(6), pp.4402–14. 
Ars, E. et al., 2000. Mutations affecting mRNA splicing are the most common 
molecular defects in patients with neurofibromatosis type 1. Human molecular 
genetics, 9(2), pp.237–47. 
Astrand, R., Undén, J. & Romner, B., 2013. Clinical use of the calcium-binding 
S100B protein. Methods in molecular biology (Clifton, N.J.), 963, pp.373–84. 
Babovic-Vuksanovic, D. et al., 2012. Multiple orbital neurofibromas, painful 
peripheral nerve tumors, distinctive face and marfanoid habitus: a new 
syndrome. European journal of human genetics : EJHG, 20(6), pp.618–25. 
P a g e  | 287 
   
  
Ball, M.P. et al., 2009. Targeted and genome-scale strategies reveal gene-body 
methylation signatures in human cells. Nature biotechnology, 27(4), pp.361–
368. 
Ballard, M.S. & Hinck, L., 2012. A roundabout way to cancer. Advances in cancer 
research, 114, pp.187–235. 
Barault, L. et al., 2008. Hypermethylator phenotype in sporadic colon cancer: study 
on a population-based series of 582 cases. Cancer research, 68(20), pp.8541–6. 
Barragán,‎ E.‎ et‎ al.,‎ 2004.‎ Prognostic‎ implications‎ of‎ Wilms’‎ tumor‎ gene‎ (WT1)‎
expression in patients with de novo acute myeloid leukemia. Haematologica, 
89(8), pp.926–33. 
Bartel, D.P., 2009. MicroRNAs: target recognition and regulatory functions. Cell, 
136(2), pp.215–233. 
Bartel, D.P.D.P., 2004. MicroRNAs: Genomics, Biogenesis, Mechanism, and 
Function. Cell, 116(2), pp.281–297. 
Baudier, J. et al., 1992. Characterization of the tumor suppressor protein p53 as a 
protein kinase C substrate and a S100b-binding protein. Proceedings of the 
National Academy of Sciences of the United States of America, 89(23), 
pp.11627–31. 
Baur, B.A.S. et al., 1999. Frequent Methylation Silencing of p15. 
Baylin, S.B., 2005. DNA methylation and gene silencing in cancer. Nature clinical 
practice. Oncology, 2 Suppl 1(December), pp.S4–11. 
Baylin, S.B. & Ohm, J.E., 2006. Epigenetic gene silencing in cancer - a mechanism 
for early oncogenic pathway addiction? Nature reviews. Cancer, 6(2), pp.107–
16. 
P a g e  | 288 
   
  
Berdasco, M. & Esteller, M., 2010. Aberrant epigenetic landscape in cancer: how 
cellular identity goes awry. Developmental cell, 19(5), pp.698–711. 
Berger, A.H., Knudson, A.G. & Pandolfi, P.P., 2011. A continuum model for tumour 
suppression. Nature, 476(7359), pp.163–169. 
Bird, A., 2007. Perceptions of epigenetics. Nature, 447(7143), pp.396–8. 
Birindelli, S. et al., 2001. Rb and TP53 pathway alterations in sporadic and NF1-
related malignant peripheral nerve sheath tumors. Laboratory investigation; a 
journal of technical methods and pathology, 81(6), pp.833–44. 
Böni, R. et al., 1997. Ca(2+)-binding proteins S100A6 and S100B in primary 
cutaneous melanoma. Journal of cutaneous pathology, 24(2), pp.76–80. 
Bottillo, I. et al., 2010. Germline mosaicism in neurofibromatosis type 1 due to a 
paternally derived multi-exon deletion. American journal of medical genetics. 
Part A, 152A(6), pp.1467–73. 
Bradtmöller, M. et al., 2012. Impaired Pten expression in human malignant 
peripheral nerve sheath tumours. PloS one, 7(11), p.e47595. 
Brems, H. et al., 2007. Germline loss-of-function mutations in SPRED1 cause a 
neurofibromatosis 1-like phenotype. Nature genetics, 39(9), pp.1120–6. 
Brems, H. et al., 2009. Glomus tumors in neurofibromatosis type 1: genetic, 
functional, and clinical evidence of a novel association. Cancer research, 
69(18), pp.7393–7401. 
Brooks, J., 1999. Disorders of soft tissue. In S. Sternberg, ed. Diagnostic Surgical 
Pathology. Philadelphia: Lipincott Williams and Wilkins, pp. 131–221. 
Brosius,‎S.,‎2010.‎A‎history‎of‎von‎Recklinghausen’s‎NF1.‎Journal of the history of 
the neurosciences, 19(4), pp.333–48. 
P a g e  | 289 
   
  
Brown, R.W., Tornos, C. & Evans, H.L., 1992. Angiosarcoma arising from 
malignant schwannoma in a patient with neurofibromatosis. Cancer, 70(5), 
pp.1141–4. 
Brueckner, B. et al., 2005. Epigenetic reactivation of tumor suppressor genes by a 
novel small-molecule inhibitor of human DNA methyltransferases. Cancer 
research, 65(14), pp.6305–11. 
Bruno, P. et al., 2012. WT1 CpG islands methylation in human lung cancer: a pilot 
study. Biochemical and biophysical research communications, 426(3), pp.306–
9. 
Calin, G.A. et al., 2005. A MicroRNA Signature Associated with Prognosis and 
Progression in Chronic Lymphocytic Leukemia — NEJM. The New England 
journal of medicine, 353(17), pp.1793–801. 
Calin, G.A. et al., 2002. Frequent deletions and down-regulation of micro- RNA 
genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. 
Proceedings of the National Academy of Sciences of the United States of 
America, 99(24), pp.15524–9. 
Calin, G.A. & Croce, C.M., 2006. MicroRNA signatures in human cancers. Nature 
reviews. Cancer, 6(11), pp.857–66. 
Call, K.M. et al., 1990. Isolation and characterization of a zinc finger polypeptide 
gene at the human chromosome 11‎Wilms’‎tumor‎locus.‎Cell, 60(3), pp.509–20. 
Camby, I. et al., 1999. Supratentorial pilocytic astrocytomas, astrocytomas, 
anaplastic astrocytomas and glioblastomas are characterized by a differential 
expression of S100 proteins. Brain pathology (Zurich, Switzerland), 9(1), pp.1–
19. 
Carroll, S.L., 2012. Molecular mechanisms promoting the pathogenesis of Schwann 
cell neoplasms. Acta neuropathologica, 123(3), pp.321–48. 
P a g e  | 290 
   
  
Carter, J.M. et al., 2012. Epithelioid malignant peripheral nerve sheath tumor arising 
in a‎schwannoma,‎in‎a‎patient‎with‎―neuroblastoma-like‖‎schwannomatosis‎and‎
a novel germline SMARCB1 mutation. The American journal of surgical 
pathology, 36(1), pp.154–60. 
Carter, T.L., Reaman, G.H. & Kees, U.R., 2001. INK4A/ARF deletions are acquired 
at relapse in childhood acute lymphoblastic leukaemia: a paired study on 25 
patients using real-time polymerase chain reaction. British journal of 
haematology, 113(2), pp.323–8. 
Castilla, M.Á. et al., 2011. Micro-RNA signature of the epithelial-mesenchymal 
transition in endometrial carcinosarcoma. The Journal of pathology, 223(1), 
pp.72–80. 
Cawthon, R.M. et al., 1990. A major segment of the neurofibromatosis type 1 gene: 
cDNA sequence, genomic structure, and point mutations. Cell, 62(1), pp.193–
201. 
Cebrian, A. et al., 2006. Genetic variants in epigenetic genes and breast cancer risk. 
Carcinogenesis, 27(8), pp.1661–9. 
Chai, G. et al., 2010. MicroRNA-10b regulates tumorigenesis in neurofibromatosis 
type 1. Cancer Science, 101(9), pp.1997–2004. 
Chan, J.A., Krichevsky, A.M. & Kosik, K.S., 2005. MicroRNA-21 Is an 
Antiapoptotic Factor in Human Glioblastoma Cells. Cancer research, 65(14), 
pp.6029–6033. 
Chang, T.-C. et al., 2007. Transactivation of miR-34a by p53 broadly influences 
gene expression and promotes apoptosis. Molecular cell, 26(5), pp.745–52. 
Chaubal, A. et al., 1994. CD34 immunoreactivity in nervous system tumors. Acta 
neuropathologica, 88(5), pp.454–8. 
P a g e  | 291 
   
  
Chen, H. et al., 2010. Slit-Robo signaling in ocular angiogenesis. Advances in 
experimental medicine and biology, 664, pp.457–63. 
Chen, M. et al., 2009. Integrin alpha6beta4 controls the expression of genes 
associated with cell motility, invasion, and metastasis, including 
S100A4/metastasin. The Journal of biological chemistry, 284(3), pp.1484–94. 
Chen, Z., 2001. The possible role and application of WT1 in human leukemia. 
International journal of hematology, 73(1), pp.39–46. 
Chintala, S.K. et al., 1996. Role of extracellular matrix proteins in regulation of 
human glioma cell invasion in vitro. Clinical & experimental metastasis, 14(4), 
pp.358–66. 
Chou, J. et al., 2013. GATA3 suppresses metastasis and modulates the tumour 
microenvironment by regulating microRNA-29b expression. Nature cell 
biology, 15(2), pp.201–13. 
Cichowski, K. et al., 1999. Mouse models of tumor development in 
neurofibromatosis type 1. Science (New York, N.Y.), 286(5447), pp.2172–6. 
Cichowski, K. & Jacks, T., 2001. NF1 tumor suppressor gene function: narrowing 
the GAP. Cell, 104(4), pp.593–604. 
Cimmino, A. et al., 2005. miR-15 and miR-16 induce apoptosis by targeting BCL2. 
Proceedings of the National Academy of Sciences of the United States of 
America, 102(39), pp.13944–13949. 
Cirstea, I.C. et al., 2010. A restricted spectrum of NRAS mutations causes Noonan 
syndrome. Nature genetics, 42(1), pp.27–9. 
Clark, A.J. et al., 2010. Effect of WT1 gene silencing on the tumorigenicity of 
human glioblastoma multiforme cells. Journal of neurosurgery, 112(1), pp.18–
25. 
P a g e  | 292 
   
  
Clark, S.J. et al., 2006. DNA methylation: bisulphite modification and analysis. 
Nature protocols, 1(5), pp.2353–64. 
Clark, S.J. et al., 1994. High sensitivity mapping of methylated cytosines. Nucleic 
acids research, 22(15), pp.2990–7. 
Claus, R., Almstedt, M. & Lübbert, M., 2005. Epigenetic treatment of hematopoietic 
malignancies: in vivo targets of demethylating agents. Seminars in oncology, 
32(5), pp.511–520. 
Coindre, J.M. et al., 1988. Immunohistochemical study of rhabdomyosarcoma. 
Unexpected staining with S100 protein and cytokeratin. The Journal of 
pathology, 155(2), pp.127–32. 
Coindre, J.-M., 2006. Grading of soft tissue sarcomas: review and update. Archives 
of pathology & laboratory medicine, 130(10), pp.1448–53. 
Colman, S.D., Williams, C.A. & Wallace, M.R., 1995. Benign neurofibromas in type 
1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nature 
Genetics, 11(1), pp.90–92. 
Coppola, D. et al., 1998. Prognostic significance of p53, bcl-2, vimentin, and S100 
protein-positive Langerhans cells in endometrial carcinoma. Human pathology, 
29(5), pp.455–62. 
Couronné, L., Bastard, C. & Bernard, O.A., 2012. TET2 and DNMT3A Mutations in 
Human T-Cell Lymphoma. The New England journal of medicine, 366(1), 
pp.95–6. 
Cox, A.D., 2001. Farnesyltransferase inhibitors: potential role in the treatment of 
cancer. Drugs, 61(6), pp.723–32. 
Créange, A. et al., 1999. Neurological complications of neurofibromatosis type 1 in 
adulthood., 
P a g e  | 293 
   
  
Cross, S.S. et al., 2005. Expression of S100 proteins in normal human tissues and 
common cancers using tissue microarrays: S100A6, S100A8, S100A9 and 
S100A11 are all overexpressed in common cancers. Histopathology, 46(3), 
pp.256–69. 
Crowe FW, Schull WJ, N.J., 1956. A Clinical, Pathologicala and Genetic Study of 
Multiple Neurofibromatosis I. C. C. T. Springfield, ed., 
Cui, H. et al., 2015. Deregulation between miR-29b/c and DNMT3A Is Associated 
with Epigenetic Silencing of the CDH1 Gene, Affecting Cell Migration and 
Invasion in Gastric Cancer R. Samant, ed. PLOS ONE, 10(4), p.e0123926. 
Daley, W.P., Peters, S.B. & Larsen, M., 2008. Extracellular matrix dynamics in 
development and regenerative medicine. Journal of cell science, 121(Pt 3), 
pp.255–64. 
Danielsen, S.A. et al., 2015. Methylated RASSF1A in malignant peripheral nerve 
sheath tumors identifies neurofibromatosis type 1 patients with inferior 
prognosis. Neuro-oncology, 17(1), pp.63–9. 
Dasgupta, B., 2003. Neurofibromatosis 1: closing the GAP between mice and men. 
Current Opinion in Genetics & Development, 13(1), pp.20–27. 
DeBella, K., Szudek, J. & Friedman, J.M., 2000. Use of the national institutes of 
health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics, 
105(3 Pt 1), pp.608–14. 
DeClue, J.E. et al., 1992. Abnormal regulation of mammalian p21ras contributes to 
malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. 
Cell, 69(2), pp.265–73. 
DiCarlo, E.F. et al., 1986. The purely epithelioid malignant peripheral nerve sheath 
tumor. The American journal of surgical pathology, 10(7), pp.478–90. 
P a g e  | 294 
   
  
Van Dieck, J. et al., 2009. Modulation of the oligomerization state of p53 by 
differential binding of proteins of the S100 family to p53 monomers and 
tetramers. The Journal of biological chemistry, 284(20), pp.13804–11. 
Van Dieck, J. et al., 2010. S100 proteins interact with the N-terminal domain of 
MDM2. FEBS letters, 584(15), pp.3269–74. 
Digilio, M.C. et al., 2002. Grouping of multiple-lentigines/LEOPARD and Noonan 
syndromes on the PTPN11 gene. American journal of human genetics, 71(2), 
pp.389–94. 
Ding, D.-P. et al., 2011. miR-29c induces cell cycle arrest in esophageal squamous 
cell carcinoma by modulating cyclin E expression. Carcinogenesis, 32(7), 
pp.1025–32. 
Doench, J.G. & Sharp, P.A., 2004. Specificity of microRNA target selection in 
translational repression. Genes & development, 18(5), pp.504–11. 
Domfeh, A.B. et al., 2008. WT1 immunoreactivity in breast carcinoma: selective 
expression in pure and mixed mucinous subtypes. Modern pathology : an 
official journal of the United States and Canadian Academy of Pathology, Inc, 
21(10), pp.1217–23. 
Donato, R. et al., 2013. Functions of S100 proteins. Current molecular medicine, 
13(1), pp.24–57. 
Donato, R., 2003. Intracellular and extracellular roles of S100 proteins. Microscopy 
research and technique, 60(6), pp.540–51. 
Donato, R., 2007. RAGE: a single receptor for several ligands and different cellular 
responses: the case of certain S100 proteins. Current molecular medicine, 7(8), 
pp.711–24. 
P a g e  | 295 
   
  
Donato, R., 2001. S100: a multigenic family of calcium-modulated proteins of the 
EF-hand type with intracellular and extracellular functional roles. The 
international journal of biochemistry & cell biology, 33(7), pp.637–68. 
Ducatman, B.S. & Scheithauer, B.W., 1984. Malignant peripheral nerve sheath 
tumors with divergent differentiation. Cancer, 54(6), pp.1049–57. 
Dulai, S. et al., 2007. Decreased bone mineral density in neurofibromatosis type 1: 
results from a pediatric cohort. Journal of pediatric orthopedics, 27(4), pp.472–
5. 
Duursma, A.M. et al., 2008. miR-148 targets human DNMT3b protein coding 
region. RNA, 14(5), pp.872–877. 
Ehrlich, M., 2002. DNA methylation in cancer: too much, but also too little. 
Oncogene, 21(35), pp.5400–13. 
Elder, J.T. & Zhao, X., 2002. Evidence for local control of gene expression in the 
epidermal differentiation complex. Experimental dermatology, 11(5), pp.406–
12. 
Ellisen, L.W., 2002. Regulation of gene expression by WT1 in development and 
tumorigenesis. International journal of hematology, 76(2), pp.110–6. 
Van Emburgh, B.O. & Robertson, K.D., 2011. Modulation of Dnmt3b function in 
vitro by interactions with Dnmt3L, Dnmt3a and Dnmt3b splice variants. 
Nucleic acids research, 39(12), pp.4984–5002. 
Endo, M. et al., 2011. Prognostic significance of p14ARF, p15INK4b, and 
p16INK4a inactivation in malignant peripheral nerve sheath tumors. Clinical 
cancer research : an official journal of the American Association for Cancer 
Research, 17(11), pp.3771–82. 
P a g e  | 296 
   
  
Esquela-Kerscher, A. & Slack, F.J., 2006. Oncomirs - microRNAs with a role in 
cancer. Nature reviews. Cancer, 6(4), pp.259–69. 
Evans, D.G. et al., 2010. Birth incidence and prevalence of tumor-prone syndromes: 
estimates from a UK family genetic register service. American journal of 
medical genetics. Part A, 152A(2), pp.327–32. 
Evans, D.G.R. et al., 2002. Malignant peripheral nerve sheath tumours in 
neurofibromatosis 1. Journal of Medical Genetics, 39(5), pp.311–314. 
Fabbri, M. et al., 2007. MicroRNA-29 family reverts aberrant methylation in lung 
cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the 
National Academy of Sciences of the United States of America, 104(40), 
pp.15805–10. 
Fan, Y. et al., 2014. Down-regulation of miR-29c in human bladder cancer and the 
inhibition of proliferation in T24 cell via PI3K-AKT pathway. Medical 
oncology (Northwood, London, England), 31(7), p.65. 
Fan, Y. et al., 2013. MiR-29c inhibits glioma cell proliferation, migration, invasion 
and angiogenesis. Journal of neuro-oncology, 115(2), pp.179–88. 
Fang, J.-H. et al., 2011. MicroRNA-29b suppresses tumor angiogenesis, invasion, 
and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology 
(Baltimore, Md.), 54(5), pp.1729–40. 
Fang, Y. et al., 2012. MicroRNA-7 inhibits tumor growth and metastasis by targeting 
the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. 
Hepatology (Baltimore, Md.), 55(6), pp.1852–62. 
Fang, Y. et al., 2015. MiR-301a Promotes Colorectal Cancer Cell Growth and 
Invasion by Directly Targeting SOCS6. Cellular physiology and biochemistry : 
international journal of experimental cellular physiology, biochemistry, and 
pharmacology, 35(1), pp.227–36. 
P a g e  | 297 
   
  
Fang, Y. et al., 2009. Molecular characterization of permanent cell lines from 
primary, metastatic and recurrent malignant peripheral nerve sheath tumors 
(MPNST) with underlying neurofibromatosis-1. Anticancer Research, 29(4), 
pp.1255–1262. 
Feber, A. et al., 2011. Comparative methylome analysis of benign and malignant 
peripheral nerve sheath tumours. Genome Research, 21(4), pp.515–24. 
Fernandez-Fernandez, M.R., Rutherford, T.J. & Fersht, A.R., 2008. Members of the 
S100 family bind p53 in two distinct ways. Protein science : a publication of 
the Protein Society, 17(10), pp.1663–70. 
Fernandez-Fernandez, M.R., Veprintsev, D.B. & Fersht, A.R., 2005. Proteins of the 
S100 family regulate the oligomerization of p53 tumor suppressor. Proceedings 
of the National Academy of Sciences, 102(13), pp.4735–4740. 
Ferner, R.E. et al., 2000. Evaluation of (18)fluorodeoxyglucose positron emission 
tomography ((18)FDG PET) in the detection of malignant peripheral nerve 
sheath tumours arising from within plexiform neurofibromas in 
neurofibromatosis 1. Journal of neurology, neurosurgery, and psychiatry, 
68(3), pp.353–357. 
Ferner, R.E. & Gutmann, D.H., 2002. International consensus statement on 
malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer 
research, 62(5), pp.1573–7. 
Ferner, R.E., Hughes, R.A. & Weinman, J., 1996. Intellectual impairment in 
neurofibromatosis 1. Journal of the neurological sciences, 138(1-2), pp.125–33. 
Ferner, R.E.H., 2007. Guidelines for the diagnosis and management of individuals 
with neurofibromatosis. Journal of Medical Genetics, 44(2), pp.81–88. 
P a g e  | 298 
   
  
Fine, S.W., McClain, S.A. & Li, M., 2004. Immunohistochemical staining for 
calretinin is useful for differentiating schwannomas from neurofibromas. 
American journal of clinical pathology, 122(4), pp.552–9. 
Fisher, C. & Schofield, J.B., 1991. S-100 protein positive synovial sarcoma. 
Histopathology, 19(4), pp.375–7. 
Fletcher, C.D.M. & Unni, K.K., 2002. World Health Organization Classification of 
Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone. C. D. 
M. Fletcher, K. K. Unni, & F. Mertens, eds. Cancer, 177(3), pp.1365–76. 
Fraizer, G. et al., 2004. Suppression of prostate tumor cell growth in vivo by WT1, 
the‎Wilms’‎ tumor‎ suppressor‎ gene.‎ International journal of oncology, 24(3), 
pp.461–71. 
Friedman, J.M. et al., 2002. Cardiovascular disease in neurofibromatosis 1: report of 
the NF1 Cardiovascular Task Force. Genetics in medicine : official journal of 
the American College of Medical Genetics, 4(3), pp.105–11. 
Friedman, J.M., 1999. Epidemiology of neurofibromatosis type 1. American Journal 
of Medical Genetics, 89(1), pp.1–6. 
Friedman, J.M., 2002. Neurofibromatosis 1: clinical manifestations and diagnostic 
criteria. Journal of child neurology, 17(8), pp.548–54; discussion 571–2, 646–
51. 
Frommer, M. et al., 1992. A genomic sequencing protocol that yields a positive 
display of 5-methylcytosine residues in individual DNA strands. Proceedings of 
the National Academy of Sciences of the United States of America, 89(5), 
pp.1827–31. 
Gao, P. et al., 2013. The molecular mechanism of microRNA-145 to suppress 
invasion-metastasis cascade in gastric cancer. Oncogene, 32(4), pp.491–501. 
P a g e  | 299 
   
  
Garzon, R. et al., 2006. MicroRNA expression and function in cancer. Trends in 
molecular medicine, 12(12), pp.580–7. 
Garzon, R. et al., 2009. MicroRNA-29b induces global DNA hypomethylation and 
tumor suppressor gene reexpression in acute myeloid leukemia by targeting 
directly DNMT3A and 3B and indirectly DNMT1. Blood, 113(25), pp.6411–8. 
Gessler, M. et al., 1990. Homozygous deletion in Wilms tumours of a zinc-finger 
gene identified by chromosome jumping. Nature, 343(6260), pp.774–8. 
Glass, J.L. et al., 2007. CG dinucleotide clustering is a species-specific property of 
the genome. Nucleic acids research, 35(20), pp.6798–807. 
Gong, M. et al., 2012. MicroRNA-204 critically regulates carcinogenesis in 
malignant peripheral nerve sheath tumors. Neuro-oncology, 14(8), pp.1007–17. 
Gray, M.H. et al., 1990. Immunohistochemical demonstration of factor XIIIa 
expression in neurofibromas. A practical means of differentiating these tumors 
from neurotized melanocytic nevi and schwannomas. Archives of dermatology, 
126(4), pp.472–6. 
Gregorian, C. et al., 2009. PTEN dosage is essential for neurofibroma development 
and malignant transformation. Proceedings of the National Academy of 
Sciences of the United States of America, 106(46), pp.19479–84. 
Griffiths, S. et al., 2007. Molecular diagnosis of neurofibromatosis type 1: 2 years 
experience. Familial cancer, 6(1), pp.21–34. 
Grigorian, M. et al., 2001. Tumor suppressor p53 protein is a new target for the 
metastasis-associated Mts1/S100A4 protein: functional consequences of their 
interaction. The Journal of biological chemistry, 276(25), pp.22699–708. 
P a g e  | 300 
   
  
Grosshans, H. et al., 2005. The temporal patterning microRNA let-7 regulates 
several transcription factors at the larval to adult transition in C. elegans. 
Developmental cell, 8(3), pp.321–30. 
Gu, J.-J., Gao, G.-Z. & Zhang, S.-M., 2015. miR-218 inhibits the migration and 
invasion of glioma U87 cells through the Slit2-Robo1 pathway. Oncology 
letters, 9(4), pp.1561–1566. 
Guillou, L. et al., 1997. Comparative study of the National Cancer Institute and 
French Federation of Cancer Centers Sarcoma Group grading systems in a 
population of 410 adult patients with soft tissue sarcoma. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology, 15(1), 
pp.350–62. 
Guo, H. et al., 2010. Mammalian microRNAs predominantly act to decrease target 
mRNA levels. Nature, 466(7308), pp.835–40. 
Hachem, S. et al., 2005. Spatial and temporal expression of S100B in cells of 
oligodendrocyte lineage. Glia, 51(2), pp.81–97. 
Hackanson, B. & Daskalakis, M., 2014. Decitabine. Recent results in cancer 
research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le 
cancer, 201, pp.269–97. 
Han, T.-S. et al., 2015. MicroRNA-29c mediates initiation of gastric carcinogenesis 
by directly targeting ITGB1. Gut, 64(2), pp.203–14. 
He, L. et al., 2007. A microRNA component of the p53 tumour suppressor network. 
Nature, 447(7148), pp.1130–4. 
Heizmann, C.W., Fritz, G. & Schäfer, B.W., 2002. S100 proteins: structure, 
functions and pathology. Frontiers in bioscience : a journal and virtual library, 
7, pp.d1356–68. 
P a g e  | 301 
   
  
Henderson, S.R. et al., 2005. A molecular map of mesenchymal tumors. Genome 
biology, 6(9), p.R76. 
Herman, J.G. et al., 1996. Methylation-specific PCR: a novel PCR assay for 
methylation status of CpG islands. Proceedings of the National Academy of 
Sciences of the United States of America, 93(18), pp.9821–6. 
Hirbe, A.C. & Gutmann, D.H., 2014. Neurofibromatosis type 1: a multidisciplinary 
approach to care. The Lancet. Neurology, 13(8), pp.834–43. 
Hirose, T. et al., 2003. Immunohistochemical demonstration of EMA/Glut1-positive 
perineurial cells and CD34-positive fibroblastic cells in peripheral nerve sheath 
tumors. Modern pathology : an official journal of the United States and 
Canadian Academy of Pathology, Inc, 16(4), pp.293–8. 
Hochberg, F.H. et al., 1974. Gastrointestinal‎ involvement‎ in‎von‎Recklinghausen’s‎
neurofibromatosis. Neurology, 24(12), pp.1144–51. 
Hohenstein,‎P.‎&‎Hastie,‎N.D.,‎2006.‎The‎many‎facets‎of‎the‎Wilms’‎tumour‎gene,‎
WT1. Human molecular genetics, 15 Spec No, pp.R196–201. 
Hollmann, T.J. & Hornick, J.L., 2011. INI1-deficient tumors: diagnostic features and 
molecular genetics. The American journal of surgical pathology, 35(10), 
pp.e47–63. 
Holtkamp, N. et al., 2007. MMP-13 and p53 in the progression of malignant 
peripheral nerve sheath tumors. Neoplasia (New York, N.Y.), 9(8), pp.671–7. 
Huang, S.S. & Huang, J.S., 2005. TGF-beta control of cell proliferation. Journal of 
cellular biochemistry, 96(3), pp.447–62. 
Huang, Z. et al., 2015. USP33 mediates Slit-Robo signaling in inhibiting colorectal 
cancer cell migration. International journal of cancer. Journal international du 
cancer, 136(8), pp.1792–802. 
P a g e  | 302 
   
  
Huson, S.M., Harper, P.S. & Compston, D. a, 1988. Von Recklinghausen 
neurofibromatosis. A clinical and population study in south-east Wales. Brain : 
a journal of neurology, 111 ( Pt 6, pp.1355–81. 
Illingworth, R.S. & Bird, A.P., 2009. CpG islands--’a‎ rough‎ guide'.‎FEBS letters, 
583(11), pp.1713–20. 
Im, A.P. et al., 2014. DNMT3A and IDH mutations in acute myeloid leukemia and 
other myeloid malignancies: associations with prognosis and potential treatment 
strategies. Leukemia, 28(9), pp.1774–1783. 
Inagaki, T. et al., 2011. No Oncogenic Role for WT1 in Peripheral Nerve Sheath 
Tumors. , pp.95–102. 
Iorio, M. V et al., 2005. MicroRNA gene expression deregulation in human breast 
cancer. Cancer research, 65(16), pp.7065–70. 
Issa, J., 2004. CpG island methylator phenotype in cancer. Nature reviews. Cancer, 
4(December), pp.988–993. 
Itani, S. et al., 2012. MicroRNA-21 correlates with tumorigenesis in malignant 
peripheral nerve sheath tumor (MPNST) via programmed cell death protein 4 
(PDCD4). Journal of cancer research and clinical oncology, 138(9), pp.1501–
9. 
Jakubícková, L. et al., 2005. Expression of S100P gene in cervical carcinoma cells is 
independent of E7 human papillomavirus oncogene. Acta virologica, 49(2), 
pp.133–7. 
Jeong, M. & Goodell, M.A., 2014. New answers to old questions from genome-wide 
maps of DNA methylation in hematopoietic cells. Experimental hematology, 
42(8), pp.609–17. 
P a g e  | 303 
   
  
Jett, K. & Friedman, J.M., 2010. Clinical and genetic aspects of neurofibromatosis 1. 
Medicine, 12(1), pp.1–11. 
Jiang, J. et al., 2014. Reduction of miR-29c enhances pancreatic cancer cell 
migration and stem cell – like phenotype. , 6(5). 
Jiang, J. et al., 2015. Reduction of miR-29c enhances pancreatic cancer cell 
migration and stem cell-like phenotype. Oncotarget, 6(5), pp.2767–78. 
Jin, B., Li, Y. & Robertson, K.D., 2011. DNA methylation: superior or subordinate 
in the epigenetic hierarchy? Genes & cancer, 2(6), pp.607–17. 
Johnson, H. et al., 2005. Psychological disturbance and sleep disorders in children 
with neurofibromatosis type 1. Developmental medicine and child neurology, 
47(4), pp.237–42. 
Johnson, S.M. et al., 2005. RAS is regulated by the let-7 microRNA family. Cell, 
120(5), pp.635–647. 
Jones, P.A., 2012. Functions of DNA methylation: islands, start sites, gene bodies 
and beyond. Nature reviews. Genetics, 13(7), pp.484–92. 
Jones, P.A. & Baylin, S.B., 2007. The epigenomics of cancer. Cell, 128(4), pp.683–
92. 
Jones, P.A. & Liang, G., 2009. Rethinking how DNA methylation patterns are 
maintained. Nature reviews. Genetics, 10(11), pp.805–11. 
Jouhilahti, E.-M. et al., 2011. The pathoetiology of neurofibromatosis 1. The 
American journal of pathology, 178(5), pp.1932–9. 
Jurkowska, R.Z., Jurkowski, T.P. & Jeltsch, A., 2011. Structure and function of 
mammalian DNA methyltransferases. Chembiochem : a European journal of 
chemical biology, 12(2), pp.206–22. 
P a g e  | 304 
   
  
Kanai, Y. & Hirohashi, S., 2007. Alterations of DNA methylation associated with 
abnormalities of DNA methyltransferases in human cancers during transition 
from a precancerous to a malignant state. Carcinogenesis, 28(12), pp.2434–
2442. 
Kaneuchi, M. et al., 2005. WT1 and WT1-AS genes are inactivated by promoter 
methylation in ovarian clear cell adenocarcinoma. Cancer, 104(9), pp.1924–30. 
Karakas, T. et al., 2002. The coexpression of the apoptosis-related genes bcl-2 and 
wt1 in predicting survival in adult acute myeloid leukemia. Leukemia, 16(5), 
pp.846–54. 
Karamchandani, J.R. et al., 2012. Sox10 and S100 in the diagnosis of soft-tissue 
neoplasms. Applied immunohistochemistry & molecular morphology : AIMM / 
official publication of the Society for Applied Immunohistochemistry, 20(5), 
pp.445–50. 
Kass, S.U., Pruss, D. & Wolffe, A.P., 1997. How does DNA methylation repress 
transcription? Trends in genetics : TIG, 13(11), pp.444–9. 
Kaufman, L.J. et al., 2005. Glioma expansion in collagen I matrices: analyzing 
collagen concentration-dependent growth and motility patterns. Biophysical 
journal, 89(1), pp.635–50. 
Kawaguchi, K. et al., 2003. Mechanisms of inactivation of the p16INK4a gene in 
leiomyosarcoma of soft tissue: decreased p16 expression correlates with 
promoter methylation and poor prognosis. The Journal of pathology, 201(3), 
pp.487–95. 
Kehrer-Sawatzki, H. & Cooper, D.N., 2008. Mosaicism in sporadic 
neurofibromatosis type 1: variations on a theme common to other hereditary 
cancer syndromes? Journal of medical genetics, 45(10), pp.622–31. 
P a g e  | 305 
   
  
Keijser, S. et al., 2006. Immunophenotypic markers to differentiate between benign 
and malignant melanocytic lesions. The British journal of ophthalmology, 
90(2), pp.213–7. 
Keng, V.W. et al., 2012. PTEN and NF1 inactivation in Schwann cells produces a 
severe phenotype in the peripheral nervous system that promotes the 
development and malignant progression of peripheral nerve sheath tumors. 
Cancer research, 72(13), pp.3405–13. 
Kerst, G. et al., 2008. WT1 protein expression in childhood acute leukemia. 
American journal of hematology, 83(5), pp.382–6. 
Khosrotehrani, K. et al., 2005. Subcutaneous neurofibromas are associated with 
mortality in neurofibromatosis 1: a cohort study of 703 patients. American 
journal of medical genetics. Part A, 132A(1), pp.49–53. 
King-Underwood, L., Renshaw, J. & Pritchard-Jones, K., 1996. Mutations in the 
Wilms’‎tumor‎gene‎WT1‎in‎leukemias.‎Blood, 87(6), pp.2171–9. 
Kleihues, P. et al., 2002. The WHO classification of tumors of the nervous system. 
Journal of neuropathology and experimental neurology, 61(3), pp.215–25; 
discussion 226–9. 
Klose, R.J. & Bird, A.P., 2006. Genomic DNA methylation: the mark and its 
mediators. Trends in biochemical sciences, 31(2), pp.89–97. 
Kluiver, J. et al., 2005. BIC and miR-155 are highly expressed in Hodgkin, primary 
mediastinal and diffuse large B cell lymphomas. The Journal of pathology, 
207(2), pp.243–9. 
Koenig, A. et al., 2006. Collagen type I induces disruption of E-cadherin-mediated 
cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. 
Cancer research, 66(9), pp.4662–71. 
P a g e  | 306 
   
  
Koesters, R. et al., 2004. WT1 is a tumor-associated antigen in colon cancer that can 
be recognized by in vitro stimulated cytotoxic T cells. International journal of 
cancer. Journal international du cancer, 109(3), pp.385–92. 
Kogure, T. et al., 2013. Involvement of microRNA-29a in epigenetic regulation of 
transforming growth factor-β-induced epithelial-mesenchymal transition in 
hepatocellular carcinoma. Hepatology research : the official journal of the 
Japan Society of Hepatology. 
Kogure, T. et al., 2014. Involvement of miRNA-29a in epigenetic regulation of 
transforming growth factor-β-induced epithelial-mesenchymal transition in 
hepatocellular carcinoma. Hepatology research : the official journal of the 
Japan Society of Hepatology, 44(8), pp.907–19. 
Korf, B.R., 1992. Diagnostic outcome in children with multiple café au lait spots. 
Pediatrics, 90(6), pp.924–927. 
Korf, B.R., 1999. Plexiform neurofibromas. American journal of medical genetics, 
89(1), pp.31–37. 
Kourea, H.P. et al., 1999. Deletions of the INK4A gene occur in malignant 
peripheral nerve sheath tumors but not in neurofibromas. The American journal 
of pathology, 155(6), pp.1855–60. 
Lagos-Quintana, M. et al., 2003. New microRNAs from mouse and human. RNA 
(New York, N.Y.), 9(2), pp.175–179. 
Lai, H.-C. et al., 2008. Identification of novel DNA methylation markers in cervical 
cancer. International journal of cancer. Journal international du cancer, 
123(1), pp.161–7. 
Laskin, W.B., Weiss, S.W. & Bratthauer, G.L., 1991. Epithelioid variant of 
malignant peripheral nerve sheath tumor (malignant epithelioid schwannoma). 
The American journal of surgical pathology, 15(12), pp.1136–45. 
P a g e  | 307 
   
  
Laux, D.E. et al.,‎1999.‎Hypermethylation‎of‎the‎Wilms’‎tumor‎suppressor‎gene‎CpG‎
island in human breast carcinomas. Breast cancer research and treatment, 
56(1), pp.35–43. 
Lázaro, C. et al., 1994. Neurofibromatosis type 1 due to germ-line mosaicism in a 
clinically normal father. The New England journal of medicine, 331(21), 
pp.1403–7. 
Le, L.Q. & Parada, L.F., 2007. Tumor microenvironment and neurofibromatosis type 
I: connecting the GAPs. Oncogene, 26(32), pp.4609–16. 
Lee, M.-J. et al., 2012. The systems biology of neurofibromatosis type 1--critical 
roles for microRNA. Experimental neurology, 235(2), pp.464–8. 
Lee, R.C., Feinbaum, R.L. & Ambros, V., 1993. The C. elegans heterochronic gene 
lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 
75(5), pp.843–854. 
Lee, S.B. & Haber, D.A., 2001. Wilms tumor and the WT1 gene. Experimental cell 
research, 264(1), pp.74–99. 
Lee, S.W. et al., 1992. Down-regulation of a member of the S100 gene family in 
mammary carcinoma cells and reexpression by azadeoxycytidine treatment. 
Proceedings of the National Academy of Sciences of the United States of 
America, 89(6), pp.2504–8. 
Lee, W. et al., 2014. PRC2 is recurrently inactivated through EED or SUZ12 loss in 
malignant peripheral nerve sheath tumors. Nature Genetics, 46(11), pp.1227–
32. 
Legg, J. a et al., 2008. Slits and Roundabouts in cancer, tumour angiogenesis and 
endothelial cell migration. Angiogenesis, 11(1), pp.13–21. 
P a g e  | 308 
   
  
Legius, E. et al., 2002. PTPN11 mutations in LEOPARD syndrome. Journal of 
medical genetics, 39(8), pp.571–4. 
Legius, E. et al., 1993. Somatic deletion of the neurofibromatosis type 1 gene in a 
neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nature 
Genetics, 3(2), pp.122–126. 
Legius, E. et al., 1994. TP53 mutations are frequent in malignant NF1 tumors. 
Genes, chromosomes & cancer, 10(4), pp.250–5. 
Leondaritis, G., Petrikkos, L. & Mangoura, D., 2009. Regulation of the Ras-GTPase 
activating protein neurofibromin by C-tail phosphorylation: implications for 
protein kinase C/Ras/extracellular signal-regulated kinase 1/2 pathway 
signaling and neuronal differentiation. Journal of neurochemistry, 109(2), 
pp.573–83. 
Leśniak,‎ W.‎ et‎ al.,‎ 2000.‎ Regulation‎ of‎ cell‎ specific‎ expression‎ of‎ calcyclin 
(S100A6) in nerve cells and other tissues. Acta neurobiologiae experimentalis, 
60(4), pp.569–75. 
Leukert, N. et al., 2006. Calcium-dependent tetramer formation of S100A8 and 
S100A9 is essential for biological activity. Journal of molecular biology, 
359(4), pp.961–72. 
Di Leva, G. & Croce, C.M., 2010. Roles of small RNAs in tumor formation. Trends 
in Molecular Medicine, 16(6), pp.257–267. 
Lévy, P. et al., 2004. Molecular profiling of malignant peripheral nerve sheath 
tumors associated with neurofibromatosis type 1, based on large-scale real-time 
RT-PCR. Molecular cancer, 3, p.20. 
Ley, T.J. et al., 2010. DNMT3A mutations in acute myeloid leukemia. The New 
England journal of medicine, 363(25), pp.2424–33. 
P a g e  | 309 
   
  
Li, J.-Y. et al., 2007. Synergistic function of DNA methyltransferases Dnmt3a and 
Dnmt3b in the methylation of Oct4 and Nanog. Molecular and cellular biology, 
27(24), pp.8748–59. 
Li, K.K. et al., 2013. DNA methyltransferases in hematologic malignancies. 
Seminars in hematology, 50(1), pp.48–60. 
Li, Y. et al., 2010. Inhibition of TGF-β‎receptor‎i‎by‎siRNA‎suppresses‎the‎motility‎
and invasiveness of T24 bladder cancer cells via modulation of integrins and 
matrix metalloproteinase. International Urology and Nephrology, 42(2), 
pp.315–323. 
Li, Y. et al., 2011. Progressive miRNA expression profiles in cervical carcinogenesis 
and identification of HPV-related target genes for miR-29. The Journal of 
pathology, 224(4), pp.484–95. 
Liang, C.-C., Park, A.Y. & Guan, J.-L., 2007. In vitro scratch assay: a convenient 
and inexpensive method for analysis of cell migration in vitro. Nature 
protocols, 2(2), pp.329–333. 
Lin, J. et al., 2004. Inhibiting S100B restores p53 levels in primary malignant 
melanoma cancer cells. The Journal of biological chemistry, 279(32), 
pp.34071–7. 
Lin, J. et al., 2001. Inhibition of p53 transcriptional activity by the S100B calcium-
binding protein. The Journal of biological chemistry, 276(37), pp.35037–41. 
Lindsey, J.C. et al., 2007. Epigenetic deregulation of multiple S100 gene family 
members by differential hypomethylation and hypermethylation events in 
medulloblastoma. British journal of cancer, 97(2), pp.267–74. 
Lister, R. et al., 2009. Human DNA methylomes at base resolution show widespread 
epigenomic differences. Nature, 462(7271), pp.315–22. 
P a g e  | 310 
   
  
Listernick, R. et al., 2004. Late-onset optic pathway tumors in children with 
neurofibromatosis 1. Neurology, 63(10), pp.1944–6. 
Listernick, R. et al., 1997. Optic pathway gliomas in children with neurofibromatosis 
1: consensus statement from the NF1 Optic Pathway Glioma Task Force. 
Annals of neurology, 41(2), pp.143–9. 
Little, M. & Wells, C., 1997. A clinical overview of WT1 gene mutations. Human 
mutation, 9(3), pp.209–25. 
Liu, J. et al., 2003. Congenital diaphragmatic hernia, kidney agenesis and cardiac 
defects associated with Slit3-deficiency in mice. Mechanisms of development, 
120(9), pp.1059–70. 
Livak, K.J. & Schmittgen, T.D., 2001. Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 
(San Diego, Calif.), 25(4), pp.402–408. 
Lodding, P., Kindblom, L.G. & Angervall, L., 1986. Epithelioid malignant 
schwannoma. A study of 14 cases. Virchows Archiv. A, Pathological anatomy 
and histopathology, 409(4), pp.433–51. 
London, N.R. et al., 2010. Targeting Robo4-dependent Slit signaling to survive the 
cytokine storm in sepsis and influenza. Science translational medicine, 2(23), 
p.23ra19. 
London, N.R. & Li, D.Y., 2011. Robo4-dependent Slit signaling stabilizes the 
vasculature during pathologic angiogenesis and cytokine storm. Current 
opinion in hematology, 18(3), pp.186–90. 
Lothe, R.A. et al., 2001. Biallelic inactivation ofTP53 rarely contributes to the 
development of malignant peripheral nerve sheath tumors. Genes, 
Chromosomes and Cancer, 30(2), pp.202–206. 
P a g e  | 311 
   
  
Luczak,‎M.W.‎&‎ Jagodziński,‎P.P.,‎ 2006.‎The‎ role‎of‎DNA‎methylation‎ in‎ cancer‎
development. Folia histochemica et cytobiologica / Polish Academy of 
Sciences, Polish Histochemical and Cytochemical Society, 44(3), pp.143–54. 
Luo, X.N. et al., 1995. The tumor suppressor gene WT1 inhibits ras-mediated 
transformation. Oncogene, 11(4), pp.743–50. 
Ma, L., Teruya-Feldstein, J. & Weinberg, R. a, 2007. Tumour invasion and 
metastasis initiated by microRNA-10b in breast cancer. Nature, 449(7163), 
pp.682–8. 
Macias, H. et al., 2011. SLIT/ROBO1 signaling suppresses mammary branching 
morphogenesis by limiting basal cell number. Developmental cell, 20(6), 
pp.827–40. 
Maelandsmo, G.M. et al., 1997. Differential expression patterns of S100A2, S100A4 
and S100A6 during progression of human malignant melanoma. International 
journal of cancer. Journal international du cancer, 74(4), pp.464–9. 
Malup, T.K. et al., 2007. Methylation of CpG dinucleotides in the promoter region of 
the gene encoding the S100b protein in BALB/cLac mice. Doklady 
Biochemistry and Biophysics, 412(1), pp.1–3. 
Marenholz, I., Heizmann, C.W. & Fritz, G., 2004. S100 proteins in mouse and man: 
from evolution to function and pathology (including an update of the 
nomenclature). Biochemical and biophysical research communications, 322(4), 
pp.1111–22. 
Mares, J. et al., 2001. Methylation changes in promoter and enhancer regions of the 
WT1‎gene‎in‎Wilms’‎tumours.‎Cancer letters, 166(2), pp.165–71. 
Mårtenson, E.D. et al., 2001. Serum S-100b protein as a prognostic marker in 
malignant cutaneous melanoma. Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology, 19(3), pp.824–31. 
P a g e  | 312 
   
  
Martinelli, S. et al., 2010. Heterozygous germline mutations in the CBL tumor-
suppressor gene cause a Noonan syndrome-like phenotype. American journal of 
human genetics, 87(2), pp.250–7. 
Masliah-Planchon, J. et al., 2013. MicroRNAome profiling in benign and malignant 
neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN 
pathway alterations in early NF1 tumorigenesis. BMC genomics, 14, p.473. 
Mautner, V.-F. et al., 2008. Assessment of benign tumor burden by whole-body MRI 
in patients with neurofibromatosis 1. Neuro-oncology, 10(4), pp.593–8. 
McCarron, K.F. & Goldblum, J.R., 1998. Plexiform neurofibroma with and without 
associated malignant peripheral nerve sheath tumor: a clinicopathologic and 
immunohistochemical analysis of 54 cases. Modern pathology : an official 
journal of the United States and Canadian Academy of Pathology, Inc, 11(7), 
pp.612–7. 
McMaster, M.L. et al., 1995. WT1 expression alters tumorigenicity of the G401 
kidney-derived cell line. Cell growth & differentiation : the molecular biology 
journal of the American Association for Cancer Research, 6(12), pp.1609–17. 
McMenamin, M.E. & Fletcher, C.D., 2001. Expanding the spectrum of malignant 
change in schwannomas: epithelioid malignant change, epithelioid malignant 
peripheral nerve sheath tumor, and epithelioid angiosarcoma: a study of 17 
cases. The American journal of surgical pathology, 25(1), pp.13–25. 
Medina, P.P., Nolde, M. & Slack, F.J., 2010. OncomiR addiction in an in vivo model 
of microRNA-21-induced pre-B-cell lymphoma. Nature, 467(7311), pp.86–90. 
Medvedeva, Y.A. et al., 2010. Intergenic, gene terminal, and intragenic CpG islands 
in the human genome. BMC genomics, 11, p.48. 
Mendez, H.M. & Opitz, J.M., 1985. Noonan syndrome: a review. American journal 
of medical genetics, 21(3), pp.493–506. 
P a g e  | 313 
   
  
Menke, a et al., 2001. Down-regulation of E-cadherin gene expression by collagen 
type I and type III in pancreatic cancer cell lines. Cancer research, 61(8), 
pp.3508–17. 
Menon, A.G. et al., 1990. Chromosome 17p deletions and p53 gene mutations 
associated with the formation of malignant neurofibrosarcomas in von 
Recklinghausen neurofibromatosis. Proceedings of the National Academy of 
Sciences of the United States of America, 87(14), pp.5435–9. 
Merlo,‎ a‎ et‎ al.,‎ 1995.‎ 5’‎CpG‎ island‎methylation‎ is‎ associated‎with‎ transcriptional‎
silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. 
Nature medicine, 1(7), pp.686–692. 
Messiaen, L.M. et al., 2000. Exhaustive mutation analysis of the NF1 gene allows 
identification of 95% of mutations and reveals a high frequency of unusual 
splicing defects. Human mutation, 15(6), pp.541–55. 
Miller, S.J. et al., 2006. Large-scale molecular comparison of human schwann cells 
to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer 
research, 66(5), pp.2584–91. 
Mo, W. et al., 2013. CXCR4/CXCL12 mediate autocrine cell- cycle progression in 
NF1-associated malignant peripheral nerve sheath tumors. Cell, 152(5), 
pp.1077–90. 
Montgomery, K.G. et al., 2004. The DNMT3B C-->T promoter polymorphism and 
risk of breast cancer in a British population: a case-control study. Breast cancer 
research : BCR, 6(4), pp.R390–4. 
Morita, S. et al., 2013. miR-29 represses the activities of DNA methyltransferases 
and DNA demethylases. International journal of molecular sciences, 14(7), 
pp.14647–58. 
P a g e  | 314 
   
  
Mott, J.L. et al., 2007. mir-29 regulates Mcl-1 protein expression and apoptosis. 
Oncogene, 26(42), pp.6133–6140. 
Mraz, M. et al., 2009. miR-34a, miR-29c and miR-17-5p are downregulated in CLL 
patients with TP53 abnormalities. Leukemia, 23(6), pp.1159–63. 
Mueller, A. et al., 2005. The calcium-binding protein S100A2 interacts with p53 and 
modulates its transcriptional activity. The Journal of biological chemistry, 
280(32), pp.29186–93. 
Murray, M.J. & Whitington, P.M., 1999. Effects of roundabout on growth cone 
dynamics, filopodial length, and growth cone morphology at the midline and 
throughout the neuropile. The Journal of neuroscience : the official journal of 
the Society for Neuroscience, 19(18), pp.7901–12. 
Mutze, K. et al., 2011. DNA methyltransferase 1 as a predictive biomarker and 
potential therapeutic target for chemotherapy in gastric cancer. European 
journal of cancer (Oxford, England : 1990), 47(12), pp.1817–25. 
Nakajima, T. et al., 1982. S-100 protein in Langerhans cells, interdigitating 
reticulum cells and histiocytosis X cells. Gann = Gan, 73(3), pp.429–32. 
Namihira, M. et al., 2009. Committed neuronal precursors confer astrocytic potential 
on residual neural precursor cells. Developmental cell, 16(2), pp.245–55. 
Namihira, M., Nakashima, K. & Taga, T., 2004. Developmental stage dependent 
regulation of DNA methylation and chromatin modification in a immature 
astrocyte specific gene promoter. FEBS letters, 572(1-3), pp.184–8. 
Navakanit, R. et al., 2007. Growth inhibition of breast cancer cell line MCF-7 by 
siRNA silencing of Wilms tumor 1 gene. Journal of the Medical Association of 
Thailand = Chotmaihet thangphaet, 90(11), pp.2416–21. 
P a g e  | 315 
   
  
Newby, A.C., 2006. Matrix metalloproteinases regulate migration, proliferation, and 
death of vascular smooth muscle cells by degrading matrix and non-matrix 
substrates. Cardiovascular research, 69(3), pp.614–24. 
Nguyen, T. et al., 2014. Downregulation of microRNA-29c is associated with 
hypermethylation of tumor-related genes and disease outcome in cutaneous 
melanoma. Epigenetics : official journal of the DNA Methylation Society, 6(3), 
pp.388–394. 
Nielsen, G.P. et al., 1999. Malignant transformation of neurofibromas in 
neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. American 
Journal of Pathology, 155(6), pp.1879–84. 
Nonaka, D. et al., 2008. Differential expression of S100 protein subtypes in 
malignant melanoma, and benign and malignant peripheral nerve sheath tumors. 
Journal of cutaneous pathology, 35(11), pp.1014–9. 
North, K.N. et al., 1997. Cognitive function and academic performance in 
neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders 
Task Force. Neurology, 48(4), pp.1121–7. 
Nussbaum, R.L., McInnes, R.R. & Willard, H.F., 2007. Genetics in medicine 7th ed., 
Elsevier. 
O’Riain,‎ C.‎ et‎ al.,‎ 2009.‎ Array-based DNA methylation profiling in follicular 
lymphoma. Leukemia, 23(10), pp.1858–66. 
Oji,‎Y.‎et‎al.,‎2002.‎Overexpression‎of‎the‎Wilms’‎tumor‎gene‎WT1‎in‎de‎novo‎lung‎
cancers. International journal of cancer. Journal international du cancer, 
100(3), pp.297–303. 
Oji, Y. et al., 2004. Overexpression of the Wilms’‎ tumor‎ gene‎WT1‎ in‎ pancreatic‎
ductal adenocarcinoma. Cancer science, 95(7), pp.583–7. 
P a g e  | 316 
   
  
Okano, M. et al., 1999. DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential 
for De Novo Methylation and Mammalian Development. Cell, 99(3), pp.247–
257. 
Ordway, J.M. et al., 2007. Identification of novel high-frequency DNA methylation 
changes in breast cancer. PloS one, 2(12), p.e1314. 
Ostler, K.R. et al., 2007. Cancer cells express aberrant DNMT3B transcripts 
encoding truncated proteins. Oncogene, 26(38), pp.5553–63. 
Ozonoff, S., 1999. Cognitive impairment in neurofibromatosis type 1. American 
journal of medical genetics, 89(1), pp.45–52. 
Pandit, B. et al., 2007. Gain-of-function RAF1 mutations cause Noonan and 
LEOPARD syndromes with hypertrophic cardiomyopathy. Nature genetics, 
39(8), pp.1007–12. 
Parenti,‎R.‎et‎al.,‎2014.‎Wilms’‎tumor‎gene‎1‎(WT1)‎silencing‎inhibits‎proliferation‎
of malignant peripheral nerve sheath tumor sNF96.2 cell line. PloS one, 9(12), 
p.e114333. 
Pasquinelli, A.E., Hunter, S. & Bracht, J., 2005. MicroRNAs: a developing story. 
Current opinion in genetics & development, 15(2), pp.200–5. 
Pass, H.I. et al., 2010. hsa-miR-29c* is linked to the prognosis of malignant pleural 
mesothelioma. Cancer Research, 70(5), pp.1916–24. 
Patterson, M.L. et al., 2001. Specific collagenolysis by gelatinase A, MMP-2, is 
determined by the hemopexin domain and not the fibronectin-like domain. 
FEBS letters, 503(2-3), pp.158–62. 
Pedrocchi, M. et al., 1994. Expression of Ca(2+)-binding proteins of the S100 family 
in malignant human breast-cancer cell lines and biopsy samples. International 
journal of cancer. Journal international du cancer, 57(5), pp.684–90. 
P a g e  | 317 
   
  
Perrin, G.Q. et al., 2007. An orthotopic xenograft model of intraneural NF1 MPNST 
suggests a potential association between steroid hormones and tumor cell 
proliferation. Laboratory investigation; a journal of technical methods and 
pathology, 87(11), pp.1092–1102. 
Perrone, F. et al., 2003. Neurofibromatosis Type 1-related Malignant Peripheral 
Nerve Sheath Tumors 1. Clinical Cancer Research, 9, pp.4132– 4138. 
Perry, A. et al., 2002. Differential NF1, p16, and EGFR patterns by interphase 
cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and 
morphologically similar spindle cell neoplasms. Journal of neuropathology and 
experimental neurology, 61(8), pp.702–9. 
Perry, A. et al., 2001. NF1 deletions in S-100 protein-positive and negative cells of 
sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas 
and malignant peripheral nerve sheath tumors. The American journal of 
pathology, 159(1), pp.57–61. 
Peter, M.E., 2009. Let-7 and miR-200 microRNAs: guardians against pluripotency 
and cancer progression. Cell cycle (Georgetown, Tex.), 8(6), pp.843–52. 
Petersson, S. et al., 2009. Expression patterns of S100 proteins in melanocytes and 
melanocytic lesions. Melanoma research, 19(4), pp.215–25. 
Pietzsch, J., 2010. S100 proteins in health and disease. Amino acids. 
Pinney, S.E., 2014. Mammalian Non-CpG Methylation: Stem Cells and Beyond. 
Biology, 3(4), pp.739–51. 
Piper, M. et al., 2000. Expression of the vertebrate Slit gene family and their putative 
receptors, the Robo genes, in the developing murine kidney. Mechanisms of 
development, 94(1-2), pp.213–7. 
P a g e  | 318 
   
  
Plass, C. et al., 2013. Mutations in regulators of the epigenome and their connections 
to global chromatin patterns in cancer. Nature reviews. Genetics, 14(11), 
pp.765–80. 
Prasad, A. et al., 2004. Slit protein-mediated inhibition of CXCR4-induced 
chemotactic and chemoinvasive signaling pathways in breast cancer cells. The 
Journal of biological chemistry, 279(10), pp.9115–24. 
Purkait, R. et al., 2011. Neurocutaneous syndrome: a prospective study. Indian 
journal of dermatology, 56(4), pp.375–9. 
Qin, W. et al., 2011. TGF-β/Smad3‎signaling‎promotes‎ renal‎ fibrosis‎by‎ inhibiting‎
miR-29. Journal of the American Society of Nephrology : JASN, 22(8), 
pp.1462–74. 
Qu, Y., Dang, S. & Hou, P., 2013. Gene methylation in gastric cancer. Clinica 
chimica acta; international journal of clinical chemistry, 424, pp.53–65. 
Que, T. et al., 2015. Decreased miRNA-637 is an unfavorable prognosis marker and 
promotes glioma cell growth, migration and invasion via direct targeting Akt1. 
Oncogene. 
Quelle, D.E. et al., 1995. Alternative reading frames of the INK4a tumor suppressor 
gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 
83(6), pp.993–1000. 
De Raedt, T. et al., 2003. Elevated risk for MPNST in NF1 microdeletion patients. 
American journal of human genetics, 72(5), pp.1288–1292. 
De Raedt, T. et al., 2014. PRC2 loss amplifies Ras-driven transcription and confers 
sensitivity to BRD4-based therapies. Nature, 514(7521), pp.247–51. 
P a g e  | 319 
   
  
Rahrmann, E.P. et al., 2013. Forward genetic screen for malignant peripheral nerve 
sheath tumor formation identifies new genes and pathways driving 
tumorigenesis. Nature genetics, 45(7), pp.756–66. 
Ramaswamy, S. et al., 2003. A molecular signature of metastasis in primary solid 
tumors. Nature genetics, 33(1), pp.49–54. 
Ramdas, V. et al., 2013. Canonical transforming growth factor-β‎signaling‎regulates‎
disintegrin metalloprotease expression in experimental renal fibrosis via miR-
29. The American journal of pathology, 183(6), pp.1885–96. 
Rauen, K.A., 2007. HRAS and the Costello syndrome. Clinical genetics, 71(2), 
pp.101–8. 
Razzaque, M.A. et al., 2007. Germline gain-of-function mutations in RAF1 cause 
Noonan syndrome. Nature genetics, 39(8), pp.1013–7. 
Reinhart, B.J. et al., 2000. The 21-nucleotide let-7 RNA regulates developmental 
timing in Caenorhabditis elegans. Nature, 403(6772), pp.901–906. 
Reynolds,‎ R.M.‎ et‎ al.,‎ 2003.‎ Von‎ Recklinghausen’s‎ neurofibromatosis:‎
neurofibromatosis type 1. Lancet, 361(9368), pp.1552–4. 
Rheinheimer, B. et al., 2013. Epigenetic silencing alters the SLIT2/ROBO1/miR-
218-1 signaling axis in pancreatic cancer. Cancer Research, 73(13 
Supplement), pp.B13–B13. 
Riccardi, V.M., 1981. Cutaneous manifestation of neurofibromatosis: cellular 
interaction, pigmentation, and mast cells. Birth defects original article series, 
17(2), pp.129–45. 
Riccardi, V.M., 1982. Neurofibromatosis: clinical heterogeneity. Current problems 
in cancer, 7(2), pp.1–34. 
P a g e  | 320 
   
  
Riccardi, V.M., 2007. The genetic predisposition to and histogenesis of 
neurofibromas and neurofibrosarcoma in neurofibromatosis type 1. 
Neurosurgical focus, 22(6), p.E3. 
Robaina, M.C. et al., 2015. Deregulation of DNMT1, DNMT3B and miR-29s in 
Burkitt lymphoma suggests novel contribution for disease pathogenesis. 
Experimental and molecular pathology, 98(2), pp.200–7. 
Roberts, A.E. et al., 2007. Germline gain-of-function mutations in SOS1 cause 
Noonan syndrome. Nature genetics, 39(1), pp.70–4. 
Robertson, K.D. et al., 1999. The human DNA methyltransferases (DNMTs) 1, 3a 
and 3b: Coordinate mRNA expression in normal tissues and overexpression in 
tumors. Nucleic Acids Research, 27(11), pp.2291–8. 
Rodriguez, F.J. et al., 2007. Low grade malignant peripheral nerve sheath tumor with 
smooth muscle differentiation. Acta neuropathologica, 113(6), pp.705–9. 
Roll, J.D. et al., 2008. DNMT3b overexpression contributes to a hypermethylator 
phenotype in human breast cancer cell lines. Molecular cancer, 7(c), p.15. 
Romano, A.A. et al., 2010. Noonan syndrome: clinical features, diagnosis, and 
management guidelines. Pediatrics, 126(4), pp.746–59. 
Rosenfeld, N. et al., 2008. MicroRNAs accurately identify cancer tissue origin. 
Nature biotechnology, 26(4), pp.462–9. 
Roth, J. et al., 2003. Phagocyte-specific S100 proteins: a novel group of 
proinflammatory molecules. Trends in immunology, 24(4), pp.155–8. 
Ruggieri, M. & Huson, S.M., 2001. The clinical and diagnostic implications of 
mosaicism in the neurofibromatoses. Neurology, 56(11), pp.1433–43. 
P a g e  | 321 
   
  
Russo, V.C. et al., 2005. Insulin-like growth factor binding protein-2 binding to 
extracellular matrix plays a critical role in neuroblastoma cell proliferation, 
migration, and invasion. Endocrinology, 146(10), pp.4445–55. 
Russo, V.E.A., Martienssen, R.A. & Riggs, A.D., 1996. Epigenetic Mechanisms of 
Gene Regulation, Cold Spring Harbor Laboratory Press, Woodbury. 
Rustandi, R.R. et al., 1998. The Ca(2+)-dependent interaction of S100B(beta beta) 
with a peptide derived from p53. Biochemistry, 37(7), pp.1951–60. 
Saito, Y. et al., 2001. Expression of mRNA for DNA methyltransferases and methyl-
CpG-binding proteins and DNA methylation status on CpG islands and 
pericentromeric satellite regions during human hepatocarcinogenesis. 
Hepatology (Baltimore, Md.), 33(3), pp.561–8. 
Salama, I. et al., 2008. A review of the S100 proteins in cancer. European journal of 
surgical oncology, 34(4), pp.357–64. 
Sandhu, R. et al., 2014. Dysregulation of microRNA expression drives aberrant 
DNA hypermethylation in basal-like breast cancer. International journal of 
oncology, 44(2), pp.563–72. 
Sandhu, R., Rivenbark, A.G. & Coleman, W.B., 2012. Loss of post-transcriptional 
regulation of DNMT3b by microRNAs: a possible molecular mechanism for the 
hypermethylation defect observed in a subset of breast cancer cell lines. 
International journal of oncology, 41(2), pp.721–32. 
Sarkozy, A., Digilio, M.C. & Dallapiccola, B., 2008. Leopard syndrome. Orphanet 
journal of rare diseases, 3, p.13. 
Sato, N. et al., 2004. Identification of maspin and S100P as novel hypomethylation 
targets in pancreatic cancer using global gene expression profiling. Oncogene, 
23(8), pp.1531–8. 
P a g e  | 322 
   
  
Sceusi, E.L., Loose, D.S. & Wray, C.J., 2011. Clinical implications of DNA 
methylation in hepatocellular carcinoma. HPB : the official journal of the 
International Hepato Pancreato Biliary Association, 13(6), pp.369–76. 
Schickel, R. et al., 2008. MicroRNAs: key players in the immune system, 
differentiation, tumorigenesis and cell death. Oncogene, 27(45), pp.5959–74. 
Schittenhelm, J. et al., 2010. WT1 expression in normal and neoplastic cranial and 
peripheral nerves is independent of grade of malignancy. Cancer biomarkers : 
section A of Disease markers, 7(2), pp.73–7. 
Schmittgen, T.D. & Livak, K.J., 2008. Analyzing real-time PCR data by the 
comparative C(T) method. Nature protocols, 3(6), pp.1101–1108. 
Schubbert, S. et al., 2006. Germline KRAS mutations cause Noonan syndrome. 
Nature genetics, 38(3), pp.331–6. 
Schwarz, D.S. et al., 2003. Asymmetry in the assembly of the RNAi enzyme 
complex. Cell, 115(2), pp.199–208. 
Scotto, C. et al., 1999. Concerted regulation of wild-type p53 nuclear accumulation 
and activation by S100B and calcium-dependent protein kinase C. Molecular 
and cellular biology, 19(10), pp.7168–80. 
Sedani, A., Cooper, D.N. & Upadhyaya, M., 2012. An emerging role for microRNAs 
in NF1 tumorigenesis. Human genomics, 6, p.23. 
Sengupta, S. et al., 2008. MicroRNA 29c is down-regulated in nasopharyngeal 
carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. 
Proceedings of the National Academy of Sciences of the United States of 
America, 105(15), pp.5874–8. 
P a g e  | 323 
   
  
Shah, M.Y. et al., 2010. DNMT3B7, a truncated DNMT3B isoform expressed in 
human tumors, disrupts embryonic development and accelerates 
lymphomagenesis. Cancer research, 70(14), pp.5840–50. 
Shanmuganathan, R. et al., 2013. Conventional and nanotechniques for DNA 
methylation profiling. The Journal of molecular diagnostics : JMD, 15(1), 
pp.17–26. 
Shen, H. et al., 2002. A novel polymorphism in human cytosine DNA-
methyltransferase-3B promoter is associated with an increased risk of lung 
cancer. Cancer research, 62(17), pp.4992–5. 
Sherman, L.S. et al., 2000. Single cell Ras-GTP analysis reveals altered Ras activity 
in a subpopulation of neurofibroma Schwann cells but not fibroblasts. The 
Journal of biological chemistry, 275(39), pp.30740–5. 
Shimada,‎ H.‎ et‎ al.,‎ 1988.‎ Pathologic‎ features‎ of‎ extraosseous‎ Ewing’s‎ sarcoma:‎ a‎
report from the Intergroup Rhabdomyosarcoma Study. Human pathology, 
19(4), pp.442–53. 
Shimozaki, K. et al., 2005. Stage- and site-specific DNA demethylation during 
neural cell development from embryonic stem cells. Journal of neurochemistry, 
93(2), pp.432–9. 
Shintani, Y. et al., 2006. Collagen I promotes metastasis in pancreatic cancer by 
activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin 
expression. Cancer research, 66(24), pp.11745–53. 
Shiraishi, M. et al., 2002. A comprehensive catalog of CpG islands methylated in 
human lung adenocarcinomas for the identi®cation of tumor suppressor genes. 
Oncogene, 21(23), pp.3804–3813. 
Siegel, P.M. et al., 2003. Transforming growth factor beta signaling impairs Neu-
induced mammary tumorigenesis while promoting pulmonary metastasis. 
P a g e  | 324 
   
  
Proceedings of the National Academy of Sciences of the United States of 
America, 100(14), pp.8430–5. 
Singal, R. et al., 2005. Polymorphisms in the DNA methyltransferase 3b gene and 
prostate cancer risk. Oncology reports, 14(2), pp.569–73. 
Singer-Sam, J. et al., 1990. A quantitative HpaII-PCR assay to measure methylation 
of DNA from a small number of cells. Nucleic acids research, 18(3), p.687. 
Singh, A. et al., 2012. Wilms tumor-1, claudin-1 and ezrin are useful 
immunohistochemical markers that help to distinguish schwannoma from 
fibroblastic meningioma. Pathology oncology research : POR, 18(2), pp.383–9. 
Smit, L.H.M. et al., Value of serum S-100B for prediction of distant relapse and 
survival in stage III B/C melanoma. Anticancer research, 28(4C), pp.2297–302. 
Smith, R.W., 1989. A treatise on the pathology, diagnosis and treatment of neuroma. 
1849. Clinical orthopaedics and related research, (245), pp.3–9. 
Smith,‎ S.I.‎ et‎ al.,‎ 2000.‎ Expression‎ of‎ the‎Wilms’‎ tumor‎ suppressor‎ gene,‎ WT1,‎
reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid 
mice. Cancer research, 60(4), pp.808–14. 
Stamatopoulos, B. et al., 2009. microRNA-29c and microRNA-223 down-regulation 
has in vivo significance in chronic lymphocytic leukemia and improves disease 
risk stratification. Blood, 113(21), pp.5237–45. 
Steele, R., Mott, J.L. & Ray, R.B., 2010. MBP-1 upregulates miR-29b that represses 
Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. 
Genes & cancer, 1(4), pp.381–387. 
Stein, G.H. et al., 1999. Differential roles for cyclin-dependent kinase inhibitors p21 
and p16 in the mechanisms of senescence and differentiation in human 
fibroblasts. Molecular and cellular biology, 19(3), pp.2109–17. 
P a g e  | 325 
   
  
Stott, F.J. et al., 1998. The alternative product from the human CDKN2A locus, 
p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. The 
EMBO journal, 17(17), pp.5001–14. 
Stowe, I.B. et al., 2012. A shared molecular mechanism underlies the human 
rasopathies Legius syndrome and Neurofibromatosis-1. Genes & development, 
26(13), pp.1421–6. 
Stumpf, D., Alksne, J. & Annegers, J., 1988. National Institutes of Health consensus 
development statement on neurofibromatosis. Arch Neurol, 45, pp.575–578. 
Subramanian, S. et al., 2010. Genome-wide transcriptome analyses reveal p53 
inactivation mediated loss of miR-34a expression in malignant peripheral nerve 
sheath tumours. Journal of Pathology, The, (October 2009), pp.58–70. 
Sugiyama, D., Kulkeaw, K. & Mizuochi, C., 2013. TGF-beta-1 up-regulates extra-
cellular matrix production in mouse hepatoblasts. Mechanisms of development, 
130(2-3), pp.195–206. 
Swarbrick, A. et al., 2010. miR-380-5p represses p53 to control cellular survival and 
is associated with poor outcome in MYCN-amplified neuroblastoma. Nature 
medicine, 16(10), pp.1134–1140. 
Takamizawa, J. et al., 2004. Reduced expression of the let-7 microRNAs in human 
lung cancers in association with shortened postoperative survival. Cancer 
research, 64(11), pp.3753–6. 
Tang, B. et al., 2003. TGF-beta switches from tumor suppressor to prometastatic 
factor in a model of breast cancer progression. The Journal of clinical 
investigation, 112(7), pp.1116–24. 
Tarhini, A.A. et al., 2009. Prognostic significance of serum S100B protein in high-
risk surgically resected melanoma patients participating in Intergroup Trial 
P a g e  | 326 
   
  
ECOG 1694. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology, 27(1), pp.38–44. 
Tartaglia, M. et al., 2007. Gain-of-function SOS1 mutations cause a distinctive form 
of Noonan syndrome. Nature genetics, 39(1), pp.75–9. 
Tartaglia, M. et al., 2001. Mutations in PTPN11, encoding the protein tyrosine 
phosphatase SHP-2, cause Noonan syndrome. Nature genetics, 29(4), pp.465–8. 
Tidyman, W.E. & Rauen, K.A., 2009. The RASopathies: developmental syndromes 
of Ras/MAPK pathway dysregulation. Current opinion in genetics & 
development, 19(3), pp.230–6. 
Tie, J. et al., 2010. MiR-218 inhibits invasion and metastasis of gastric cancer by 
targeting the Robo1 receptor. PLoS Genetics, 6(3), p.e1000879. 
Tost, J. & Gut, I.G., 2007. DNA methylation analysis by pyrosequencing. Nature 
Protocols, 2(9), pp.2265–75. 
Trevisson, E. et al., 2013. Neurofibromatosis type 1 in two siblings due to maternal 
germline mosaicism. Clinical genetics. 
Tripathy, K. et al., 2010. A Rare Malignant Triton Tumor. Case reports in 
neurology, 2(2), pp.69–73. 
Trojani, M. et al., 1984. Soft-tissue sarcomas of adults; study of pathological 
prognostic variables and definition of a histopathological grading system. 
International journal of cancer. Journal international du cancer, 33(1), pp.37–
42. 
Tsang, E., Birch, P. & Friedman, J.M., 2012. Valuing gene testing in children with 
possible neurofibromatosis 1. Clinical genetics, 82(6), pp.591–3. 
P a g e  | 327 
   
  
Tucker, T. et al., 2005. Association between benign and malignant peripheral nerve 
sheath tumors in NF1. Neurology, 65(2), pp.205–11. 
Tulchinsky, E. et al., 1995. Transcriptional regulation of the mts1 gene in human 
lymphoma cells: the role of DNA-methylation. Biochimica et biophysica acta, 
1261(2), pp.243–8. 
Ueda,‎T.‎et‎al.,‎2003.‎Overexpression‎of‎the‎Wilms’‎tumor‎gene‎WT1‎in‎human‎bone‎
and soft-tissue sarcomas. Cancer science, 94(3), pp.271–6. 
Upadhyaya, M., 2011. Genetic basis of tumorigenesis in NF1 malignant peripheral 
nerve sheath tumors. Frontiers in bioscience (Landmark edition), 16, pp.937–
51. 
Upadhyaya, M. et al., 2008. Germline and somatic NF1 gene mutation spectrum in 
NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Human 
mutation, 29(1), pp.74–82. 
Upadhyaya, M., 2008. NF1 Gene Structure and NF1 Genotype / Phenotype 
Correlations. Structure, 16, pp.162200–162200. 
Upadhyaya, M. et al., 2003. Three different pathological lesions in the NF1 gene 
originating de novo in a family with neurofibromatosis type 1. Human genetics, 
112(1), pp.12–7. 
Vaissière, T. et al., 2010. Quantitative analysis of DNA methylation profiles in lung 
cancer identifies aberrant DNA methylation of specific genes and its association 
with gender and cancer risk factors. Cancer, 69(1), pp.243–252. 
Valeri, N. et al., 2010. Modulation of mismatch repair and genomic stability by miR-
155. Proceedings of the National Academy of Sciences of the United States of 
America, 107(15), pp.6982–7. 
P a g e  | 328 
   
  
Veeck, J. & Esteller, M., 2010. Breast cancer epigenetics: from DNA methylation to 
microRNAs. Journal of mammary gland biology and neoplasia, 15(1), pp.5–17. 
Verdijk, R.M. et al., 2010. TP53 Mutation Analysis of Malignant Peripheral Nerve 
Sheath Tumors. Experimental Neurology, 69(1), pp.16–26. 
Vivarelli, R. et al., 2003. Epilepsy in neurofibromatosis 1. Journal of child 
neurology, 18(5), pp.338–342. 
Wagner,‎ N.‎ et‎ al.,‎ 2008.‎ The‎ Wilms’‎ tumor‎ suppressor‎ WT1‎ is‎ associated‎ with‎
melanoma proliferation. Pflügers Archiv : European journal of physiology, 
455(5), pp.839–47. 
Wakefield, L.M. & Roberts, A.B., 2002. TGF-beta signaling: positive and negative 
effects on tumorigenesis. Current opinion in genetics & development, 12(1), 
pp.22–9. 
Wakioka, T. et al., 2001. Spred is a Sprouty-related suppressor of Ras signalling. 
Nature, 412(6847), pp.647–51. 
Wallace, M.R. et al., 1990. Type 1 neurofibromatosis gene: identification of a large 
transcript disrupted in three NF1 patients. Science (New York, N.Y.), 249(4965), 
pp.181–6. 
Walter, M.J. et al., 2011. Recurrent DNMT3A mutations in patients with 
myelodysplastic syndromes. Leukemia, 25(7), pp.1153–8. 
Wang, B. et al., 2015. MiR-194, commonly repressed in colorectal cancer, 
suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling 
pathway. Cell cycle (Georgetown, Tex.). 
Wang, C.-M. et al., 2011. miR-29c targets TNFAIP3, inhibits cell proliferation and 
induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. 
Biochemical and biophysical research communications, 411(3), pp.586–92. 
P a g e  | 329 
   
  
Wang, Q. et al., 2007. Hypomethylation of WNT5A, CRIP1 and S100P in prostate 
cancer. Oncogene, 26(45), pp.6560–5. 
Wang,‎X.‎et‎al.,‎2013.‎Wilms’‎ tumour‎suppressor‎gene‎1‎ (WT1)‎ is‎ involved‎ in‎ the‎
carcinogenesis of Lung cancer through interaction with PI3K/Akt pathway. 
Cancer cell international, 13(1), p.114. 
Wang, Y. et al., 2006. Functional CpG methylation system in a social insect. Science 
(New York, N.Y.), 314(5799), pp.645–7. 
Wang, Y. et al., 2013. Tumor-suppressive effects of miR-29c on gliomas. 
Neuroreport, 24(12), pp.637–45. 
Wang, Z. et al., 2013. MicroRNA-210 promotes proliferation and invasion of 
peripheral nerve sheath tumor cells targeting EFNA3. Oncology research, 
21(3), pp.145–54. 
Watabe, T. & Miyazono, K., 2009. Roles of TGF-beta family signaling in stem cell 
renewal and differentiation. Cell research, 19(1), pp.103–15. 
Watanabe, T. et al., 2001. Malignant peripheral nerve sheath tumour arising within 
neurofibroma. An immunohistochemical analysis in the comparison between 
benign and malignant components. Journal of clinical pathology, 54(8), 
pp.631–6. 
Weber, M. et al., 2005. Chromosome-wide and promoter-specific analyses identify 
sites of differential DNA methylation in normal and transformed human cells. 
Nature Genetics, 37(8), pp.853–862. 
Weemaes, C.M.R. et al., 2013. Heterogeneous clinical presentation in ICF 
syndrome: correlation with underlying gene defects. European journal of 
human genetics : EJHG, 21(11), pp.1219–25. 
P a g e  | 330 
   
  
Weiss, S.W. & Goldblum, J.R., 2007. Enzinger and Weiss’s Soft Tissue Tumors 5th 
ed.,‎St.‎Louis,‎Mo. ;‎London :‎Mosby,‎2007. 
Weiss, S.W., Langloss, J.M. & Enzinger, F.M., 1983. Value of S-100 protein in the 
diagnosis of soft tissue tumors with particular reference to benign and 
malignant Schwann cell tumors. Laboratory investigation; a journal of 
technical methods and pathology, 49(3), pp.299–308. 
Weiss, S.W. & Nickoloff, B.J., 1993. CD-34 is expressed by a distinctive cell 
population in peripheral nerve, nerve sheath tumors, and related lesions. The 
American journal of surgical pathology, 17(10), pp.1039–45. 
Wicki, R. et al., 1997. Repression of the candidate tumor suppressor gene S100A2 in 
breast cancer is mediated by site-specific hypermethylation. Cell calcium, 
22(4), pp.243–54. 
Wiercinska, E. et al., 2010. The TGF-??/Smad pathway induces breast cancer cell 
invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a 
spheroid invasion model system. Breast Cancer Research and Treatment, 128, 
pp.657–666. 
Wild, L. & Flanagan, J.M., 2010. Genome-wide hypomethylation in cancer may be a 
passive consequence of transformation. Biochimica et biophysica acta, 1806(1), 
pp.50–7. 
Wilson, A.J., Maddox, P.H. & Jenkins, D., 1991. CD1a and S100 antigen expression 
in skin Langerhans cells in patients with breast cancer. The Journal of 
pathology, 163(1), pp.25–30. 
Wilson, A.S., Power, B.E. & Molloy, P.L., 2007. DNA hypomethylation and human 
diseases. Biochimica et biophysica acta, 1775(1), pp.138–62. 
P a g e  | 331 
   
  
Winbanks, C.E. et al., 2011. TGF-beta regulates miR-206 and miR-29 to control 
myogenic differentiation through regulation of HDAC4. The Journal of 
biological chemistry, 286(16), pp.13805–14. 
Wojtkowiak, J.W. et al., 2008. Induction of apoptosis in neurofibromatosis type 1 
malignant peripheral nerve sheath tumor cell lines by a combination of novel 
farnesyl transferase inhibitors and lovastatin. The Journal of pharmacology and 
experimental therapeutics, 326(1), pp.1–11. 
Woodruff, J.M. & Christensen, W.N., 1993. Glandular peripheral nerve sheath 
tumors. Cancer, 72(12), pp.3618–28. 
Wu, J.Y. et al., 2001. The neuronal repellent Slit inhibits leukocyte chemotaxis 
induced by chemotactic factors. Nature, 410(6831), pp.948–52. 
Wu, M.Y. & Hill, C.S., 2009. Tgf-beta superfamily signaling in embryonic 
development and homeostasis. Developmental cell, 16(3), pp.329–43. 
Xiong, Y. et al., 2010. Effects of microRNA-29 on apoptosis, tumorigenicity, and 
prognosis of hepatocellular carcinoma. Hepatology (Baltimore, Md.), 51(3), 
pp.836–45. 
Xu, G.L. et al., 1999. Chromosome instability and immunodeficiency syndrome 
caused by mutations in a DNA methyltransferase gene. Nature, 402(6758), 
pp.187–91. 
Xu, X. et al., 2005. Matrix metalloproteinase-2 contributes to cancer cell migration 
on collagen. Cancer research, 65(1), pp.130–6. 
Yakulis, R., Manack, L. & Murphy, A.I., 1996. Postradiation malignant triton tumor. 
A case report and review of the literature. Archives of pathology & laboratory 
medicine, 120(6), pp.541–8. 
P a g e  | 332 
   
  
Yamaguchi, U. et al., 2003. Low grade malignant peripheral nerve sheath tumour: 
varied cytological and histological patterns. Journal of clinical pathology, 
56(11), pp.826–30. 
Yanaihara, N. et al., 2006. Unique microRNA molecular profiles in lung cancer 
diagnosis and prognosis. Cancer cell, 9(3), pp.189–98. 
Yang, J.C. et al., 1998. Randomized prospective study of the benefit of adjuvant 
radiation therapy in the treatment of soft tissue sarcomas of the extremity. 
Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology, 16(1), pp.197–203. 
Yeh, M.L. et al., 2014. Robo1 modulates proliferation and neurogenesis in the 
developing neocortex. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, 34(16), pp.5717–31. 
Yilmaz, K. et al., 2007. Bone mineral density in children with neurofibromatosis 1. 
Acta paediatrica (Oslo, Norway : 1992), 96(8), pp.1220–2. 
Yu, F. et al., 2007. Let-7 Regulates Self Renewal and Tumorigenicity of Breast 
Cancer Cells. Cell, 131(6), pp.1109–23. 
Zamora-Avila, D.E. et al., 2007. RNAi silencing of the WT1 gene inhibits cell 
proliferation and induces apoptosis in the B16F10 murine melanoma cell line. 
Melanoma research, 17(6), pp.341–8. 
Zapata-Benavides,‎ P.‎ et‎ al.,‎ 2002.‎ Downregulation‎ of‎ Wilms’‎ tumor 1 protein 
inhibits breast cancer proliferation. Biochemical and biophysical research 
communications, 295(4), pp.784–90. 
Zenker, M., 2011. Clinical manifestations of mutations in RAS and related 
intracellular signal transduction factors. Current opinion in pediatrics, 23(4), 
pp.443–51. 
P a g e  | 333 
   
  
Zhang, M. et al., 2014. Somatic mutations of SUZ12 in malignant peripheral nerve 
sheath tumors. Nature genetics, 46(11), pp.1170–2. 
Zhang, Y. et al., 2014. miR-29b as a therapeutic agent for angiotensin II-induced 
cardiac fibrosis by targeting TGF-β/Smad3‎ signaling.‎Molecular therapy : the 
journal of the American Society of Gene Therapy, 22(5), pp.974–85. 
Zhang, Y.-J. et al., 2012. Global hypomethylation in hepatocellular carcinoma and 
its relationship to aflatoxin B(1) exposure. World journal of hepatology, 4(5), 
pp.169–75. 
Zhao, J.-J. et al., 2010. microRNA expression profile and identification of miR-29 as 
a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell 
lymphoma. Blood, 115(13), pp.2630–9. 
Zheng, P.-P. et al., 2009. Cell proliferation and migration are mutually exclusive 
cellular phenomena in vivo: implications for cancer therapeutic strategies. Cell 
cycle (Georgetown, Tex.), 8(6), pp.950–1. 
Zimmer, D.B. et al., 2013. Evolution of the S100 family of calcium sensor proteins. 
Cell calcium, 53(3), pp.170–9. 
Zitzmann, F. et al., 2014. Frequent hypermethylation of a CTCF binding site 
influences Wilms tumor 1 expression in Wilms tumors. Oncology Reports, 
31(4), pp.1871–1876. 
 
